GOVERNMENT NOTICE

DEPARTMENT OF HEALTH

No. R. 1022

16 November 2007

NATIONAL HEALTH ACT, 2003 (ACT NO. 61 OF 2003)

DETERMINATION AND PUBLICATION OF THE REFERENCE PRICE LIST FOR 2008

The Director-General: Health has, in terms of regulation 10 of the Regulations Relating to the Obtainment of Information and the Process of Determination and Publication of Reference Price List published under Notice No. R.681 of 23 July 2007, (Gazette No. 30110 of 23 July 2007), determined the Reference Price List for 2008 in the Schedule.

DIRECTOR-GENERAL: HEALTH

NATIONAL HEALTH REFERENCE PRICE LIST

FOR

2008 SCHEDULES

MEDICAL SCIENTISTS

NATIONAL REFERENCE PRICE LIST FOR MEDICAL SCIENTISTS WITH EFFECT FROM 1 JANUARY 2008

The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well.

In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+rounded to the nearest 10cent. Modifier values are rounded to the nearest cent. When new item prices are calculated, e.g. when applying a modifier, the same rounding scheme should be followed. VAT EXCLUSIVE PRICES APPEAR IN BRACKETS.

GENERAL RULES

- Each practitioner must acquaint him-/herself with the provisions of the Medical Schemes Act, as amended, and the regulations 01 promulgated under the Act and shall render a monthly account in respect of any service rendered during the month, irrespective of whether or not the treatment has been completed. NB. Every account shall contain the following particulars
 - 05.03

- The name and practice code number of the referring practitioner.
- The name of the member.
- The name of the patient.
- The name of the medical scheme.
- The membership number of the member.
- The nature of the treatment.
- The date on which the service was rendered.
- The relevant diagnostic codes and NHRPL item code numbers relating to the health service rendered.

| ITEMS | | 104111 | | 1 mail 2 my | |
|--------|---|--------|------|-------------|---------------------------------------|
| Code | Description | Ver | Add | | Scientist : Counselling |
| | | | | RVU | Fee |
| 107 | Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 04.00 | | | |
| 200 | Genetic counselling. Duration: 1-10min. | 05.03 | | 0.500 | 31.60 (27.70) |
| 201 | Genetic counselling. Duration: 11-20min. | 05.03 | | 1.500 | 94.90 (83.20) |
| 202 | Genetic counselling. Duration: 21-30min. | 05.03 | | 2.500 | 158.20 (138.80) |
| 203 | Genetic counselling. Duration: 31-40min. | 05.03 | | 3.500 | 221.40 (194.20) |
| 204 | Genetic counselling. Duration: 41-50min. | 05.03 | | 4.500 | 284.70 (249.70) |
| 205 | Genetic counselling. Duration: 51-60min. | 05.03 | | 5.500 | 348.00 |
| 206 | Genetic counselling. Duration: 61-70min. | 05.03 | | 6.500 | 411.20 |
| 207 | Genetic counselling. Duration: 71-80min. | 05.03 | | 7.500 | 474.50 (416.20) |
| 208 | Genetic counselling. Duration: 81-90min. | 05.03 | | 8.500 | 537.80 (471.80) |
| Sample | extraction | | 1911 | - 30.50 | 2 (10 m) 2 m 2 m |
| 300 | DNA extraction - Blood | 06.02 | | - | |
| 310 | DNA extraction - Tissue (other than blood and including CVS and amniotic fluid) | 06.02 | | - | |
| 320 | DNA extraction - Tissue (paraffin blocks) | 06.02 | | - | |
| 330 | RNA extraction - Blood | 06.02 | | | |
| 340 | RNA extraction - Tissue (other than blood and including CVS and amniotic fluid) | 06.02 | | | |
| 350 | RNA extraction - Tissue (paraffin blocks) | 06.02 | | _ | |
| PCR | | 47.5 | | | |
| 400 | PCR-basic (up to four PCR primer sets) | 06.02 | | _ | |
| 410 | PCR-multiplex (five or more primer sets) | 06.02 | | | |
| 420 | PCR-realtime | 06.02 | _ | | |
| 430 | PCR-reverse transcriptase | 06.02 | | | |
| | on Methods | | 4 | 13 (13) | 7 |
| 500 | Diagnostic electrophoresis (agarose and polyacrylamide gel electrophoresis and capillary electrophoresis) | 06.02 | | - | · · · · · · · · · · · · · · · · · · · |
| 510 | Restriction enzyme digestion (use multiples based on cost of enzyme) | 06.02 | | - | |
| 520 | Probe hybridisation assays | 06.02 | | - | |
| 530 | dHPLC | 06.02 | | - | |
| 540 | MLPA | 06.02 | | - | |
| Southe | rn Blotting | 4., | | 1.6.70 | |
| 610 | DNA probe labelling (including hybridisation and autoradiography) | 06.02 | _ | | |
| 600 | Southern blot (digest, gel and blotting) | 06.02 | · | | _ |

| Code | Description | Ve | r A | | i Scientist : Counselling |
|-------|---|----------------|------------|------------------|------------------------------|
| | | | | RVU | Fee |
| Other | <u> 하는 당한 하는 이 이 다른 경험이 하는 것이 없었다. 그 동안 되는 이 전한 경우와 살아 있는 이 없이 하고 있다. 아</u> | `;; <u>`</u> ; | (<u>(</u> | : \$140.34.265°) | 类的存在这 |
| 700 | Protein truncation test | 06.0 | 02 | - | |
| 730 | Interpretation and reporting | 06.0 | 02 | - | • |
| 720 | DNA sequencing | 06.0 | 02 | - | |
| 710 | Maternal contamination test (prenatal testing) | 06.0 | 02 | 1 | • |

| | | | | 36901 | | | | |
|------------|---|--------------------|----------|------------------------|----------------|--|-------|-------------|
| | NATIONAL REFERENCE PRICE LIST FOR MEDICAL SCIENTISTS WITH EFFECT FROM 1 | | | | | | | |
| | JANUARY 2008 | Version | Add | CF | Units | BF | Value | Flag |
| | The following reference price list is not a set of tariffs that must be applied by medical schemes | l | | ΙI | | | | |
| | and/or providers. It is rather intended to serve as a baseline against which medical schemes can | l | l | ΙI | | | | |
| | individually determine benefit levels and health service providers can individually determine fees | l | l | ΙI | | | | |
| | charged to patients. Medical schemes may, for example, determine in their rules that their benefit in | l | | | | | | |
| | respect of a particular health service is equivalent to a specified percentage of the national health | l | | | | | | |
| | reference price list. It is especially intended to serve as a basis for negotiation between individual | l | | | | | | |
| | funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to | | l | ΙI | | | | |
| | determine benefit structures, and individual providers determine fee structures, on some other basis | l | | ΙI | | | | |
| | without reference to this list, they may do so as well. | l | l | ΙI | | | | |
| | In calculating the prices in this schedule, the following rounding method is used: Values R10 and | l | ı | ΙI | | | | |
| | below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded | | ı | ΙI | | 1 | | |
| | VAT EXCLUSIVE PRICES APPEAR IN BRACKETS. | 2004.00 | | ΙI | | | | |
| _ | GENERAL RULES | 2007.00 | \vdash | Н | | | | + |
| | Each practitioner must acquaint him-/herself with the provisions of the Medical Schemes Act, as | | | $\vdash \vdash \vdash$ | | \vdash | | + |
| | amended, and the regulations promulgated under the Act and shall render a monthly account in | l | | ll | | | | |
| | respect of any service rendered during the month, irrespective of whether or not the treatment has | l | | ΙI | | | | 1 / |
| | been completed. NB. Every account shall contain the following particulars | l | | ΙI | | | | |
| | | l | | ΙI | | | | 1 |
| | · The name and practice code number of the referring practitioner. | l | | Ιİ | | | | |
| | · The name of the member. | l | | ΙI | | | | |
| | · The name of the patient. | l | ı | ΙI | | | | |
| | The name of the medical scheme. | l | ı | ΙI | | | | |
| | The membership number of the member. | l | ı | ΙI | | | | |
| | · The nature of the treatment. | l | ı | ΙI | | | | |
| | · The date on which the service was rendered. | l | ı | ΙI | | | | |
| | · The relevant diagnostic codes and NHRPL item code numbers relating to the health service | l | • | ΙI | | | | |
| 01 | rendered. | 2005.03 | | Ш | | | | |
| | ITEMS | | <u> </u> | Ш | | Ш | | |
| 407 | Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall | | | ΙI | | | | |
| 107 200 | into the "By arrangement with the scheme" or "Patient own account" category). | 2004.00 | | 070 | 0.500 | | | _— |
| 201 | Genetic counselling, Duration: 1-10min. Genetic counselling, Duration: 11-20min. | 2005.03 2005.03 | | 370 370 | 0.500 1.500 | | | - |
| 202 | Genetic counselling, Duration: 11-20min. | 2005.03 | ⊢ | 370 | 2.500 | | | _ |
| 203 | Genetic counselling, Duration; 21-30min. Genetic counselling, Duration; 31-40min. | 2005.03 | \vdash | 370 | 3,500 | | | |
| 204 | Genetic counselling, Duration: 41-50min. | 2005.03 | | 370 | 4.500 | | | _ |
| 205 | Genetic counselling, Duration: 51-60min. | 2005.03 | \vdash | 370 | 5.500 | | | |
| 206 | Genetic counselling, Duration: 61-70min. | 2005.03 | \vdash | 370 | 6.500 | | | _ |
| 207 | Genetic counselling. Duration: 71-80min. | 2005.03 | _ | 370 | 7,500 | | | • |
| 208 | Genetic counselling, Duration: 81-90min. | 2005.03 | _ | 370 | 8,500 | | | _ |
| | Sample extraction | 1 | | | | | 22110 | \top |
| 300 | DNA extraction - Blood | 2006.02 | | 370 | | 1.0 | R - | $\neg \neg$ |

| 310 | DNA extraction - Tissue (other than blood and including CVS and amniotic fluid) | 2006.02 | 370 | - 1.0 | R | |
|-----|--|---------|--------|-------|-----|---|
| 320 | DNA extraction - Tissue (paraffin blocks) | 2006.02 | 370 | - 1.0 | R - | |
| 330 | RNA extraction - Blood | 2006.02 | 370 | - 1.0 | R - | |
| 340 | RNA extraction - Tissue (other than blood and including CVS and amniotic fluid) | 2006.02 | 370 | - 1.0 | R - | |
| 350 | RNA extraction - Tissue (paraffin blocks) | 2006.02 | 370 | - 1.0 | R - | |
| | PCR | | | | | |
| 400 | PCR-basic (up to four PCR primer sets) | 2006.02 | 370 | - 1.0 | R - | |
| 410 | PCR-multiplex (five or more primer sets) | 2006.02 | 370 | - 1.0 | R - | |
| 420 | PCR-realtime | 2006.02 | 370 | - 1.0 | Ř - | |
| 430 | PCR-reverse transcriptase | 2006.02 | 370 | - 1.0 | R | |
| | Detection Methods | | | | | |
| | Diagnostic electrophoresis (agarose and polyacrylamide gel electrophoresis and capillary | | \Box | | | |
| 500 | electrophoresis) | 2006.02 | 370 | - 1.0 | R | |
| 510 | Restriction enzyme digestion (use multiples based on cost of enzyme) | 2006.02 | 370 | - 1.0 | R - | |
| 520 | Probe hybridisation assays | 2006.02 | 370 | - 1.0 | R - | |
| 530 | dHPLC | 2006.02 | 370 | - 1.0 | R - | |
| 540 | MLPA | 2006.02 | 370 | - 1.0 | R - | |
| | Southern Biotting | | \Box | | | Т |
| 610 | DNA probe labelling (including hybridisation and autoradiography) | 2006.02 | 370 | - 1.0 | R - | |
| 600 | Southern blot (digest, gel and blotting) | 2006.02 | 370 | - 1.0 | R | |
| | Other | | | | | |
| 700 | Protein truncation test | 2006.02 | 370 | - 1.0 | R - | |
| 730 | Interpretation and reporting | 2006.02 | 370 | - 1.0 | R - | L |
| 720 | DNA sequencing | 2006.02 | 370 | - 1.0 | R - | |
| 710 | Maternal contamination test (prenatal testing) | 2006.02 | 370 | - 1.0 | R - | |

| Code | Description |
|-------|---|
| 36901 | Medical Scientist : Genetic Counseiling |

| Code | Description | RCF |
|------------------------|--------------|--------|
| 370 Genetic Councellor | | 63.268 |

MEDICAL TECHNOLOGY

NATIONAL REFERENCE PRICE LIST FOR SERVICES BY MEDICAL LABORATORY TECHNOLOGISTS, WITH EFFECT FROM 1 JANUARY 2008

The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotilation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well.

In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded to the nearest cent. When new item prices are calculated, e.g. when applying a modifier, the same rounding scheme should be followed.

VAT EXCLUSIVE PRICES APPEAR IN BRACKETS.

Preamble

It is recommended that, when such benefits are granted, the following should be clearly specified in the scheme's rules.

Services must only be on referral.

General Rules

Each practitioner must acquaint him-therself with the provisions of the Medical Schemes Act, and the regulations promulgated under the Act and shall render a monthly account in respect of any service rendered. NB: Every account shall contain the following particulars:

The account or statement contemplated in section 59(1) of the Act must contain the following -

- The sumame and initials of the member;
- (b) the sumame, first name and other initials, if any, of the patient;
- the name of the scheme concerned; (c)
 - the membership number of the member,
- the practice code number, group practice number and individual provider registration number issued by the registering authorities for providers, if applicable, of the supplier of service and, in the case of a group practice, the name of the practitioner who provided the service;
- the relevant diagnostic and such other item code numbers that relates to such relevant health service;
 - the date on which each relevant health service was rendered;
- (g) the nature and cost of each relevant health service rendered, including the supply of medicine to the member concerned or to a dependant of that member; and the name, quantity and dosage of and net amount payable by the member in respect of, the medicine:

| 002 | No "shopping list" must be distributed to doctors and no group tests will be carried out. | 04.00 |
|-----|---|-------|
| 003 | No charge to be raised in respect of services such as sample handling and after hours services. | 04.00 |
| 004 | Interaction with patient for collecting of specimens shall be limited to those specimens that are physiologically expelled, such as | 05.02 |
| | sputum and urine and taking of venous and peripheral blood. | |
| 005 | It is recommended that, when such benefits are granted, drugs, consumables and disposable items used during a procedure or | 04.00 |
| | I have also a matter than the second of the second transfer of the manufactor and the second of the | |

issued to a patient on discharge will only be reimbursed by a medical scheme if the appropriate code is supplied on the account.

| Code | Description | Ver | Add | Medical | Technology |
|--------------|--|-------|-----|---------|--------------------|
| | | | | RVU | Fee |
| 3705 | Alkali resistant haemoglobin | 04.00 | | 4.500 | 30.40 (26.70 |
| 3709 | Antiglobulin test (Coombs' or trypsinzied red cells) | 04.00 | | 3.650 | 24.60 (21.60) |
| 3710 | Antibody titration | 04.00 | | 7.200 | 48.60 (42.60) |
| 3711 | Arneth count | 04.00 | | 2.250 | 15.20 (13.30) |
| 3712 | Antibody identification | 04.00 | | 8.450 | 57.00 (50.00) |
| 3713 | Bleeding time (does not include the cost of the simplate device) | 04.00 | | 6.940 | 46.80 (41.10) |
| 3714 | Blood volume, dye method | 04.00 | | 7.200 | 48.60 (42.60 |
| 3715 | Buffy layer examination | 04.00 | | 19.900 | 134.20 (117.70) |
| 37 17 | Bone marrow cytological examination only | 04.00 | | 19.900 | 134.20 (117.70) |
| 3722 | Capillary fragility: Hess | 04.00 | | 2.020 | 13.60 (11.90) |
| 3723 | Circulating anticoagulants | 04.00 | | 5.850 | 39.50 (34.60) |
| 3724 | Coagulation factor inhibitor assay | 04.00 | | 57.560 | 388.20 (340.50) |
| 3726 | Activated protein C resistance | 04.00 | | 26.000 | 175.40 (153.90) |
| 3727 | Coagulation time | 04.00 | | 3.160 | 21.30 (18.70) |

| Code | Description | Ver | | Technology |
|--------------|---|-------|--------|------------------|
| <i>i</i> 1.7 | | | RVU | . F88 |
| 3729 | Cold agglutinins | 04.00 | 3.600 | 24.30 (21.30) |
| 3730 | Protein S: Functional | 04.00 | 37.500 | |
| 3731 | Compatibility for blood transfusion | 04.00 | 3.600 | |
| 3732 | Cryoglobulin | 04.00 | 3.600 | |
| 3734 | Protein C (chromogenic) | 04.00 | 30.290 | |
| 3735 | Anti-thrombin III (chromogenic) | 04.00 | 22.000 | |
| 3736 | Plasminogen (chromogenic) | 04.00 | 61.650 | |
| 3737 | Lupus Russel Viper method | 04.00 | 17.000 | |
| 3738 | Lupus Kaolin Exner method | 04.00 | 25.000 | 168.60 |
| 3739 | Erythrocyte count | 04.00 | 2.250 | |
| 3740 | Factors V and VII: Qualitative | 04.00 | 7.200 | |
| 3741 | Coagulation factor assay: Functional | 04.00 | 9.450 | |
| 3742 | Coagulation factor assay: Immunological | 04.00 | 4.500 | |
| 3743 | Erythrocyte sedimentation rate | 04.00 | 3.000 | |
| 3744 | Fibrin stabilizing factor (urea test) | 04.00 | 4.500 | (17.70) |
| 3746 | Fibrin monomers | 04.00 | 2.700 | |
| 3751 | Osmotic fragility (screen) | 04.00 | 2.250 | |
| 3752 | Osmotic fragility test: Quantitative | 04.00 | 10.000 | |
| 3753 | Osmotic fragility (before and after incubation) | 04.00 | 18.000 | |
| 3755 | Full blood count (including items 3739, 3762, 3783, 3785, 3791) | 04.00 | 10.500 | |
| 3756 | Full cross match | 04.00 | 7.200 | |
| 3757 | Coagulation factors: Quantitative | 04.00 | 32.200 | |
| 3758 | Factor VIII related antigen | 04.00 | 60.460 | |
| 3759 | Coagulation factor correction study | 04.00 | 11.720 | |
| 3762 | Haemoglobin estimation | 04.00 | 1.800 | |
| 3763 | Contact activated product assay | 04.00 | 16.200 | |
| 3764 | Grouping: A B and O antigens | 04.00 | 3.600 | |
| 3765 | Grouping: Rh antigen | 04.00 | 3.600 | |
| 3767 | Euglobulin Lysis time | 04.00 | 25.580 | |
| 3768 | Haemoglobin A2 (column chromatography) | 04.00 | 15.000 | |
| 3769 | Haemoglobin electrophoresis | 04.00 | 26.820 | |
| 3770 | Haemoglobin-S (solubility test) | 04.00 | 3.600 | |
| 3771 | Factor III-availability test | 04.00 | 5.850 | |
| 3772 | Haptoglobin: Quantitative | 04.00 | 9.450 | |
| 3773 | Ham's acidified serum test | 04.00 | 8.000 | (55.90) 54.00 |

| Code | Description | Ver | Add Medical 7 | |
|------|---|----------|---------------|--------------------|
| 7.1 | | <u> </u> | RVU | Fee |
| 3775 | Heinz bodies | 04.00 | 2.250 | 15.20 (13.30) |
| 3776 | Haemosiderin in urinary sediment | 04.00 | 2.250 | 15.20 (13.30) |
| 3781 | Heparin tolerance | 04.00 | 7.200 | 48.60 (42.60) |
| 3783 | Leucocyte differential count | 04.00 | 6.200 | 41.80 (36.70) |
| 3785 | Leucocytes: Total count | 04.00 | 1.800 | 12.10 (10.60) |
| 3786 | QBC malaria concentration and fluorescent staining | 04.00 | 25.000 | 168.60 (147.90) |
| 3787 | LE-cells | 04.00 | 8.300 | 56.00 (49.10) |
| 3789 | Neutrophil alkaline phosphatase | 04.00 | 28.000 | 188.90 (165.70) |
| 3791 | Packed cell volume: Haematocrit | 04.00 | 1.800 | 12.10 (10.60) |
| 3792 | Plasmodium falciparum: Monoclonal immunological identification | 04.00 | 9.000 | 60.70 (53.20) |
| 3793 | Plasma haemoglobin | 04.00 | 6.750 | 45.50 (39.90) |
| 3795 | Platelet aggregation per aggregant | 04.00 | 12.140 | 81.90 (71.80) |
| 3796 | Platelet antibodies: Agglutination | 04.00 | 5.400 | 36.40 (31.90) |
| 3797 | Platelet count | 04.00 | 2.250 | 15.20 (13.30) |
| 3799 | Platelet adhesiveness | 04.00 | 4.500 | 30.40 (26.70) |
| 3801 | Prothrombin consumption | 04.00 | 5.850 | 39.50 (34.60) |
| 3803 | Prothrombin determination (two stages) | 04.00 | 5.850 | 39.50 (34.60) |
| 3805 | Prothrombin index | 04.00 | 6.000 | 40.50 (35.50) |
| 3806 | Therapeutic drug level: Dosage | 04.00 | 4.500 | 30.40 (26.70) |
| 3807 | Recalcification time | 04.00 | 2.250 | 15.20 (13.30) |
| 3809 | Reticulocyte count | 04.00 | 3.000 | 20.20 (17.70) |
| 3810 | Schumm's test | 04.00 | 3.600 | 24.30 (21.30) |
| 3811 | Sickling test | 04.00 | 2.250 | 15.20 (13.30) |
| 3814 | Sucrose lysis test for PNH | 04.00 | 3.600 | 24.30 (21.30) |
| 3816 | T and B-cells EAC markers (limited to ONE marker only for CD4/8 counts) | 04.00 | 21.100 | 142.30 (124.80) |
| 3820 | Thrombo - Elastogram | 04.00 | 26.000 | 175.40 (153.90) |
| 3825 | Fibrinogen titre | 04.00 | 3.600 | 24.30 (21.30) |
| 3829 | Glucose 6-phosphate-dehydrogenase: Qualitative | 04.00 | 8.000 | 54.00 (47.40) |
| 3830 | Glucose 6-phosphate-dehydrogenase: Quantitative | 04.00 | 16.000 | 107.90 (94.60) |
| 3832 | Red cell pyruvate kinase: Quantitative | 04.00 | 16.000 | 107.90 (94.60) |
| 3834 | Red cell Rhesus phenotype | 04.00 | 9.900 | 66.80 (58.60) |
| 3835 | Haemoglobin F in blood smear | 04.00 | 5.850 | 39.50 (34.60) |
| 3837 | Partial thromboplastin time | 04.00 | 5.850 | 39.50 (34.60) |
| 3841 | Thrombin time (screen) | 04.00 | 7.160 | 48.30 (42.40) |
| | | | | |

| Code | Description | Ver | Add | Medical RVU | Technology Fee |
|--------|--|-------------|-------------|----------------|--|
| 3847 | Haemoglobin H | 04.00 | | 2.250 | 15.20 (13.30) |
| 3851 | Fibrin degeneration products (diffusion plate) | 04.00 | | 10.350 | 69.80 (61.20) |
| 3853 | Fibrin degeneration products (latex slide) | 04.00 | | 4.500 | 30.40 (26.70) |
| 3854 | XDP (Dimer test or equivalent latex slide test) | 04.00 | | 8.500 | 57.30 (50.30) |
| 3855 | Haemagglutination inhibition | 04.00 | | 9.900 | 66.80 (58.60) |
| Micros | copic and miscellaneous tests | | | J. (1940) | and the second of the second o |
| 3863 | Autogenous vaccine | 04.00 | | 12.600 | 85.00 (74.60) |
| 3864 | Entomological examination | 04.00 | | 20.700 | 139.60 (122.50) |
| 3865 | Parasites in blood smear | 04.00 | | 5.600 | 37.80 (33.20) |
| 3867 | Miscellaneous (body fluids, urine, exudate, fungi, puss, scrapings, etc.) | 04.00 | | 4.900 | 33.10 (29.00) |
| 3868 | Fungus identification | 04.00 | | 8.300 | 56.00 (49.10) |
| 3869 | Faeces (including parasites) | 04.00 | | 4.900 | 33.10 (29.00) |
| 3875 | Inclusion bodies | 04.00 | | 4.500 | 30.40 (26.70) |
| 3878 | Crystal identification polarized light microscopy | 04.00 | | 4.500 | 30.40 (26.70) |
| 3879 | Campylobacter in stool: Fastidious culture | 04.00 | | 9.900 | 66.80 (58.60) |
| 3880 | Antigen detection with polyclonal antibodies | 04.00 | | 4.500 | 30.40 (26.70) |
| 3881 | Mycobacteria | 04.00 | | 3.000 | 20.20 (17.70) |
| 3882 | Antigen detection with monoclonal antibodies | 04.00 | | 10.800 | 72.80 (63.90) |
| 3883 | Concentration techniques for parasites | 04.00 | | 3.000 | 20.20 (17.70) |
| 3884 | Dark field, phase or interference contrast microscopy, Nomarski or Fontana | 04.00 | | 6.300 | 42.50 (37.30) |
| 3885 | Cytochemical stain | 04.00 | | 5.450 | 36.80 (32.30) |
| Bacter | ology | | | 27,000 | (02.00) |
| 3887 | Antibiotic susceptibility test: Per organism | 04.00 | | 8.000 | 54.00 (47.40) |
| 3888 | Adhesive tape preparation | 04.00 | | 2.700 | 18.20 (16.00) |
| 3889 | Clostridium difficile toxin: Monoclonal immunological | 04.00 | | 12.400 | 83.60 (73.30) |
| 3890 | Antibiotic assay of tissues and fluids | 04.00 | | 13.900 | 93.80 |
| 3891 | Blood culture: Aerobic | 04.00 | | 5.850 | 39.50 (34.60) |
| 3892 | Blood cuiture: Anaerobic | 04.00 | | 5.850 | 39.50 (34.60) |
| 3893 | Bacteriological culture: Miscellaneous | 04.00 | | 6.300 | 42.50 (37.30) |
| 3894 | Radiometric blood culture | 04.00 | | 10.800 | 72.80 (63.90) |
| 3895 | Bacteriological culture: Fastidious organisms | 04.00 | | 9.900 | 66.80 (58.60) |
| 3896 | In vivo culture: Bacteria | 04.00 | | 16.000 | 107.90 (94.60) |
| 3897 | In vivo culture: Virus | 04.00 | | 16.000 | 107.90 (94.60) |
| 3898 | Bacterial exotoxin production (in vitro assay) | 04.00 | | 4.500 | 30.40 (26.70) |
| 3899 | Bacterial exotoxin production (in vivo assay) | 04.00 | | 20.700 | 139.60 (122.50) |
| 3901 | Fungal culture | 04.00 | | 4.500 | 30.40 (26.70) |

| Code | Description Control of the Control o | Ver | Add Medical RVU | |
|------|--|-------|--------------------|--------------------|
| | | | | Fee |
| 3962 | Rebuck skin window | 04.00 | 5.400 | 36.40 (31.90 |
| 3963 | Serum complement level: Each component | 04.00 | 3.150 | 21.20 (18.60 |
| 3967 | Auto-antibody: Sensitized erythrocytes | 04.00 | 4.500 | 30.40 (26.70 |
| 3968 | Herpes virus typing: Monoclonal immunological | 04.00 | 20.690 | 139.60 (122.50 |
| 3969 | Western blot technique | 04.00 | 74.000 | 499.10 (437.80 |
| 3970 | Epstein-Barr virus antibody titer | 04.00 | 6.750 | 45.50 (39.90 |
| 3932 | Antibodies to human immunodeficiency virus (HIV): ELISA | 04.00 | 14.100 | 95.10 (83.40 |
| 3933 | IgE: Total: EMIT or ELISA | 04.00 | 11.700 | 78.90 (69.20 |
| 3934 | Auto antibodies by labelled antibodies | 04.00 | 16.000 | 107.90 |
| 3935 | Sperm antibodies | 04.00 | 16.000 | 107.90 |
| 3936 | Virus neutralisation test: First antibody | 04.00 | 75.000 | 505.90 (443.80 |
| 3937 | Virus neutralisation test: Each additional antibody | 04.00 | 15.000 | 101.20 |
| 3938 | Precipitation test per antigen | 04.00 | 4.500 | 30.40 (26.70 |
| 3939 | Agglutination test per antigen | 04.00 | 5.500 | 37.10 (32.50) |
| 3940 | Haemagglutination test: Per antigen | 04.00 | 9.900 | 66.80 (58.60) |
| 3941 | Modified Coombs' test for brucellosis | 04.00 | 4.500 | 30.40 (26.70) |
| 3943 | Antibody titer to bacterial exotoxin | 04.00 | 3.600 | 24.30 (21.30) |
| 3944 | lgE: Specific antibody titer: ELISA/EMIT: Per Ag | 04.00 | 12.400 | 83.60 (73.30) |
| 3945 | Complement fixation test | 04.00 | 5.850 | 39.50 (34.60) |
| 3946 | IgM: Specific antibody titer:ELISA/EMIT: Per Ag | 04.00 | 14.050 | 94.80 |
| 3947 | C-reactive protein | 04.00 | 10.840 | 73.10 (64.10) |
| 3948 | lgG: Specific antibody titer: ELISA/EMIT: Per Ag | 04.00 | 12.950 | 87.30 (76.60) |
| 3949 | Qualitative Kahn, VDRL or other flocculation | 04.00 | 2.250 | 15.20 (13.30) |
| 3950 | Neutrophil phagocytosis | 04.00 | 25.200 | 170.00 (149.10 |
| 3951 | Quantitative Kahn, VDRL or other flocculation | 04.00 | 3.600 | 24.30 (21.30) |
| 3952 | Neutrophil chemotaxis | 04.00 | 67.950 | 458.30 (402.00) |
| 3953 | Tube agglutination test | 04.00 | 4.150 | 28.00 (24.60) |
| 3955 | Paul Bunnell: Presumptive | 04.00 | 2.250 | 15.20 |
| 3956 | Infectious mononucleosis latex slide test (Monospot or equivalent) | 04.00 | 8.500 | 57.30 (50.30) |
| 3957 | Paul Bunnell: Absorption | 04.00 | 4.500 | 30.40 (26.70) |
| 3971 | Immuno-diffusion test: Per antigen | 04.00 | 3.150 | 21.20 (18.60) |
| 3972 | Respiratory syncytial virus (ELISA technique) | 04.00 | 35.000 | 236.10 (207.10) |
| 3973 | Immuno electrophoresis: Per immune serum | 04.00 | 9.450 | 63.70 (55.90) |
| 3974 | Polymerase chain reaction | 04.00 | . 75.000 | 505.90 (443.80) |
| 3975 | Indirect immuno-fluorescence test (bacterial, viral, parasitic) | 04.00 | 12.000 | 80.90 (71.00) |

| Code | Description | Ver | Add Medical | |
|-----------------------|--|----------|-------------|-------------------------------|
| | | <u> </u> | RVU | Fee |
| 3902 | Clostridium difficile (cytotoxicity neutralisation) | 04.00 | 30.000 | 202.40 (177.50) |
| 3903 | Antibiotic level: Biological fluids | 04.00 | 11.700 | 78.90 (69.20) |
| 3904 | Rotavirus latex slide test | 04.00 | 5.620 | 37.90 (33.20) |
| 3905 | Identification of virus or rickettsía | 04.00 | 20.700 | 139.60 (122.50) |
| 3906 | Identification: Chlamydia | 04.00 | 16.000 | 107.90 (94.60) |
| 3907 | Culture for staphylococcus aureus | 04.00 | 2.250 | 15.20 (13.30) |
| 3908 | Anaerobe culture: Comprehensive | 04.00 | 9.900 | 66.80 (58.60) |
| 3909 | Anaerobe culture: Limited procedure | 04.00 | 4.500 | 30.40 (26.70) |
| 3911 | Beta-lactamase assay | 04.00 | 4.500 | 30.40 (26.70) |
| 3914 | Sterility control test: Biological method | 04.00 | 4.500 | 30.40 (26.70) |
| 3915 | Mycobacterium culture | 04.00 | 4.500 | 30.40 (26.70) |
| 3916 | Radiometric tuberculosis culture | 04.00 | 10.800 | 72.80 (63.90) |
| 3917 | Mycoplasma culture: Limited | 04.00 | 2.250 | 15.20 |
| 3918 | Mycoplasma culture: Comprehensive | 04.00 | 9.900 | (13.30) 66.80 |
| 3919 | Identification of mycobacterium | 04.00 | 9.900 | (58.60) 66.80 |
| 3920 | Mycobacterium: Antibiotic sensitivity | 04.00 | 9.900 | (58.60) 66.80 |
| 3921 | Antibiotic synergistic study | 04.00 | 20.700 | (58.60) 139.60 |
| 3922 | Viable cell count | 04.00 | 1.350 | (122.50) 9.11 (7.99) |
| 3923 | Biochemical identification of bacterium: Abridged | 04.00 | 3.150 | 21.20 (18.60) |
| 3924 | Biochemical identification of bacterium: Extended | 04.00 | 12.500 | 84.30 (73.90) |
| 3925 | Serological identification of bacterium: Abridged | 04.00 | 3.150 | 21.20 (18.60) |
| 3926 | Serological identification of bacterium: Extended | 04.00 | 10.200 | 68.80 |
| 3927 | Grouping for streptococci | 04.00 | 7.300 | (60.40) 49.20 |
| 3928 | Antimicrobic substances | 04.00 | 3.800 | (43.20) 25.60 |
| 3929 | Radiometric mycobacterium identification | 04.00 | 14.000 | (22.50) 94.40 |
| 3930 | Radiometric mycobacterium antibiotic sensitivity | 04.00 | 25.000 | (82.80) 168.60 (147.90) |
| 3931 | Helicobacter: Monoclonal immunological | 04.00 | 12.400 | 83.60 |
| 4650 | Antibiotic MIC per organism per antibiotic | 04.00 | 8.000 | (73.30) 54.00 |
| 4651 | Non-radiometric automated blood cultures | 04.00 | 13.900 | 93.80 (93.20) |
| 4652 | Rapid automated bacterial identification per organism | 04.00 | 15.000 | (82.30) 101.20 |
| 4653 | Rapid automated antibiotic susceptibility per organism | 04.00 | 17.000 | (88.80) 11 4 .70 |
| 4654 | Rapid automated MIC per organism per antibiotic | 04.00 | 17.000 | (100.60) 114.70 |
| Carolo | v | | | (100.60) |
| Serolo 3959 | Rose Waaler agglutination test | 04.00 | 4.500 | 30.40 |
| 3960 | Gonococcal, listeria or echinococcus agglutination | 04.00 | 9.500 | (26.70) 64.10 |
| 3961 | Slide agglutination test | 04.00 | 2.630 | (56.20 <u>)</u> 17.70 |
| | | | | (15.50) |

| Code | Description | Ver | Add Medical | 7 - 5 |
|--------|---|--------|-------------|--------------------|
| ٠. | | 1. 12. | RVU | Fee |
| 3977 | Counter immuno-electrophoresis | 04.00 | 6.750 | 45.50 (39.90) |
| 3978 | Lymphocyte transformation | 04.00 | 51.700 | 348.70 (305.90) |
| 4601 | Panel typing: Antibody detection: Class I | 04.00 | 36.000 | 242.80 (213.00) |
| 4602 | Panel typing: Antibody detection: Class II | 04.00 | 44.000 | 296.80 (260.40) |
| 4603 | HLA test for specific locus/antigen - serology | 04.00 | 27.000 | 182.10 (159.70) |
| 4604 | HLA typing: Class I - serology | 04.00 | 52.000 | 350.70 (307.60) |
| 4605 | HLA typing: Class II - serology | 04.00 | 52.000 | 350.70 (307.60) |
| 4606 | HLA typing: Class I & II - serology | 04.00 | 90.000 | 607.10 (532.50) |
| 4607 | Cross matching T-cells (per tray) | 04.00 | 18.000 | 121.40 |
| 4608 | Cross matching B-cells | 04.00 | 38.000 | 256.30 (224.80) |
| 4609 | Cross matching T- & B-cells | 04.00 | 48.000 | |
| Bioche | mical tests: Blood | | | (204.00) |
| 3991 | Abnormal pigments: Qualitative | 04.00 | 4.500 | 30.40 (26.70) |
| 3993 | Abnormal pigments: Quantitative | 04.00 | 9.000 | 60.70 (53.20) |
| 3995 | Acid phosphate | 04.00 | 5.180 | 34.90 (30.60) |
| 3997 | Acid phosphatase fractionation | 04.00 | 1.800 | 12.10 (10.60) |
| 3996 | Amino acids Quantitative (Post derivatisation HPLC) | 04.00 | 78.120 | 526.90 (462.20) |
| 3999 | Albumin | 04.00 | 4.800 | 32.40 (28.40) |
| 4000 | Alcohol | 04.00 | 12.400 | 83.60 (73.30) |
| 4001 | Alkaline phosphatase | 04.00 | 5.180 | 34.90 (30.60) |
| 4002 | Alkaline phosphatase-iso-enzymes | 04.00 | 11.700 | 78.90 (69.20) |
| 4003 | Ammonia: Enzymatic | 04.00 | 7.710 | 52.00 (45.60) |
| 4004 | Ammonia: Monitor | 04.00 | 4.500 | 30.40 (26.70) |
| 4005 | Alpha-1-antitrypsin: Total | 04.00 | 7.200 | 48.60 (42.60) |
| 4006 | Amylase | 04.00 | 5.180 | |
| 4007 | Arsenic in blood, hair or nails | 04.00 | 36.250 | 244.50 (214.50) |
| 4009 | Bilirubin: Total | 04.00 | 4.770 | 32.20 (28.20) |
| 4010 | Bilirubin: Conjugated | 04.00 | 3.620 | 24.40 (21.40) |
| 4014 | Cadmium: Atomic absorption | 04.00 | 18.120 | 122.20 (107.20) |
| 4016 | Calcium: Ionized | 04.00 | 6.750 | 45.50 (39.90) |
| 4017 | Calcium: Spectrophotometric | 04.00 | 3.620 | 24.40 (21.40) |
| 4018 | Calcium: Atomic absorption | 04.00 | 7.250 | 48.90 (42.90) |
| 4019 | Carotene | 04.00 | 2.250 | 15.20 (13.30) |
| 4020 | Carnitine (Total or free) in biological fluid: Each | 04.00 | 11.690 | 78.80 (69.10) |
| 4021 | Carnitine (Total or free) in muscle: Each | 04.00 | 23.380 | 157.70 (138.30) |
| 4022 | Acyl Camitine | 04.00 | 23.380 | |

| Code | Description | Ver Ad | d Medical T | |
|------|---|--------|-------------|-----------------------------|
| | | | RVU | Fee |
| 4023 | Chloride | 04.00 | 2.590 | 17.50 (15.40) |
| 4026 | LDL cholesterol (chemical determination) | 04.00 | 6.900 | 46.50 (40.80) |
| 4027 | Cholesterol total | 04.00 | 5.340 | 36.00 (31.60) |
| 4028 | HDL cholesterol | 04.00 | 6.900 | 46.50 (40.80) |
| 4029 | Cholinesterase: Serum or erythrocyte: Each | 04.00 | 7.480 | 50.50 (44.30) |
| 4030 | Cholinesterase phenotype (Dibucaine or fluoride each) | 04.00 | 9.000 | 60.70 (53.20) |
| 4031 | Total CO2 | 04.00 | 5.180 | 34.90 (30.60) |
| 4032 | Creatinine | 04.00 | 3.620 | 24.40 |
| 4040 | Homocysteine (random) | 04.00 | 15.300 | (21.40) 103.20 |
| 4041 | Homocysteine (after Methionine load) | 04.00 | 18.100 | (90.50) 122.10 |
| 4042 | D-Xylose absorption test: Two hours | 04.00 | 13.150 | (107.10) 88.70 |
| 4045 | Fibrinogen: Quantitative | 04.00 | 3.600 | (77.80) 24.30 |
| 4045 | rionnogen. Quantitative | | | (21.30) |
| 4047 | Hollander test | 04.00 | 24.750 | 166.90 (1 4 6.40) |
| 4049 | Glucose tolerance test (2 specimens) | 04.00 | 8.970 | 60.50 (53.10) |
| 4050 | Glucose strip-test with photometric reading | 04.00 | 1.800 | 12.10 (10.60) |
| 4051 | Galactose | 04.00 | 11.250 | 75.90 (66.60) |
| 4052 | Glucose tolerance test (3 specimens) | 04.00 | 13.170 | 88.80 (77.90) |
| 4053 | Glucose tolerance test (4 specimens) | 04.00 | 17.370 | 117.20 |
| 4057 | Glucose: Quantitative | 04.00 | 3.620 | 24.40 (21.40) |
| 4061 | Glucose tolerance test (5 specimens) | 04.00 | 21.560 | 145.40 (127.50) |
| 4062 | Galactose-1-phosphate unidyl transferase | 04.00 | 16.000 | 107.90 |
| 4063 | Fructosamine | 04.00 | 7.200 | 48.60 (42.60) |
| 4064 | HbA1C | 06.04 | 14.250 | 96.10 (84.30) |
| 4066 | Immunofixation: Total protein, IgG, IgA, IgM, Kappa, Lambda | 04.00 | 46.880 | 316.20 (277.40) |
| 4067 | Lithium: Flame ionisation | 04.00 | 5.180 | 34.90 |
| 4068 | Lithium: Atornic absorption | 04.00 | 7.480 | 50.50 |
| 4071 | Iron | 04.00 | 6.750 | 45.50 (39.90) |
| 4073 | Iron-binding capacity | 04.00 | 7.650 | 51.60 (45.30) |
| 4078 | Oximetry analysis: MetHb, COHb, O2Hb, RHb, SulfHb | 04.11 | 6.750 | 45.50 |
| 4079 | Ketones in plasma: Qualitative | 04.00 | 2.250 | (39.90) 15.20 |
| 4081 | Drug level-biological fluid: Quantitative | 04.00 | 10.800 | 72.80 (63.90) |
| 4083 | Lysosomal enzyme assay | 04.00 | 36.560 | 246.60 |
| 4085 | Lipase | 04.00 | 5.180 | (216.30) 34.90 |
| 4091 | Lipoprotein electrophoresis | 04.00 | 9.000 | (30.60) 60.70 |
| 4093 | Osmolality: Serum or urine | 04.00 | 6.750 | (53.20) 45.50 |

| Code | Description | Ver Ad | d Medical T | |
|------|---|--------|-------------|-----------------------------|
| | | | RVU | Fee |
| 4023 | Chloride | 04.00 | 2.590 | 17.50 (15.40) |
| 4026 | LDL cholesterol (chemical determination) | 04.00 | 6.900 | 46.50 (40.80) |
| 4027 | Cholesterol total | 04.00 | 5.340 | 36.00 (31.60) |
| 4028 | HDL cholesterol | 04.00 | 6.900 | 46.50 (40.80) |
| 4029 | Cholinesterase: Serum or erythrocyte: Each | 04.00 | 7.480 | 50.50 (44.30) |
| 4030 | Cholinesterase phenotype (Dibucaine or fluoride each) | 04.00 | 9.000 | 60.70 (53.20) |
| 4031 | Total CO2 | 04.00 | 5.180 | 34.90 (30.60) |
| 4032 | Creatinine | 04.00 | 3.620 | 24.40 |
| 4040 | Homocysteine (random) | 04.00 | 15.300 | (21.40) 103.20 |
| 4041 | Homocysteine (after Methionine load) | 04.00 | 18.100 | (90.50) 122.10 |
| 4042 | D-Xylose absorption test: Two hours | 04.00 | 13.150 | (107.10 <u>)</u> 88.70 |
| 4045 | Fibrinogen: Quantitative | 04.00 | 3.600 | (77.80) 24.30 |
| 4045 | rionnogen. Quantitative | | | (21.30) |
| 4047 | Hollander test | 04.00 | 24.750 | 166.90 (1 4 6.40) |
| 4049 | Glucose tolerance test (2 specimens) | 04.00 | 8.970 | 60.50 (53.10) |
| 4050 | Glucose strip-test with photometric reading | 04.00 | 1.800 | 12.10 (10.60) |
| 4051 | Galactose | 04.00 | 11.250 | 75.90 (66.60) |
| 4052 | Glucose tolerance test (3 specimens) | 04.00 | 13.170 | 88.80 (77.90) |
| 4053 | Glucose tolerance test (4 specimens) | 04.00 | 17.370 | 117.20 |
| 4057 | Glucose: Quantitative | 04.00 | 3.620 | 24.40 (21.40) |
| 4061 | Glucose tolerance test (5 specimens) | 04.00 | 21.560 | 145.40 (127.50) |
| 4062 | Galactose-1-phosphate unidyl transferase | 04.00 | 16.000 | 107.90 |
| 4063 | Fructosamine | 04.00 | 7.200 | 48.60 (42.60) |
| 4064 | HbA1C | 06.04 | 14.250 | 96.10 (84.30) |
| 4066 | Immunofixation: Total protein, IgG, IgA, IgM, Kappa, Lambda | 04.00 | 46.880 | 316.20 (277.40) |
| 4067 | Lithium: Flame ionisation | 04.00 | 5.180 | 34.90 |
| 4068 | Lithium: Atornic absorption | 04.00 | 7.480 | 50.50 |
| 4071 | Iron | 04.00 | 6.750 | 45.50 (39.90) |
| 4073 | Iron-binding capacity | 04.00 | 7.650 | 51.60 (45.30) |
| 4078 | Oximetry analysis: MetHb, COHb, O2Hb, RHb, SulfHb | 04.11 | 6.750 | 45.50 |
| 4079 | Ketones in plasma: Qualitative | 04.00 | 2.250 | (39.90) 15.20 |
| 4081 | Drug level-biological fluid: Quantitative | 04.00 | 10.800 | 72.80 (63.90) |
| 4083 | Lysosomal enzyme assay | 04.00 | 36.560 | 246.60 |
| 4085 | Lipase | 04.00 | 5.180 | (216.30) 34.90 |
| 4091 | Lipoprotein electrophoresis | 04.00 | 9.000 | (30.60) 60.70 |
| 4093 | Osmolality: Serum or urine | 04.00 | 6.750 | (53.20) 45.50 |

| Code | Description | Ver Ad | | Technology |
|--------------|---|--------|--------|-----------------------------|
| | | | RVU | Fee |
| 4094 | Magnesium: Spectrophotometric | 04.00 | 3.620 | 24.40 (21.40) |
| 4095 | Magnesium: Atomic absorption | 04.00 | 7.250 | |
| 40 96 | Mercury: Atomic absorption | 04.00 | 18.120 | |
| 4098 | Copper: Atomic absorption | 04.00 | 18.120 | |
| 4105 | Protein electrophoresis | 04.00 | 9.000 | |
| 4106 | IgG sub-class 1, 2, 3 or 4: Per sub-class | 04.00 | 20.000 | |
| 4109 | Phosphate | 04.00 | 3.620 | |
| 4111 | Phospholipids | 04.00 | 3.150 | |
| 4113 | Potassium | 04.00 | 3.620 | 24.40 (21.40) |
| 4114 | Sodium | 04.00 | 3.620 | |
| 4117 | Protein: Total | 04.00 | 3.110 | |
| 4121 | pH, pCO2 or pO2: Each | 04.00 | 6.750 | |
| 4123 | Pyruvic acid | 04.00 | 4.500 | 30.40 |
| 4125 | Salicylates | 04.00 | 4.500 | (26.70) 30.40 (26.70) |
| 4126 | Secretin-pancreozymin response | 04.00 | 26.100 | |
| 4127 | Caeruloptasmin | 04.00 | 4.500 | |
| 4128 | Phenylalanine: Quantitative | 04.00 | 11.250 | 75.90 |
| 4129 | Glutamate dehydrogenase (GDH) | 04.00 | 5.400 | (66.60) 36.40 (31.90) |
| 4130 | Aspartate aminotransferase (AST) | 04.00 | 5.400 | 36.40 (31.90) |
| 4131 | Alanine aminotransferase (ALT) | 04.00 | 5.400 | |
| 4132 | Creatine kinase (CK) | 04.00 | 5.400 | |
| 4133 | Lactate dehidrogenase (LD) | 04.00 | 5.400 | 36.40 |
| 4134 | Gamma glutamyl transferase (GGT) | 04.00 | 5.400 | |
| 4135 | Aldolase | 04.00 | 5.400 | (31.90) 36.40 (31.90) |
| 4136 | Angiotensin converting enzyme (ACE) | 04.00 | 9.000 | 60.70 |
| 4137 | Lactate dehydrogenase isoenzyme | 04.00 | 10.800 | |
| 4138 | CK-MB: Immunoinhibition/precipitation | 04.11 | 10.800 | |
| 4139 | Adenosine deaminase | 04.00 | 5.400 | |
| 4142 | Red cell enzymes: Each | 04.00 | 7.800 | (31.90) 52.60 |
| 4143 | Serum/plasma enzymes | 04.00 | 5.400 | |
| 4144 | Transferrin | 04.00 | 11.700 | (31.90) 78.90 (69.20) |
| 4146 | Lead: Atomic absorption | 04.00 | 15.000 | 101.20 (88.80) |
| 4147 | Triglyceride | 04.00 | 7.930 | 53.50 (46.90) |
| 4149 | Red cell magnesium | 04.00 | 11.700 | 78.90) (69.20) |
| 4151 | Urea | 04.00 | 3.620 | |

| Code | Description — | Ver | Add | | Technology |
|--------------|--|-------|-----|--------|-------------------------------|
| | | 8.6 | | RVU | Fee |
| 4152 | CK-MB: Mass determination: Quantitative (Automated) | 04.00 | | 12.400 | 83.60 (73.30) |
| 4153 | CK-MB: Mass determination: Quantitative (Not automated) | 04.00 | | 17.470 | 117.80 |
| 4154 | Myoglobin quantitative: Monoclonal immunological | 04.00 | | 12.400 | 83.60 (73.30) |
| 4155 | Uric acid | 04.00 | | 3.780 | 25.50 (22.40) |
| 4157 | Vitamin A-saturation test | 04.00 | | 15.300 | 103.20 (90.50) |
| 4158 | Vitamin E (tocopherof) | 04.00 | | 3.600 | 24.30 (21.30) |
| 4159 | Vitamin A | 04.00 | | 6.300 | 42.50 (37.30) |
| 4160 | Vitamin C (ascorbic acid) | 04.00 | | 2.250 | 15.20 (13.30) |
| 4161 | Troponin isoforms: Each | 04.00 | | 20.000 | 134.90 (118.30) |
| 4163 | Apoprotein Al: Turbidometric method | 04.00 | | 8.280 | 55.80 (48.90) |
| 4165 | Apoprotein All: Turbidometric method | 04.00 | | 8.280 | 55.80 (48.90) |
| 4167 | Apoprotein B: Turbidometric method | 04.00 | | 8.280 | 55.80 (48.90) |
| 4170 | Lipoprotein (a)(Lp(a)) assay | 04.00 | | 12.420 | 83.80 (73.50) |
| 4171 | Sodium + potassium + chloride + CO2 + urea | 04.00 | | 15.840 | 106.80 |
| 4172 | ELISA/EMIT technique | 04.00 | | 12.420 | 83.80 (73.50) |
| 4181 | Quantitative protein estimation: Mancini method | 04.00 | | 7.760 | 52.30 (45.90) |
| 4182 | Quantitative protein estimation: Nephelometer or Turbidometeric method | 04.00 | | 8.280 | 55.80 (48.90) |
| 4183 | Quantitative protein estimation: Labelled antibody | 04.00 | | 12.420 | 83.80 (73.50) |
| 4185 | Lactose | 04.00 | | 10.800 | 72.80 (63.90) |
| 4187 | Zinc: Atomic absorption | 04.00 | | 18.120 | 122.20 (107.20) |
| Bloche | mical tests: Urine | 12.7 | | 1000 | (107.20) |
| 4188 | Urine dipstick, per stick (irrespective of the number of tests on stick) | 04.00 | | 1.500 | 10.10 (8.86) |
| 4189 | Abnormal pigments | 04.00 | | 4.500 | 30.40 (26.7 0) |
| 4193 | Alkapton test: Homogentisic acid | 04.00 | | 4.500 | 30.40 (26.70) |
| 4194 | Amino acids: Quantitative (Post derivatisation HPLC) | 04.00 | | 78.120 | |
| 4195 | Amino laevulinic acid | 04.00 | | 18.000 | 121.40 (106.50) |
| 4197 | Amylase | 04.00 | | 5.180 | 34.90 (30.60) |
| 4198 | Arsenic | 04.00 | | 18.120 | 122.20 |
| 4199 | Ascorbic acid | 04.00 | | 2.250 | 15.20 (13.30) |
| 4201 | Bence-Jones protein | 04.00 | | 2.700 | 18.20 (16.00) |
| 4203 | Phenol | 04.00 | | 3.600 | 24.30 (21.30) |
| 4204 | Calcium: Atomic absorption | 04.00 | | 7.250 | 48.90 (42.90) |
| 4205 | Calcium: Spectrophotometric | 04.00 | | 3.620 | 24.40 (21.40) |
| | Calcium: Absorption and excretion studies | 04.00 | | 25.000 | 168.60 |
| 4206 | | | | | (147.90) |
| 4206 4209 | Lead: Atomic absorption | 04.00 | | 15.000 | (147.90) 101.20 (88.80) |

| Code | Description | Ver A | td Medical | Technology |
|------|---|-------|------------|--------------------|
| | | | RVU | Fee |
| 4213 | Protein: Quantitative | 04.00 | 2.250 | 15.20 (13.30) |
| 4216 | Mucopolysaccharides: Qualitative | 04.00 | 3.600 | 24.30 (21.30) |
| 4217 | Oxalate | 04.00 | 9.380 | 63.30 |
| 4218 | Glucose: Quantitative | 04.00 | 2.250 | (55.50) 15.20 |
| 4219 | Steroids: Chromatography (each) | 04.00 | 7.200 | (13.30) 48.60 |
| 4221 | Creatinine | 04.00 | 3.620 | (42.60) 24.40 |
| 4223 | Creatinine clearance | 04.00 | 7.650 | (21.40) 51.60 |
| 4227 | Electrophoresis: Qualitative | 04.00 | 4.500 | (45.30) 30.40 |
| 4229 | Uric acid clearance | 04.00 | 7.650 | (26.70) |
| 4237 | 5-Hydroxy-indole-acetic acid: Screen test | 04.00 | 2.700 | (45.30) 18.20 |
| | | | | (16.00) |
| 4239 | 5-Hydroxy-indole-acetic acid: Quantitative | 04.00 | 6.750 | 45.50 (39.90) |
| 4247 | Ketones: Excluding dip-stick method | 04.00 | 2.250 | 15.20 (13.30) |
| 4248 | Reducing substances | 04.00 | 1.800 | 12.10 (10.60) |
| 4251 | Metanephrines: Column chromatography | 04.00 | 22.050 | 148.70 (130.40) |
| 4253 | Aromatic amines (gas chromatography/mass spectrophotometry) | 04.00 | 27.000 | 182.10 (159.70) |
| 4254 | Nitrosonaphtol test for tyrosine | 04.00 | 2.250 | 15.20 (13.30) |
| 4263 | pH: Excluding dip-stick method | 04.00 | 0.900 | 6.07 (5.32) |
| 4265 | Thin layer chromatography: One way | 04.00 | 6.750 | 45.50 |
| 4266 | Thin layer chromatography: Two way | 04.00 | 11.250 | (39.90) 75.90 |
| 4267 | Total organic matter screen: Infrared | 04.00 | 31.250 | (66.60) 210.80 |
| 4268 | Organic acids: Quantitative; GCMS | 04.00 | 109.380 | (184.90) 737.80 |
| 4269 | Phenylpyruvic acid: Ferric chloride | 04.00 | 2.250 | (647.20) 15.20 |
| 4271 | Phosphate excretion index | 04.00 | 22.050 | (13.30) 148.70 |
| 4272 | Porphobilinogen qualitative screen: Urine | 04.00 | 5.000 | (130.40) 33,70 |
| 4273 | Porphobilinogen/ALA: Quantitative each | 04.00 | 15.000 | (29.60) 101.20 |
| 4283 | | 04.00 | 3.620 | (88.80) |
| | Magnesium: Spectrophotometric | | | (21.40) |
| 4284 | Magnesium: Atomic absorption | 04.00 | 7.250 | 48.90 (42.90) |
| 4285 | Identification of carbohydrate | 04.00 | 7.650 | 51.60 (45.30) |
| 4287 | Identification of drug: Qualitative | 04.00 | 4.500 | 30.40 (26.70) |
| 4288 | Identification of drug: Quantitative | 04.00 | 10.800 | 72.80 (63.90) |
| 4293 | Urea clearance | 04.00 | 5.400 | 36.40 (31.90) |
| 4297 | Copper: Spectrophotometric | 04.00 | 3.620 | 24.40 (21.40) |
| 4298 | Copper. Atomic absorption | 04.00 | 18.120 | 122.20 (107.20) |
| 4300 | Indican or indole: Qualitative | 04.00 | 3,150 | 21.20 (18.60) |
| 4301 | Chloride | 04.00 | 2.590 | 17.50 |
| 4307 | Ammonium chloride loading test | 04.00 | 22.050 | (15.40) 148.70 |
| | | | | (130.4 |

| Code | Description Description | Ver | Add Medical RVU | Fee |
|--------------|--|-------|--------------------|-------------------|
| 4309 | Urobilinogen: Quantitative | 04.00 | 6.750 | 45.50 (39.90 |
| 4313 | Phosphates | 04.00 | 3.620 | 24.4 (21.40 |
| 4315 | Potassium | 04.00 | 3.620 | 24.40 (21.40 |
| 4316 | Sodium | 04.00 | 3.620 | 24.40 (21.40 |
| 4319 | Urea | 04.00 | 3.620 | 24.4 (21.40 |
| 4321 | Uric acid | 04.00 | 3.620 | 24.4 |
| 4322 | Fluoride | 04.00 | 5.180 | (21.40 34.9 |
| 4323 | Total protein and protein electrophoresis | 04.00 | 11.250 | 75.9 |
| 4325 | VMA: Quantitative | 04.00 | 11.250 | 75.9 |
| 4326 | Catecholamines (HPLC) | 04.00 | 78.120 | (66.60 526.9 |
| 4327 | Immunofixation: Total protein, IgG, IgA, IgM, Kappa, Lambda | 04.11 | 46.880 | (462.20 316.20 |
| 4335 | Cystine: Quantitative | 04.00 | 12.600 | (277.40 85.0 |
| 4336 | Dinitrophenol hydrazine test: Ketoacids | 04.00 | 2.250 | (74.60 15.2 |
| 4337 | Hydroxyproline: Quantitative | 04.00 | 18.900 | (13.30 127.5 |
| Bioche | mical tests; Faeces | | | (111.80 |
| 4339 | Chloride | 04.00 | 2.590 | 17.50 (15.40 |
| 4343 | Fat: Qualitative | 04.00 | 3.150 | 21.20 |
| 4345 | Fat: Quantitative | 04.00 | 22.050 | 148.70 (130.40 |
| 4347 | Ph | 04.00 | 0.900 | 6.07 (5.32 |
| 4351 | Occult blood: Chemical test | 04.00 | 2.250 | 15.20 (13.30 |
| 4352 | Occult blood: Monoclonal antibodies | 04.00 | 10.000 | 67.50 (59.20 |
| 4357 | Potassium | 04.00 | 3.620 | 24.40 (21.40 |
| 4358 | Sodium | 04.00 | 3.620 | 24.40 (21.40 |
| 436 1 | Stercobilin | 04.00 | 2.250 | 15.20 (13.30 |
| 4362 | Elastase quantitative ELISA | 04.00 | 47.000 | 317.0 (278.10 |
| 4363 | Stercobilinogen: Quantitative | 04.00 | 6.750 | 45.56 (39.90 |
| 4364 | Chymotrypsin determination: Enzymatic | 04.00 | 7.470 | 50.44 (44.20 |
| Bioche | mical tests: Miscellaneous | | 1 1 1000 | (44.20 |
| 4366 | Porphyrin screen qualitative: Urine, stool, red blood cells: Each | 04.00 | 5.000 | 33.70 (29.60 |
| 4367 | Porphyrin qualitative analysis by TLC: Urine, stool, red blood cells: Each | 04.00 | 20.000 | 134.96 (118.30 |
| 4368 | Porphyrin: Total quantisation: Urine, stool, red blood cells: Each | 04.00 | 20.000 | 134.90 (118.30 |
| 4369 | Porphyrin quantitative analysis by TLC/HPLC: Urine, stool, red blood cells: Each | 04.00 | 30.000 | 202.40 (177.50 |
| 4370 | Drug level in biological fluid: Monoclonal immunological | 04.00 | 12.400 | 83.60 (73.30 |
| 4371 | Amylase in exudate | 04.00 | 5.180 | 34.90 (30.60 |
| 4372 | Fluoride in biological fluids and water | 04.00 | 15.620 | 105.40 (92.50 |
| 4373 | Breast milk analysis | 04.00 | 6.750 | 45.50 (39.90 |
| | | | | 1.5M MU |

| Code | Description | Ver A | | Technology |
|--------------|---|-------------|----------------|--|
| ٠ | | <u> </u> | RVU | Fee |
| 4375 | Calcium in fluid: Spectrophotometric | 04.00 | 3.620 | 24.40 (21.40) |
| 4376 | Calcium in fluid: Atomic absorption | 04.00 | 7.250 | 48.90 (42.90) |
| 4377 | Gallstone analysis: (Bilirubin, Ca, P, Oxalate, Cholesterol) | 04.11 | 21.880 | 147.60 (129.50) |
| 4380 | Lecithin in amniotic fluid: L/S ratio | 04.00 | 27.000 | 182.10 (159.70) |
| 4382 | Bilirubin in amniotic fluid: Spectrophotometric essay | 04.00 | 9.450 | 63.70 (55.90) |
| 4386 | Oestrogen/Progesterone receptors: Fluorescent method | 04.00 | 20.700 | 139.60 (122.50) |
| 4387 | Oestrogen/Progesterone receptors: Cytosol radio-isotope technique | 04.00 | 230.000 | 1551.40 (1360.90) |
| 4388 | Gastric contents: Maximal stimulation test | 04.00 | 27.000 | 182.10 (159.70) |
| 4389 | Gastric fluid: Total acid per specimen | 04.00 | 2.250 | 15.20 (13.30) |
| 4390 | Foam test: Amniotic fluid | 04.00 | 3.150 | 21.20 (18.60) |
| 4391 | Renal calculus: Chemistry | 04.00 | 5.400 | 36.40 (31.90) |
| 4392 | Renal calculus: Crystallography | 04.00 | 16.250 | 109.60 (96.10) |
| 4393 | Saliva: Potassium | 04.00 | 3.620 | 24.40 (21.40) |
| 4394 | Saliva: Sodium | 04.00 | 3.620 | 24.40 (21.40) |
| 4395 | Sweat: Sodium | 04.00 | 3.620 | 24.40 (21.40) |
| 4396 | Sweat: Potassium | 04.00 | 3.620 | 24.40 |
| 4397 | Sweat: Chloride | 04.00 | 2.590 | (21.40) 17.50 |
| 4399 | Sweat collection by iontophoresis (excluding collection material) | 04.00 | 4.500 | (15.40) 30.40 (26.70) |
| 4400 | Tryptophane loading test | 04.00 | 22.050 | 148.70 (130.40) |
| Cerebro | ospinal fluid | | | (130.40) |
| 4401 | Cell count | 04.00 | 3.450 | 23.30 |
| 4407 | Cell count, protein, glucose and chloride | 04.00 | 7.650 | (20.40) 51.60 |
| 4409 | Chloride | 04.00 | 2.590 | (45.30) 17.50 |
| 4415 | Potassium | 04.00 | 3.620 | (15.40 <u>)</u> 24.40 |
| 4416 | Sodium | 04.00 | 3.620 | (21.40) 24.40 |
| | | | | (21.40) |
| 4417 4419 | Protein: Qualitative Protein: Quantitative | 04.00 | 0.900 3.110 | 6.07 (5.32) 21.00 |
| 4421 | Glucose | 04.00 | 3.620 | (18.40) 24.40 |
| 4423 | Urea | 04.00 | 3.620 | (21.40) 24.40 |
| 4425 | Protein electrophoresis | 04.00 | 12.600 | (21.40) 85.00 |
| RNA/DN | IA based tests and andrology | | | (74.60) |
| | A based tests and andrology; RNA/DNA based tests | | 10,50 | ······································ |
| 4430 | Recombinant DNA technique | 04.00 | 25.000 | 168.60 (147.90) |
| 4431 | Ribosomal RNA targeting for bacteriological identification | 04.00 | 35.000 | 236.10 (207.10) |
| 4432 | Ribosomal RNA amplification for bacteriological identification | 04.00 | 75.000 | 505.90 (443.80) |
| 4433 | Bacteriological DNA identification (LCR) | 04.00 | 25.000 | 168.60 (147.90) |
| 4434 | Bacteriological DNA identification (PCR) | 04.00 | 75.000 | 505.90 |

| Code | Description | | Add Medical | |
|--------------|---|-------|------------------|-----------------------------------|
| - 1/4 | | * * | RVU | Fee |
| RNA/D | NA based tests and andrology: Andrology | 72.5 | | |
| 4435 | Mixed antiglobulin reaction: Semen | 04.00 | 6.600 | 44.50 (39.00) |
| 4436 | Friberg test: Semen | 04.00 | 14.500 | 97 .80 (85 .80) |
| 4437 | Kremer test: Semen | 04.00 | 3.600 | 24.30 (21.30) |
| 4440 | Semen analysis: Cell count | 04.00 | 7.650 | 51.60 (45.30) |
| 4441 | Semen analysis: Cytology | 04.00 | 7.200 | 48.60 (42.60) |
| 4442 | Semen analysis: Viability + motility - 6 hours | 04.00 | 6.000 | 40 .50 (35.50) |
| 4443 | Semen analysis: Supravital stain | 04.00 | 5.440 | 36.70 (32.20) |
| 4445 | Seminal fluid: Alpha glucosidase | 04.00 | 20.000 | 134.90 (118.30) |
| 4446 | Seminal fluid fructose | 04.00 | 3.150 | 21.20 (18.60) |
| 4447 | Seminal fluid: Acid phosphatase | 04.00 | 5.180 | 34.90 (30.60) |
| lmmur | ology | : | 11 1 1 1 1 1 1 1 | |
| 4448 | HCG: Latex agglutination: Qualitative (side room) | 04.00 | 4.000 | 27.00 (23.70) |
| 4449 | HCG: Latex agglutination: Semi-quantitative (side room) | 04.00 | 9.310 | 62.80 (55.10) |
| 4450 | HCG: Monoclonal immunological: Qualitative | 04.00 | 10.000 | 67.50 (59.20) |
| 44 51 | HCG: Monoclonal immunological: Quantitative | 04.00 | 12.400 | 83.60 (73.30) |
| 4455 | Anti IgE receptor antibody test (10 samples and dilution) | 04.00 | 161.560 | 1089.70 (955.90) |
| 4456 | Eosinophil cationic protein | 04.00 | 27.810 | 187.60 (164.60) |
| 4457 | Mast cell tryptase | 04.00 | 96.870 | 653.40 (573.20) |
| 4458 | Micro-albuminuria: Radio-isotope method | 04.00 | 12.420 | 83.80 (73.50) |
| 4459 | Acetyl choline receptor antibody | 04.00 | 158.120 | 1066.50 (935.50) |
| 4460 | CA-199 tumour marker | 04.00 | 20.000 | 134.90 (118.30) |
| 4462 | CA-125 tumour marker | 04.00 | 20.000 | 134.90 (118.30) |
| 4463 | C6 complement functional essay | 04.00 | 45.00 0 | 303.50 (266.20) |
| 4464 | House dust mite antigen ELIZA | 04.00 | 20.310 | 137.00 (120.20) |
| 4466 | Beta-2-microglobulin | 04.00 | 12.420 | 83.80 (73.50) |
| 4468 | CA-549 | 04.00 | 20.000 | 134.90 (118.30) |
| 4469 | Tumour markers: Monoclonal immunological (each) | 04.00 | 20.000 | 134.90 (118.30) |
| 4470 | CA-195 tumour marker | 04.00 | 20.000 | 134.90 (118.30) |
| 4471 | Carcino-embryonic antigen | 04.00 | 20.000 | 134.90 (118.30) |
| 4472 | MCA antigen turnour marker | 04.00 | 20.000 | 134.90 (118.30) |
| 4476 | Neopterin | 04.00 | 20.000 | 134.90 (118.30) |
| 4477 | Neuron specific enolase | 04.00 | 20.000 | 134.90 (118.30) |
| 4479 | Vitamin B12-absorption: Shilling test | 04.00 | 11.700 | 78.90 (69.20) |
| 4480 | Serotonin | 04.00 | 18.750 | 126.50 (111.00) |
| 4482 | Free thyroxine (FT4) | 04.00 | 17.480 | 117.90 (103.40) |

| Code | Description | Ver | Add | Medical | Technology |
|--------------|--|-------|-----|---------|--------------------|
| Coue | and out special | | | RVU | Fee |
| 4485 | Insulin | 04.00 | | 12.420 | 83.80 (73.50) |
| 4490 | Releasing hormone response | 04.00 | | 50.000 | 337.30 (295.90) |
| 4491 | Vitamin B12 | 04.00 | | 12.420 | 83.80 (73.50) |
| 4492 | Vitamin D3: Calcitroil (RIA) | 04.00 | | 75.000 | 505.90 (443.80) |
| 4493 | Drug concentration: Quantitative | 04.00 | | 12.420 | 83.80 (73.50) |
| 4494 | Free hormone assay | 04.00 | | 17.480 | 117.90 (103.40) |
| 4495 | Growth hormone | 04.00 | | 12.420 | 83.80 (73.50) |
| 4496 | Hormone concentration: Quantitative | 04.00 | | 12.420 | 83.80 (73.50) |
| 4497 | Carbohydrate deficient transferrin | 04.00 | | 29.060 | 196.00 (171.90) |
| 4499 | Cortisol | 04.00 | | 12.420 | 83.80 (73.50) |
| 4500 | DHEA sulphate | 04.00 | | 12.420 | 83.80 (73.50) |
| 4501 | Testosterone | 04.00 | | 12.420 | 83.80 (73.50) |
| 4502 | Free testosterone | 04.00 | | 17.480 | 117.90 (103.40) |
| 4503 | Oestradiol | 04.00 | | 12.420 | 83.80 (73.50) |
| 4505 | Oestriol | 04.00 | | 10.800 | |
| 4506 | Multiple antigen specific IgE screening test for Atopy | 04.00 | | 37.260 | 251.30 (220.40) |
| 4507 | Thyrotropin (TSH) | 04.00 | | 19.600 | 132.20 (116.00) |
| 4508 | Combined antigen specific IgE | 04.00 | | 24.480 | 165.10 (144.80) |
| 4509 | Free tri-iodothyronine (FT3) | 04.00 | | 17.480 | 117.90 (103.40) |
| 4512 | Parathormone | 04.00 | | 17.080 | 115.20 (101.10) |
| 4513 | IgE: Total | 04.00 | | 12.420 | 83.80 (73.50) |
| 4 514 | Antigen specific IgE | 04.00 | | 12.420 | 83.80 (73.50) |
| 4515 | Aldosterone | 04.00 | | 12.420 | 83.80 (73.50) |
| 4516 | Follitropin (FSH) | 04.00 | | 12.420 | 83.80 (73.50) |
| 4517 | Lutropin (LH) | 04.00 | | 12.420 | |
| 4519 | Prostate specific antigen | 04.00 | | 14.490 | |
| 4520 | 17 Hydroxy progesterone | 04.00 | | 12.420 | 83.80 (73.50) |
| 4521 | Progesterone | 04.00 | | 12.420 | 83.80 (73.50) |
| 4522 | Alpha-feto protein | 04.00 | | 12.420 | 83.80 (73.50) |
| 4523 | ACTH | 04.00 | | 21.740 | 146.60 (128.60) |
| 4526 | Sex hormone binding globulin | 04.00 | | 12.420 | 83.80 (73.50) |
| 4527 | Gastrin | 04.00 | | 12.420 | |
| 4528 | Ferritin | 04.00 | | 12.420 | 83.80 (73.50) |
| 4529 | Anti-DNA antibodies | 04.00 | | 12.420 | |
| 4530 | Antiplatelet antibodies | 04.00 | | 15.300 | |

| Code | Description | Ver | Add | Medical | Technology |
|---------|---|-------|-----|---------|-----------------------------|
| | | | | RVU | Fee |
| 4531 | Hepatitis: Per antigen or antibody | 04.00 | | 14.490 | 97.70 (85.7 0) |
| 4532 | Transcobalamine | 04.00 | | 12.420 | 83.80 (73.50) |
| 4533 | Folic acid | 04.00 | | 12.420 | 83.80 (73.50) |
| 4534 | Prostatic acid phosphatase | 04.00 | | 12.420 | 83.80 (73.50) |
| 4536 | Erythrocyte folate | 04.00 | | 17.480 | 117.90 (103.40) |
| 4537 | Prolactin | 04.00 | | 12.420 | 83.80 (73.50) |
| 4540 | HCG: Quantitative as used for Down's screen | 04.00 | | 15.000 | 101.20 (88.80) |
| Clinica | pathology: Miscellaneous | | | | |
| 4544 | Attendance in theatre | 04.00 | | 27.000 | 1 82 .10 (159.70) |
| | tive cytology | | | | |
| 4561 | Sputum, all body fluids and tumour aspirates: First unit | 04.00 | | 13.400 | 104.20 (91.40) |
| 4563 | Sputum, all body fluids and turnour aspirates: Each additional unit | 04.00 | | 7.800 | 60.70 (5 <u>3.20)</u> |
| 4564 | Performance of fine-needle aspiration for cytology | 04.00 | | 15.000 | 116.70 (102.40) |
| 4565 | Examination of fine needle aspiration in theatre | 04.00 | | 90.000 | 700.10 (614.10) |
| 4566 | Vaginal or cervical smears, each | 04.00 | | 11.000 | 85.60 (75.10) |
| | Genetics | | | | |
| Cytoge | | 1 | | | : |
| 4750 | Cell culture: Lymphocytes, cord blood | 04.00 | | 15.000 | 103.60 (90.90) |
| 4751 | Cell culture: Amniotic fluid, fibroblasts, leukaemia bloods, bone marrow, other specialised cultures | 04.00 | | 45.000 | 310.80 (272.60) |
| 4752 | Cell culture: Chorionic villi | 04.00 | | 60.000 | 414.40 (363.50) |
| 4754 | Cytogenetic analysis: Lymphocytes: Idiograms, karyotyping, one staining technique | 04.00 | | 135.000 | 932.40 (817.90) |
| 4755 | Cytogenetic analysis: Amniotic fluid, fibroblasts, chorionic villi, products of conception, bone marrow, leukamia bloods: Idiograms, karyotyping, one straining technique | 04.00 | | 270.000 | 1864.90 (1635.90) |
| 4757 | Specified additional analysis e.g. mosaicism, Fanconi anaemia, Fra X, additional staining techniques | | | 70.000 | 483.50 (424.10) |
| 4760 | FISH procedure, including cell culture | 04.00 | | 115.000 | 794.30 (696.80) |
| 4761 | FISH analysis per probe system | 04.00 | | 35.000 | 241.70 (212.00 <u>)</u> |
| DNA-te | | T | · | | |
| 4763 | Blood: DNA extraction | 04.00 | | 45.000 | 310.80 (272.60) |
| 4764 | Blood: Genotype per person: Southern blotting | 04.00 | | 89.000 | 614.70 (539.20) |
| 4765 | Blood: Genotype per person: PCR | 04.00 | _ | 60.000 | 414.40 (363.50) |
| 4767 | Prenatal diagnosis: Amniotic fluid or chorionic tissue: DNA extraction | 04.00 | | 90.000 | 621.60 (545.30) |
| 4768 | Prenatal diagnosis: Amniotic fluid or chorionic tissue: Genotype per person: Southern blotting | 04.00 | j | 188.000 | 1298.50 (1139.00) |
| 4769 | Prenatal diagnosis: Amniotic fluid or chorionic tissue: Genotype per person: PCR | 04.00 | | 120.000 | 828.80 (727.00) |

| TECHNOLOGISTS, WI The following reference and/or providers. It is rat individually determine be charged to patients. Med respect of a particular he reference price list. It is funders and individual he balance billing against m | THE FECT FROM 1 JANUARY 2008 THE FECT FROM 1 JANUARY 2008 The intended to serve as a baseline against which medical schemes can nefit levels and health service providers can individually determine fees lical schemes may, for example, determine in their rules that their benefit in earth service is equivalent to a specified percentage of the national health especially intended to serve as a basis for negotiation between individual earth care providers with a view to facilitating agreements which will minimise tembers of medical schemes. Should individual medical schemes wish to | Version | Add | CF | Units | BF | Value | Flag |
|---|--|---------|------------|-----|-------|----------|-------|--------|
| The following reference and/or providers. It is rat individually determine be charged to patients. Mecrespect of a particular he reference price list. It is funders and individual he balance billing against m | price list is not a set of tariffs that must be applied by medical schemes ther intended to serve as a baseline against which medical schemes can inefit levels and health service providers can individually determine fees lical schemes may, for example, determine in their rules that their benefit in ealth service is equivalent to a specified percentage of the national health especially intended to serve as a basis for negotiation between individual ealth care providers with a view to facilitating agreements which will minimise | | Add | CF | Units | BF | Value | Flag |
| and/or providers. It is rat individually determine be charged to patients. Med respect of a particular he reference price list. It is funders and individual he balance billing against m | her intended to serve as a baseline against which medical schemes can nefit levels and health service providers can individually determine fees lical schemes may, for example, determine in their rules that their benefit in ealth service is equivalent to a specified percentage of the national health especially intended to serve as a basis for negotiation between individual ealth care providers with a view to facilitating agreements which will minimise | | | | | | | |
| individually determine be charged to patients. Med respect of a particular he reference price list. It is funders and individual he balance billing against m | nefit levels and health service providers can individually determine fees lical schemes may, for example, determine in their rules that their benefit in ealth service is equivalent to a specified percentage of the national health especially intended to serve as a basis for negotiation between individual ealth care providers with a view to facilitating agreements which will minimise | | | | | | | |
| charged to patients. Med respect of a particular he reference price list. It is funders and individual he balance billing against m | lical schemes may, for example, determine in their rules that their benefit in eaith service is equivalent to a specified percentage of the national health especially intended to serve as a basis for negotiation between individual eaith care providers with a view to facilitating agreements which will minimise | | | | | | | |
| respect of a particular he reference price list. It is funders and individual hi balance billing against m | ealth service is equivalent to a specified percentage of the national health especially intended to serve as a basis for negotiation between individual ealth care providers with a view to facilitating agreements which will minimise | | | | | ΙÏ | | |
| reference price list. It is funders and individual he balance billing against m | especially intended to serve as a basis for negotiation between individual ealth care providers with a view to facilitating agreements which will minimise | | | ll | | | | 1 1 |
| funders and individual he balance billing against m | ealth care providers with a view to facilitating agreements which will minimise | | | | | 1 1 | | 1 [|
| balance billing against m | | | | | | ΙI | | 1 1 |
| | lembers of medical schemes. Should individual medical schemes wish to | ı | i 1 | | | ΙI | | 1 1 |
| | ires, and individual providers determine fee structures, on some other basis | | | l | | ΙI | | 1 1 |
| | ist, they may do so as well. | | | ı | | Ιİ | | 1 1 |
| | in this schedule, the following rounding method is used: Values R10 and | | | ll | | ΙI | | 1 1 |
| | arest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded | 2004.00 | | | | ΙI | | 1 1 |
| Preamble | And some tree to the new out to the lines of the cur and the Adides are localided | 2007.00 | \vdash | | | ╅ | | + |
| | when such benefits are granted, the following should be clearly specified in | | | | | 1 1 | | \top |
| the scheme's rules. 🗆 | | | l | 1 1 | | ΙI | | 1 1 |
| | | l | | 1 | | 1 1 | | 1 1 |
| - Services must only be | on referral | 2004.00 | | | | Ш | | |
| General Rules | | | | | | | | |
| | cquaint him-/herself with the provisions of the Medical Schemes Act, and | | | | | | | 1 1 |
| | ted under the Act and shall render a monthly account in respect of any | | | | | | | 1 1 |
| service rendered. NB: E | very account shall contain the following particulars: | | | | | | | |
| The account or statemen | nt contemplated in section 59(1) of the Act must contain the following - | | | | | | | 11 |
| (a)⊟The surname and in | | | l | | | 1 1 | | 1 1 |
| (b) □the surname, first n | ame and other initials, if any, of the patient; | | l . | | | ll | | 1 1 |
| (c) the name of the sch | eme concerned; | l | | l | | ΙI | | 1 1 |
| (d) □the membership nu | mber of the member; | l | | l | | 1 1 | | 1 1 |
| (e) □the practice code no | mber, group practice number and individual provider registration number | l | | | | ΙI | | 1 1 |
| issued by the registering | authorities for providers, if applicable, of the supplier of service and, in the | | | | | 1 1 | | 1 1 |
| case of a group practice | , the name of the practitioner who provided the service; | i | | | | 1 1 | | 1 1 |
| (f) □the relevant diagnos | tic and such other item code numbers that relates to such relevant health | l | | | | ΙI | | 1 1 |
| service; | | l | | Ιí | | H | | 1 1 |
| 147 | ach relevant health service was rendered; | | | | | | | |
| | of each relevant health service rendered, including the supply of medicine | | | | | | | |
| | d or to a dependant of that member; and the name, quantity and dosage of a | | | Щ | | \sqcup | | |
| | be distributed to doctors and no group tests will be carried out. | 2004.00 | <u> </u> | Щ | | \vdash | | + |
| No charge to be raised in | respect of services such as sample handling and after hours services. | 2004.00 | | | | | | 1 |
| | or collecting of specimens shall be limited to those specimens that are | 2004.00 | | | | \vdash | | + |
| | such as sputum and urine and taking of venous and peripheral blood. | 2005.02 | | | | | | |

| | It is recommended that, when such benefits are granted, drugs, consumables and disposable items | | | | | | | \neg |
|------|--|----------|-----|--------|-----|---|--------|--------|
| | used during a procedure or issued to a patient on discharge will only be reimbursed by a medical | | | | | | | |
| 005 | scheme if the appropriate code is supplied on the account. | 2004.00 | | | | | | |
| | Haematology | 200 1100 | + + | | | | | \neg |
| 3705 | Alkali resistant haemoglobin | 2004,00 | 350 | 4.500 | 1.0 | R | 30.40 | ヿ |
| | Antiglobulin test (Coombs' or trypsinzied red cells) | 2004.00 | 350 | 3,650 | 1.0 | _ | 24.60 | \neg |
| 3710 | Antibody titration | 2004.00 | 350 | 7.200 | | | 48.60 | ヿ |
| 3711 | Ameth count | 2004.00 | 350 | 2.250 | 1.0 | | 15.20 | \neg |
| | Antibody identification | 2004.00 | 350 | 8.450 | 1.0 | | 57.00 | \neg |
| 3713 | Bleeding time (does not include the cost of the simplate device) | 2004.00 | 350 | 6.940 | | | 46.80 | \neg |
| | Blood volume, dye method | 2004.00 | 350 | 7.200 | 1.0 | R | 48.60 | |
| 3715 | Buffy layer examination | 2004.00 | 350 | 19.900 | 1.0 | R | 134.20 | \neg |
| | Bone marrow cytological examination only | 2004.00 | 350 | 19.900 | 1.0 | R | 134.20 | |
| 3722 | Capillary fragility: Hess | 2004.00 | 350 | 2.020 | 1.0 | R | 13.60 | |
| 3723 | Circulating anticoagulants | 2004.00 | 350 | 5.850 | 1.0 | R | 39.50 | \neg |
| 3724 | Coagulation factor inhibitor assay | 2004.00 | 350 | 57.560 | 1.0 | R | 388,20 | \neg |
| 3726 | Activated protein C resistance | 2004.00 | 350 | 26.000 | 1.0 | R | 175.40 | \Box |
| 3727 | Coagulation time | 2004.00 | 350 | 3.160 | 1.0 | R | 21.30 | |
| 3729 | Cold agglutinins | 2004.00 | 350 | 3.600 | 1.0 | R | 24.30 | |
| 3730 | Protein S: Functional | 2004.00 | 350 | 37.500 | 1.0 | R | 252.90 | \neg |
| 3731 | Compatibility for blood transfusion | 2004.00 | 350 | 3.600 | 1.0 | R | 24.30 | |
| 3732 | Cryoglobulin | 2004.00 | 350 | 3.600 | 1.0 | R | 24.30 | |
| 3734 | Protein C (chromogenic) | 2004.00 | 350 | 30.290 | | R | 204.30 | |
| 3735 | Anti-thrombin III (chromogenic) | 2004.00 | 350 | 22.000 | | ĸ | 148,40 | |
| 3736 | Plasminogen (chromogenic) | 2004.00 | 350 | 61.650 | | R | 415,80 | |
| 3737 | Lupus Russel Viper method | 2004.00 | 350 | 17.000 | | ĸ | 114.70 | i |
| 3738 | Lupus Kaolin Exner method | 2004.00 | 350 | 25.000 | 1.0 | α | 168.60 | |
| 3739 | Erythrocyte count | 2004.00 | 350 | 2.250 | 1.0 | æ | 15.20 | |
| 3740 | Factors V and VII: Qualitative | 2004.00 | 350 | 7.200 | | | 48.60 | |
| 3741 | Coagulation factor assay: Functional | 2004.00 | 350 | 9.450 | | R | 63.70 | |
| 3742 | Coagulation factor assay: Immunological | 2004.00 | 350 | 4.500 | | | 30.40 | |
| 3743 | Erythrocyte sedimentation rate | 2004.00 | 350 | 3.000 | _ | R | 20.20 | |
| 3744 | Fibrin stabilizing factor (urea test) | 2004.00 | 350 | 4.500 | | R | 30.40 | |
| 3746 | Fibrin monomers | 2004.00 | 350 | 2.700 | | | 18.20 | |
| 3751 | Osmotic fragility (screen) | 2004.00 | 350 | 2.250 | | | 15.20 | |
| 3752 | Osmotic fragility test: Quantitative | 2004.00 | 350 | 10.000 | | | 67.50 | ш |
| 3753 | Osmotic fragility (before and after incubation) | 2004.00 | 350 | 18.000 | | | 121.40 | لـــا |
| 3755 | Full blood count (including items 3739, 3762, 3783, 3785, 3791) | 2004.00 | 350 | 10.500 | | | 70.80 | |
| | Full cross match | 2004.00 | 350 | 7.200 | | | _48.60 | Ш |
| 3757 | Coagulation factors: Quantitative | 2004.00 | 350 | | | | 217.20 | |
| 3758 | Factor VIII related antigen | 2004.00 | 350 | | _ | _ | 407.80 | Ш |
| 3759 | Coagulation factor correction study | 2004.00 | 350 | 11.720 | | | 79.10 | Ш |
| 3762 | Haemoglobin estimation | 2004.00 | 350 | 1.800 | | | 12.10 | Ш |
| 3763 | Contact activated product assay | 2004.00 | 350 | | _ | | 109.30 | Ш |
| 3764 | Grouping: A B and O antigens | 2004.00 | 350 | 3.600 | 1.0 | R | 24.30 | Ш |

| 3765 | Grouping: Rh antigen | 2004.00 | 350 | 3.600 1.0 R | 24.30 |
|--------------|---|---------|-----|--------------|--------|
| 3767 | Euglobulin Lysis time | 2004.00 | 350 | 25.580 1.0 R | 172.50 |
| | Haemoglobin A2 (column chromatography) | 2004.00 | 350 | 15.000 1.0 R | 101.20 |
| | Haemoglobin electrophoresis | 2004.00 | 350 | 26.820 1.0 R | 180.90 |
| | Haemoglobin-S (solubility test) | 2004.00 | 350 | 3.600 1.0 R | 24.30 |
| | Factor III-availability test | 2004.00 | 350 | 5.850 1.0 R | 39,50 |
| | Haptoglobin: Quantitative | 2004.00 | 350 | 9.450 1.0 R | 63.70 |
| | Ham's acidified serum test | 2004.00 | 350 | 8.000 1.0 R | 54.00 |
| | Heinz bodies | 2004.00 | 350 | 2.250 1.0 R | 15.20 |
| | Haemosiderin in urinary sediment | 2004.00 | 350 | 2.250 1.0 R | 15.20 |
| 3781 | Heparin tolerance | 2004.00 | 350 | 7.200 1.0 R | 48.60 |
| 3783 | Leucocyte differential count | 2004.00 | 350 | 6.200 1.0 R | 41.80 |
| 3785 | Leucocytes: Total count | 2004.00 | 350 | 1.800 1.0 R | 12.10 |
| 3786 | QBC malaria concentration and fluorescent staining | 2004.00 | 350 | 25.000 1.0 R | 168,60 |
| | LE-cells | 2004.00 | 350 | 8.300 1.0 R | 56.00 |
| | | 2004.00 | 350 | 28.000 1.0 R | 188.90 |
| | Neutrophil alkaline phosphatase | 2004.00 | 350 | 1.800 1.0 R | 12.10 |
| | Packed cell volume: Haematocrit | 2004.00 | 350 | 9.000 1.0 R | 60.70 |
| | Plasmodium falciparum: Monoclonal immunological identification | 2004.00 | 350 | 6.750 1.0 R | 45.50 |
| | Plasma haemoglobin | | 350 | 12.140 1.0 R | 81.90 |
| | Platelet aggregation per aggregant | 2004.00 | | | |
| 3796 | Platelet antibodies: Agglutination | 2004.00 | 350 | 5.400 1.0 R | 36.40 |
| 3797 | Platelet count | 2004.00 | 350 | 2.250 1.0 R | 15.20 |
| 3799 | Platelet adhesiveness | 2004.00 | 350 | 4.500 1.0 R | 30.40 |
| 3801 | Prothrombin consumption | 2004.00 | 350 | 5.850 1.0 R | 39.50 |
| 3803 | Prothrombin determination (two stages) | 2004.00 | 350 | 5.850 1.0 R | 39.50 |
| | Prothrombin index | 2004.00 | 350 | 6.000 1.0 R | 40.50 |
| 3806 | Therapeutic drug level: Dosage | 2004.00 | 350 | 4.500 1.0 R | 30.40 |
| | Recalcification time | 2004.00 | 350 | 2.250 1.0 R | 15.20 |
| | Reticulocyte count | 2004.00 | 350 | 3.000 1.0 R | 20.20 |
| 381 <u>0</u> | Schumm's test | 2004.00 | 350 | 3.600 1.0 R | 24.30 |
| 3811 | Sickling test | 2004.00 | 350 | 2.250 1.0 R | 15.20 |
| 3814 | Sucrose lysis test for PNH | 2004.00 | 350 | 3.600 1.0 R | 24.30 |
| 3816 | T and B-cells EAC markers (limited to ONE marker only for CD4/8 counts) | 2004.00 | 350 | 21.100 1.0 R | 142.30 |
| 3820 | Thrombo - Elastogram | 2004.00 | 350 | 26.000 1.0 R | 175.40 |
| 3825 | Fibrinogen titre | 2004.00 | 350 | 3.600 1.0 R | 24.30 |
| 3829 | Glucose 6-phosphate-dehydrogenase: Qualitative | 2004.00 | 350 | 8.000 1.0 R | 54.00 |
| | Glucose 6-phosphate-dehydrogenase: Quantitative | 2004.00 | 350 | 16.000 1.0 R | 107.90 |
| 3832 | Red cell pyruvate kinase: Quantitative | 2004.00 | 350 | 16.000 1.0 R | 107.90 |
| 3834 | Red cell Rhesus phenotype | 2004.00 | 350 | 9.900 1.0 R | 66.80 |
| 3835 | Haemoglobin F in blood smear | 2004.00 | 350 | 5.850 1.0 R | 39.50 |
| 3837 | Partial thromboplastin time | 2004.00 | 350 | | 39.50 |
| 3841 | Thrombin time (screen) | 2004.00 | 350 | 7.160 1.0 R | 48.30 |
| 3843 | Thrombin time (serial) | 2004.00 | 350 | | 51.60 |
| 3847 | Haemoglobin H | 2004.00 | 350 | 2.250 1.0 R | 15.20 |
| 3851 | Fibrin degeneration products (diffusion plate) | 2004.00 | 350 | | 69.80 |
| | · · · · · · · · · · · · · · · · · · · | | | | |

33

| 3555 MP (Dimer test or equivalent latex side test) 2004.00 350 8.500 1.0 R 57.30 3855 3 | 3853 | Fibrin degeneration products (latex slide) | 2004.00 | 13 | 50 | 4.500 | 10 | R | 30.40 | _ |
|--|---------------|---|----------|-----------------|-----|--------|-----|---|--------|--------|
| Hemagglutination inhibition | | | | | | | | | | ᅱ |
| Microscopic and miscellaneous tests 2004.00 360 1260 1,0 R 85,00 3884 Attornological examination 2004.00 360 20,700 1,0 R 139,60 3885 Entromological examination 2004.00 360 20,700 1,0 R 37,80 3886 Entromological examination 2004.00 360 40,00 1,0 R 37,80 3887 Miscellaneous (body fluids, urine, exudate, fungi, puss, sorapings, etc.) 2004.00 360 40,00 1,0 R 33,10 3886 Flanges (including parasites) 2004.00 360 40,00 1,0 R 33,10 3886 Flanges (including parasites) 2004.00 360 40,00 1,0 R 33,10 3875 Inclusion bodies 2004.00 360 4500 1,0 R 30,40 3876 Chystal identification polarized light microscopy 2004.00 360 4500 1,0 R 30,40 3879 Campylobacter in stool: Fastidious culture 2004.00 360 4500 1,0 R 30,40 3879 Campylobacter in stool: Fastidious culture 2004.00 360 4500 1,0 R 30,40 3881 Mycobacteria 2004.00 360 4500 1,0 R 30,40 3881 Mycobacteria 2004.00 360 4500 1,0 R 30,40 3881 Mycobacteria 2004.00 360 30,00 1,0 R 20,20 3882 Affigen detection with monoclonal artibodies 2004.00 360 30,00 1,0 R 20,20 3882 Affigen detection with monoclonal artibodies 2004.00 360 30,00 1,0 R 20,20 3883 Concentration techniques for parasites 2004.00 360 360 1,0 R 20,20 3885 Cytochemical stain 2004.00 360 6,300 1,0 R 20,20 3885 Cytochemical stain 2004.00 360 6,300 1,0 R 20,20 3885 Cytochemical stain 2004.00 360 6,300 1,0 R 20,20 3885 Cytochemical stain 2004.00 360 6,300 1,0 R 30,800 1,0 R 30,800 | | | | | | | | | ᅥ |
| 3863 | - | | 12007.00 | - ` | ~ | 0.000 | 1.0 | Ë | 00.00 | ᅱ |
| Entomological examination 2004.00 350 20,700 1.0 R 139.60 380 380 300 1.0 R 37.80 380 380 380 380 380 380 1.0 R 37.80 380 380 380 380 1.0 R 33.10 380 380 380 380 380 1.0 R 33.10 380 | 3863 | | 2004.00 | - 13 | 50 | 12 600 | 1.0 | R | 85.00 | ㅓ |
| 3885 Parasites in blood smear 2004.00 350 5.00 1.0 R 37.00 | | | | | | | | | | ᅱ |
| | | | | | | | | | | ヿ |
| 3868 Fungus identification 2004.00 350 8.300 1.0 R 55.00 3878 Facese (including parasites) 2004.00 350 4.500 1.0 R 33.10 3878 Facese (including parasites) 2004.00 350 4.500 1.0 R 30.40 3878 2004.00 350 4.500 1.0 R 30.40 3878 2004.00 350 4.500 1.0 R 30.40 3879 2004.00 350 4.500 1.0 R 30.40 3879 2004.00 350 4.500 1.0 R 30.40 3879 2004.00 350 4.500 1.0 R 30.40 3881 Mycobacter in stool culture 2004.00 350 9.900 1.0 R 30.40 3881 Mycobacteria 2004.00 350 3.000 1.0 R 20.20 3883 2004.00 350 3.000 1.0 R 36.80 3884 2004.00 350 3.000 350 3.000 1.0 R 36.80 3884 2004.00 350 3.000 350 3.000 350 3.000 3.0 R 36.80 3884 2004.00 350 3.000 350 3.000 3.0 R 36.80 3884 2004.00 350 3.000 350 3.000 3.0 R 36.80 3884 2004.00 350 3.000 350 3.000 3.0 R 38.80 | | | | | | | | | | ᅱ |
| Sample Paces (Including parasites) 2004.00 350 4.900 1.0 R 33.10 | | | | | | | | | | ᅥ |
| Record R | | | | | | | | | | ┪ |
| 3878 Crystal Identification polarized light microscopy 2004.00 350 4.500 1.0 R 30.40 3379 Campylobacter in stool: Fasticious culture 2004.00 350 350 4.500 1.0 R 66.80 3381 Mycobacteria 2004.00 350 4.500 1.0 R 20.20 3381 Mycobacteria 2004.00 350 3.000 1.0 R 20.20 3382 Artigen detection with monoclonal antibodies 2004.00 350 3.000 1.0 R 20.20 3382 Artigen detection with monoclonal antibodies 2004.00 350 3.000 1.0 R 20.20 3382 Artigen detection with monoclonal antibodies 2004.00 350 3.000 1.0 R 20.20 3382 Artigen detection with monoclonal antibodies 2004.00 350 3.000 1.0 R 20.20 3384 Dark fleid, phase or interference contrast microscopy, Nomarski or Fontana 2004.00 350 3.000 1.0 R 22.50 3885 Cytochemical stain 2004.00 350 5.450 1.0 R 36.80 3885 Artigen detection with monoclonal mimoclogical 2004.00 350 5.450 1.0 R 36.80 3887 Artibiotic susceptibility test: Per organism 2004.00 350 2.700 1.0 R 54.00 3888 Achestive tape preparation 2004.00 350 2.700 1.0 R 38.80 3899 Artibiotic susceptibility test: Per organism 2004.00 350 2.400 1.0 R 38.80 3899 | $\overline{}$ | | | | | | | | | ┪ |
| Campylobacler in stooi; Fastidious culture 2004.00 350 9.900 1.0 R 66.80 3850 Antigen detection with polyclonal antibodies 2004.00 350 4.500 1.0 R 30.40 3881 Mycobacleria 2004.00 350 3.000 1.0 R 20.20 3882 Antigen detection with monoclonal antibodies 2004.00 350 10.800 1.0 R 20.20 3883 Antigen detection with monoclonal antibodies 2004.00 350 10.800 1.0 R 20.20 3884 Dark field, phase or interference contrast microscopy, Nomarski or Fontana 2004.00 350 6.300 1.0 R 20.20 3885 Cytochemical stain 2004.00 350 5.650 1.0 R 36.80 3885 Cytochemical stain 2004.00 350 5.650 1.0 R 36.80 3886 Achesive tage preparation 2004.00 350 8.000 1.0 R 54.00 3887 Antibiotic susceptibility test: Per organism 2004.00 350 8.000 1.0 R 54.00 3888 Constraintion technique 2004.00 350 2.700 1.0 R 16.20 3889 Achesive tage preparation 2004.00 350 2.700 1.0 R 83.80 3890 Antibiotic assay of tissues and fluids 2004.00 350 13.900 1.0 R 33.80 3891 3892 Bacteriological culture: Aerobic 2004.00 350 5.850 1.0 R 39.50 3893 3893 Bacteriological culture: Miscellaneous 2004.00 350 5.850 1.0 R 39.50 3893 3893 Bacteriological culture: Miscellaneous 2004.00 350 5.850 1.0 R 39.50 3893 3894 Radiometric blood culture: Bacteria 2004.00 350 6.000 1.0 R 42.50 3898 Bacteriological culture: Bacteria 2004.00 350 6.000 1.0 R 42.50 3898 Bacteriological culture: Bacteria 2004.00 350 6.000 1.0 R 107.90 3898 Bacterial excloxin production (in vitro assay) 2004.00 350 16.000 1.0 R 107.90 3898 Bacterial excloxin production (in vitro assay) 2004.00 350 350 0.10 R 70.90 3908 Bacterial excloxin production (in vitro assay) 2004.00 350 350 0.10 R 70.90 3908 Bacterial excloxin production (in vitro assay) 2004.00 350 350 | | | | | | | | | | ᅱ |
| 3880 | 3879 | Campylobacter in stool: Fastidious culture | | | | | | | | ┪ |
| Antipart extension 2004.00 350 3.000 1.0 R 20.20 20.400 20.400 350 3.400 1.0 R 20.400 20.400 350 3.400 1.0 R 30.80 20.400 350 3.400 2.700 1.0 R 54.00 20.400 350 3.400 2.700 1.0 R 33.60 20.400 350 3.400 2.700 1.0 R 33.60 20.400 350 3.400 2.700 1.0 R 33.60 20.400 350 3.400 2.700 | | | | _ | _ | | | | | ┪ |
| 3882 Antigen detection with monoclonal antibodies 2004.00 350 10.800 1.0 R 72.80 | | | | - 13 | 50 | | | | | ┪ |
| Sample Concentration techniques for parasites 2004.00 350 3.000 1.0 R 20.20 | | | | | | | | | | ヿ |
| Dark field, phase or interference contrast microscopy, Nomarski or Fontana 2004.00 350 6.300 1.0 R 42.50 | | | | | | | | | | \neg |
| Section Sect | 3884 | | | | | | | | | \neg |
| Bacteriology | | | | | 50 | | | | | ヿ |
| 3887 Antibiotic susceptibility test: Per organism 2004.00 350 8.000 1.0 R 54.00 | | Bacteriology | | 一十 | | | | | | ヿ |
| 3888 Adhesive tape preparation 2004.00 350 2.700 1.0 R 18.20 3889 Clostridium difficile toxin: Monoclonal immunological 2004.00 350 12.400 1.0 R 83.60 3890 Antibiotic assay of tissues and fluids 2004.00 350 15.850 1.0 R 93.80 3891 Blood culture: Aerobic 2004.00 350 5.850 1.0 R 39.50 3892 Blood culture: Anaerobic 2004.00 350 5.850 1.0 R 39.50 3893 Bacteriological culture: Miscellaneous 2004.00 350 6.300 1.0 R 42.50 3894 Radiometric blood culture 2004.00 350 10.800 1.0 R 72.80 3895 Bacteriological culture: Fastidious organisms 2004.00 350 10.800 1.0 R 72.80 3895 In vivo culture: Bacterial 2004.00 350 16.000 1.0 R 10.790 3897 In vivo culture: Virus 2004.00 350 16.000 1.0 < | 3887 | Antibiotic susceptibility test: Per organism | 2004.00 | 13 | 50 | 8.000 | 1.0 | R | 54.00 | ヿ |
| 3889 Clostridium difficile toxin: Monoclonal immunological 2004.00 350 12.400 1.0 R 83.60 3890 Antibiotic assay of tissues and fluids 2004.00 350 13.900 1.0 R 39.80 3891 Blood culture: Anaerobic 2004.00 350 5.850 1.0 R 39.50 3892 Blood culture: Anaerobic 2004.00 350 5.850 1.0 R 39.50 3893 Bacteriological culture: Miscelianeous 2004.00 350 6.300 1.0 R 42.50 3894 Radiometric blood culture 2004.00 350 10.800 1.0 R 72.80 3895 Bacteriological culture: Fastidious organisms 2004.00 350 9.900 1.0 R 66.80 3896 In vivo culture: Bacteria 2004.00 350 16.000 1.0 R 107.90 3897 In vivo culture: Virus 2004.00 350 16.000 1.0 R 107.90 3898 Bacterial exotoxin production (in vitro assay) 2004.00 350 4.500 1.0 R 30.40 3899 Bacterial exotoxin production (in vivo assay) 2004.00 350 4.500 1.0 R 30.40 3901 Fungal culture 2004.00 350 4.500 1.0 R 30.40 3902 Clostridium difficile (cytotoxicity neutralisation) 2004.00 350 30.000 1.0 R 202.40 3903 Antibiotic level: Biological fluids 2004.00 350 350 30.00 1.0 R 37.90 3904 Radiometric blood culture 2004.00 350 30.00 350 30.00 1.0 R 37.90 3905 Identification: Chiamydia 2004.00 350 350 4.500 1.0 R 37.90 3905 Identification: Chiamydia 2004.00 350 350 4.500 1.0 R 37.90 3906 Identification: Chiamydia 2004.00 350 4.500 1.0 R 107.90 3908 Anaerobe culture: Comprehensive 2004.00 350 4.500 1.0 R 30.40 3908 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3901 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 3901 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 3901 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 3901 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 3901 Beta-lactamase a | 3888 | Adhesive tape preparation | 2004.00 | | 50 | | | | 18.20 | ヿ |
| Antibiotic assay of tissues and fluids 2004.00 350 13.900 1.0 R 93.80 | 3889 | Clostridium difficile toxin: Monoclonal immunological | 2004.00 | 7 | 50 | 12.400 | 1.0 | R | 83.60 | П |
| Blood culture: Anaerobic 2004.00 350 5.850 1.0 R 39.50 3893 Bacteriological culture: Miscellaneous 2004.00 350 6.300 1.0 R 42.50 3894 Radiometric blood culture 2004.00 350 10.800 1.0 R 72.80 3895 Bacteriological culture: Fastidious organisms 2004.00 350 9.900 1.0 R 66.80 3896 In vivo culture: Bacterial 2004.00 350 16.000 1.0 R 107.90 3897 In vivo culture: Virus 2004.00 350 4.500 1.0 R 107.90 3898 Bacterial exotoxin production (in vitro assay) 2004.00 350 4.500 1.0 R 30.40 3899 Bacterial exotoxin production (in vivo assay) 2004.00 350 4.500 1.0 R 30.40 3901 Fungal culture 2004.00 350 4.500 1.0 R 30.40 3902 Clostridium difficile (cytotoxicity neutralisation) 2004.00 350 30.000 1.0 R 202.40 3903 Antibiotic level: Biological fluids 2004.00 350 350 30.000 1.0 R 78.90 3904 Rotavirus latex silde test 2004.00 350 350 350 350 30.00 1.0 R 37.90 3905 Identification of virus or rickettsja 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 20.700 1.0 R 139.60 3907 Culture for staphylococcus aureus 2004.00 350 20.700 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | | 2004.00 | 1 | 50 | 13.900 | 1.0 | R | 93.80 | |
| September Sept | 3891 | Blood culture: Aerobic | 2004.00 | | 50 | 5.850 | 1.0 | R | 39.50 | ╗ |
| 3894 Radiometric blood culture 2004.00 350 10.800 1.0 R 72.80 3895 Bacteriological culture: Fastidious organisms 2004.00 350 9.900 1.0 R 66.80 3896 In vivo culture: Bacteria 2004.00 350 16.000 1.0 R 107.90 3897 In vivo culture: Virus 2004.00 350 16.000 1.0 R 107.90 3898 Bacterial exotoxin production (in vitro assay) 2004.00 350 4.500 1.0 R 107.90 3899 Bacterial exotoxin production (in vivo assay) 2004.00 350 20.700 1.0 R 139.60 3901 Fungal culture 2004.00 350 4.500 1.0 R 139.60 3901 Fungal culture 2004.00 350 4.500 1.0 R 139.60 3901 Fungal culture 2004.00 350 4.500 1.0 R 30.40 3902 Clostridium difficile (cytotoxicity neutralisation) 2004.00 350 30.000 1.0 R | 3892 | Blood culture: Anaerobic | 2004.00 | 7 | 50 | 5.850 | 1.0 | R | 39.50 | \neg |
| Sasteriological culture: Fastidious organisms 2004.00 350 9.900 1.0 R 66.80 | 3893 | Bacteriological culture: Miscellaneous | 2004.00 | 7 | 50 | 6.300 | 1.0 | R | 42.50 | П |
| 3896 In vivo culture: Bacteria 2004.00 350 16.000 1.0 R 107.90 3897 In vivo culture: Virus 2004.00 350 16.000 1.0 R 107.90 3898 Bacterial exotoxin production (in vitro assay) 2004.00 350 4.500 1.0 R 30.40 3899 Bacterial exotoxin production (in vivo assay) 2004.00 350 20.700 1.0 R 139.60 3901 Fungal culture 2004.00 350 4.500 1.0 R 30.40 3902 Clostridium difficile (cytotoxicity neutralisation) 2004.00 350 30.000 1.0 R 202.40 3903 Antibiotic level: Biological fluids 2004.00 350 11.700 1.0 R 78.90 3904 Rotavirus latex silide test 2004.00 350 5.620 1.0 R 37.90 3905 Identification of virus or rickettsia 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 2.250 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 4.500 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | 3894 | Radiometric blood culture | 2004.00 | 1 | 50 | 10.800 | 1.0 | R | 72.80 | П |
| 3897 In vivo culture: Virus 2004.00 350 16.000 1.0 R 107.90 3898 Bacterial exotoxin production (in vitro assay) 2004.00 350 4.500 1.0 R 30.40 3899 Bacterial exotoxin production (in vivo assay) 2004.00 350 20.700 1.0 R 139.60 3901 Fungal culture 2004.00 350 4.500 1.0 R 30.40 3902 Clostridium difficile (cytotoxicity neutralisation) 2004.00 350 30.000 1.0 R 202.40 3903 Antibiotic level: Biological fluids 2004.00 350 11.700 1.0 R 78.90 3904 Rotavirus latex slide test 2004.00 350 5.620 1.0 R 37.90 3905 Identification of virus or rickettsia 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 16.000 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 4.500 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | | 2004.00 | 1 | 50 | 9.900 | 1.0 | R | 66.80 | |
| 3898 Bacterial exotoxin production (in vitro assay) 2004.00 350 4.500 1.0 R 30.40 3899 Bacterial exotoxin production (in vivo assay) 2004.00 350 20.700 1.0 R 139.60 3901 Fungal culture 2004.00 350 4.500 1.0 R 30.40 3902 Clostridium difficile (cytotoxicity neutralisation) 2004.00 350 30.000 1.0 R 202.40 3903 Antibiotic level: Biological fluids 2004.00 350 11,700 1.0 R 78.90 3904 Rotavirus latex silde test 2004.00 350 5.620 1.0 R 37.90 3905 Identification of virus or rickettsia 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 16.000 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 4.500 | | In vivo culture: Bacteria | 2004.00 | | 50 | 16.000 | 1.0 | R | 107.90 | |
| 3899 Bacterial exotoxin production (in vivo assay) 2004.00 350 20.700 1.0 R 139.60 3901 Fungal culture 2004.00 350 4.500 1.0 R 30.40 3902 Clostridium difficile (cytotoxicity neutralisation) 2004.00 350 30.000 1.0 R 202.40 3903 Antibiotic level: Biological fluids 2004.00 350 11,700 1.0 R 78.90 3904 Rotavirus latex slide test 2004.00 350 5.620 1.0 R 37.90 3905 Identification of virus or rickettsia 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 16.000 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 4.500 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | 3897 | In vivo culture: Virus | 2004.00 | | 50 | 16.000 | 1.0 | R | 107.90 | |
| 3901 Fungal culture 2004.00 350 4.500 1.0 R 30.40 3902 Clostridium difficile (cytotoxicity neutralisation) 2004.00 350 30.000 1.0 R 202.40 3903 Antibiotic level: Biological fluids 2004.00 350 11.700 1.0 R 78.90 3904 Rotavirus latex silde test 2004.00 350 5.620 1.0 R 37.90 3905 Identification of virus or rickettsia 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 16.000 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 9.900 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | Bacterial exotoxin production (in vitro assay) | | | | | | | | |
| 3902 Clostridium difficile (cytotoxicity neutralisation) 2004.00 350 30,000 1.0 R 202.40 3903 Antibiotic level: Biological fluids 2004.00 350 11,700 1.0 R 78.90 3904 Rotavirus latex slide test 2004.00 350 5.620 1.0 R 37.90 3905 Identification of virus or rickettsia 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 16.000 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 9.900 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | | 2004.00 | | | | | | 139.60 | |
| 3903 Antibiotic level: Biological fluids 2004.00 350 11,700 1.0 R 78.90 3904 Rotavirus latex slide test 2004.00 350 5.620 1.0 R 37.90 3905 Identification of virus or rickettsia 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 16.000 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 9.900 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | | | | | | | | 30,40 | |
| 3904 Rotavirus latex slide test 2004.00 350 5.620 1.0 R 37.90 3905 Identification of virus or rickettsia 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 16.000 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 9.900 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | 3902 | Clostridium difficile (cytotoxicity neutralisation) | 2004.00 | | - | 30,000 | 1.0 | R | 202.40 | |
| 3905 Identification of virus or rickettsia 2004.00 350 20.700 1.0 R 139.60 3906 Identification: Chlamydia 2004.00 350 16.000 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 9.900 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | Antibiotic level: Biological fluids | 2004.00 | | _ | | | | 78.90 | \Box |
| 3906 Identification: Chiamydia 2004.00 350 16.000 1.0 R 107.90 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 9.900 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | | | | | | | | 37.90 | |
| 3907 Culture for staphylococcus aureus 2004.00 350 2.250 1.0 R 15.20 3908 Anaerobe culture: Comprehensive 2004.00 350 9.900 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | Identification of virus or rickettsia | 2004.00 | | | | | | 139.60 | |
| 3908 Anaerobe culture: Comprehensive 2004.00 350 9.900 1.0 R 66.80 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | Identification: Chlamydia | 2004.00 | | | 16.000 | 1.0 | æ | 107.90 | |
| 3909 Anaerobe culture: Limited procedure 2004.00 350 4.500 1.0 R 30.40 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | | | | | | | | | |
| 3911 Beta-lactamase assay 2004.00 350 4.500 1.0 R 30.40 | | | | | | | | | 66.80 | |
| | | | 2004.00 | | | 4.500 | 1.0 | R | 30.40 | |
| 3914 Sterility control test: Biological method 2004.00 350 4.500 1.0 R 30.40 | | | 2004.00 | | _ | 4.500 | 1.0 | R | | |
| | | Sterility control test: Biological method | 2004.00 | | | 4.500 | 1.0 | R | 30.40 | |
| 3915 Mycobacterium culture 2004.00 350 4.500 1.0 R 30.40 | | | 2004.00 | : | 350 | 4.500 | 1.0 | R | | |

| 3917 Mycoplasma culture: Limited 2004.00 350 2.250 1.0 R | 15.20 66.80 66.80 139.60 9.11 21.20 84.30 21.20 68.80 49.20 25.60 94.40 168.60 |
|--|--|
| 3918 Mycoplasma culture: Comprehensive 2004.00 350 9.900 1.0 R 3919 Identification of mycobacterium 2004.00 350 9.900 1.0 R 3920 Mycobacterium: Antibiotic sensitivity 2004.00 350 9.900 1.0 R 3921 Antibiotic synergistic study 2004.00 350 20.700 1.0 R 3922 Vlable cell count 2004.00 350 1.350 1.0 R 3923 Biochemical identification of bacterium: Abridged 2004.00 350 3.150 1.0 R 3924 Biochemical identification of bacterium: Extended 2004.00 350 3.150 1.0 R 3925 Serological identification of bacterium: Extended 2004.00 350 3.150 1.0 R 3926 Serological identification of bacterium: Extended 2004.00 350 3.150 1.0 R 3927 Grouping for streptococci 2004.00 350 3.500 1.0 R </td <td>66.80 139.60 9.11 21.20 84.30 21.20 68.80 49.20 25.60 94.40 168.60</td> | 66.80 139.60 9.11 21.20 84.30 21.20 68.80 49.20 25.60 94.40 168.60 |
| 3920 Mycobacterium: Antibiotic sensitivity 2004.00 350 9.900 1.0 R 3921 Antibiotic synergistic study 2004.00 350 20.700 1.0 R 3922 Vable cell count 2004.00 350 1.350 1.0 R 3923 Biochemical identification of bacterium: Abridged 2004.00 350 3.150 1.0 R 3924 Biochemical identification of bacterium: Extended 2004.00 350 3.150 1.0 R 3925 Serological identification of bacterium: Abridged 2004.00 350 3.150 1.0 R 3926 Serological identification of bacterium: Extended 2004.00 350 10.200 1.0 R 3927 Grouping for streptococci 2004.00 350 10.200 1.0 R 3928 Antimicrobic substances 2004.00 350 3.800 1.0 R 3929 Radiometric mycobacterium identification 2004.00 350 3.500 1.0 R </td <td>66.80 139.60 9.11 21.20 84.30 21.20 68.80 49.20 25.60 94.40 168.60</td> | 66.80 139.60 9.11 21.20 84.30 21.20 68.80 49.20 25.60 94.40 168.60 |
| 3920 Mycobacterium: Antibiotic sensitivity 2004.00 350 9.900 1.0 R 3921 Antibiotic synergistic study 2004.00 350 20.700 1.0 R 3922 Vable cell count 2004.00 350 1.350 1.0 R 3923 Biochemical identification of bacterium: Abridged 2004.00 350 3.150 1.0 R 3924 Biochemical identification of bacterium: Extended 2004.00 350 3.150 1.0 R 3925 Serological identification of bacterium: Abridged 2004.00 350 3.150 1.0 R 3926 Serological identification of bacterium: Extended 2004.00 350 10.200 1.0 R 3927 Grouping for streptococci 2004.00 350 10.200 1.0 R 3928 Antimicrobic substances 2004.00 350 3.800 1.0 R 3929 Radiometric mycobacterium identification 2004.00 350 3.500 1.0 R </td <td>139.60 9.11 21.20 84.30 21.20 68.80 49.20 25.60 94.40 168.60</td> | 139.60 9.11 21.20 84.30 21.20 68.80 49.20 25.60 94.40 168.60 |
| 3922 Vlable cell count 2004,00 350 1,350 1,0 R 3923 Blochemical identification of bacterium: Abridged 2004,00 350 3,150 1,0 R 3924 Biochemical identification of bacterium: Extended 2004,00 350 12,500 1,0 R 3925 Serological identification of bacterium: Abridged 2004,00 350 3,150 1,0 R 3926 Serological identification of bacterium: Extended 2004,00 350 10,200 1,0 R 3927 Grouping for streptococci 2004,00 350 7,300 1,0 R 3928 Antimicrobic substances 2004,00 350 7,300 1,0 R 3929 Radiometric mycobacterium identification 2004,00 350 14,000 1,0 R 3930 Radiometric mycobacterium antibiotic sensitivity 2004,00 350 14,000 1,0 R 3931 Helicobacter: Monoclonal immunological 2004,00 350 25,000 1,0 R 4651 Non-radiometric automated blood cultures 2004,00 350 | 9.11 21.20 84.30 21.20 68.80 49.20 25.60 94.40 168.60 |
| 3923 Biochemical identification of bacterium: Abridged 2004.00 350 3.150 1.0 R 3924 Biochemical identification of bacterium: Extended 2004.00 350 12.500 1.0 R 3925 Serological identification of bacterium: Abridged 2004.00 350 3.150 1.0 R 3926 Serological identification of bacterium: Extended 2004.00 350 3.150 1.0 R 3927 Grouping for streptococci 2004.00 350 7.300 1.0 R 3928 Antimicrobic substances 2004.00 350 3.800 1.0 R 3929 Radiometric mycobacterium identification 2004.00 350 3.800 1.0 R 3930 Radiometric mycobacterium antibiotic sensitivity 2004.00 350 25.000 1.0 R 3931 Helicobacter: Monoclonal Immunological 2004.00 350 350 25.000 1.0 R 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 350 350 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 350 15.000 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid a | 21.20 84.30 21.20 68.80 49.20 25.60 94.40 168.60 |
| 3924 Biochemical identification of bacterium: Extended 2004.00 350 12.500 1.0 R 3925 Serological identification of bacterium: Abridged 2004.00 350 3.150 1.0 R 3926 Serological identification of bacterium: Extended 2004.00 350 10.200 1.0 R 3927 Grouping for streptococci 2004.00 350 7.300 1.0 R 3928 Antimicrobic substances 2004.00 350 3.800 1.0 R 3929 Radiometric mycobacterium identification 2004.00 350 3.800 1.0 R 3930 Radiometric mycobacterium antibiotic sensitivity 2004.00 350 25.000 1.0 R 3931 Helicobacter: Monoclonal Immunological 2004.00 350 25.000 1.0 R 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 350 13.900 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 350 15.000 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated antibiotic 2004.00 350 17.000 1.0 R 4654 Rapid automated antibiotic 2004.00 350 17.000 1.0 R 4655 Rapid automated antibiotic 2004.00 350 17.000 1.0 R 4655 Rapid automated antibiotic 2 | 84.30 21.20 68.80 49.20 25.60 94.40 168.60 |
| 3925 Serological identification of bacterium: Abridged 2004.00 350 3.150 1.0 R 3926 Serological identification of bacterium: Extended 2004.00 350 10.200 1.0 R 3927 Grouping for streptococci 2004.00 350 7.300 1.0 R 3928 Antimicrobic substances 2004.00 350 3.800 1.0 R 3929 Radiometric mycobacterium identification 2004.00 350 14.000 1.0 R 3930 Radiometric mycobacterium antibiotic sensitivity 2004.00 350 25.000 1.0 R 3931 Helicobacter: Monoclonal Immunological 2004.00 350 12.400 1.0 R 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 8.000 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 15.000 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 17.000 | 21.20 68.80 49.20 25.60 94.40 168.60 |
| 3926 Serological identification of bacterium: Extended 2004.00 350 10.200 1.0 R 3927 Grouping for streptococci 2004.00 350 7.300 1.0 R 3928 Antimicrobic substances 2004.00 350 3.800 1.0 R 3929 Radiometric mycobacterium identification 2004.00 350 14.000 1.0 R 3930 Radiometric mycobacterium antibiotic sensitivity 2004.00 350 25.000 1.0 R 3931 Helicobacter: Monocional immunological 2004.00 350 12.400 1.0 R 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 8.000 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 13.900 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 15.000 1.0 R 4653 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 | 68.80 49.20 25.60 94.40 168.60 |
| 3927 Grouping for streptococci 2004.00 350 7.300 1.0 R 3928 Antimicrobic substances 2004.00 350 3.800 1.0 R 3929 Radiometric mycobacterium identification 2004.00 350 14.000 1.0 R 3930 Radiometric mycobacterium antibiotic sensitivity 2004.00 350 25.000 1.0 R 3931 Helicobacter: Monoclonal immunological 2004.00 350 12.400 1.0 R 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 8.000 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 13.900 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 15.000 1.0 R 4653 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 <td>49.20 25.60 94.40 168.60</td> | 49.20 25.60 94.40 168.60 |
| 3928 Antimicrobic substances 2004.00 350 3.800 1.0 R 3929 Radiometric mycobacterium identification 2004.00 350 14.000 1.0 R 3930 Radiometric mycobacterium antibiotic sensitivity 2004.00 350 25.000 1.0 R 3931 Helicobacter: Monoclonal immunological 2004.00 350 12.400 1.0 R 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 8.000 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 13.900 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 15.000 1.0 R 4653 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R Serology 3959 Rose Waaler agglutination test 2004.00 350 4.500 1.0 R | 25.60 94.40 168.60 |
| 3929 Radiometric mycobacterium identification 2004.00 350 14.000 1.0 R 3930 Radiometric mycobacterium antibiotic sensitivity 2004.00 350 25.000 1.0 R 3931 Helicobacter: Monoclonal immunological 2004.00 350 12.400 1.0 R 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 8.000 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 13.900 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 15.000 1.0 R 4653 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MiC per organism per antibiotic 2004.00 350 17.000 1.0 R Serology 3959 Rose Waaler agglutination test 2004.00 350 4.500 1.0 R | 94.40 168.60 |
| 3930 Radiometric mycobacterium antibiotic sensitivity 2004.00 350 25.000 1.0 R 3931 Helicobacter: Monocional immunological 2004.00 350 12.400 1.0 R 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 8.000 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 13.900 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 15.000 1.0 R 4653 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R Serology 3959 Rose Waaler agglutination test 2004.00 350 4.500 1.0 R | 168.60 |
| 3931 Helicobacter: Monocional Immunological 2004.00 350 12.400 1.0 R 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 8.000 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 13.900 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 15.000 1.0 R 4653 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R Serology 3959 Rose Waaler agglutination test 2004.00 350 4.500 1.0 R | |
| 4650 Antibiotic MIC per organism per antibiotic 2004.00 350 8.000 1.0 R 4651 Non-radiometric automated blood cultures 2004.00 350 13.900 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 15.000 1.0 R 4653 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MIC per organism per antibiotic 2004.00 350 17.000 1.0 R Serology 3959 Rose Waaler agglutination test 2004.00 350 4.500 1.0 R | 90.60 |
| 4651 Non-radiometric automated blood cultures 2004.00 350 13.900 1.0 R 4652 Rapid automated bacterial identification per organism 2004.00 350 15.000 1.0 R 4653 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MiC per organism per antibiotic 2004.00 350 17.000 1.0 R Serology 3959 Rose Waaler agglutination test 2004.00 350 4.500 1.0 R | 83.60 |
| 4652 Rapid automated bacterial identification per organism 2004.00 350 15.000 1.0 R 4653 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MiC per organism per antibiotic 2004.00 350 17.000 1.0 R Serology 3959 Rose Waaler agglutination test 2004.00 350 4.500 1.0 R | 54.00 |
| 4653 Rapid automated antibiotic susceptibility per organism 2004.00 350 17.000 1.0 R 4654 Rapid automated MiC per organism per antibiotic 2004.00 350 17.000 1.0 R Serology 3959 Rose Waaler agglutination test 2004.00 350 4.500 1.0 R | 93.80 |
| 4654 Rapid automated MiC per organism per antibiotic 2004.00 350 17,000 1.0 R Serology 3959 Rose Waaler agglutination test 2004.00 350 4,500 1.0 R | 101.20 |
| Serology | 114.70 |
| 3959 Rose Waaler agglutination test 2004.00 350 4.500 1.0 R | 114.70 |
| | |
| | 30.40 |
| 3960 Gonococcal, listeria or echinococcus agglutination 2004.00 350 9.500 1.0 R | 64.10 |
| 3961 Slide agglutination test 2004.00 350 2.630 1.0 R | 17.70 |
| 3962 Rebuck skin window 2004.00 350 5.400 1.0 R | 36.40 |
| 3963 Serum complement level; Each component 2004.00 350 3.150 1.0 R | 21.20 |
| 3967 Auto-antibody: Sensitized erythrocytes 2004.00 350 4.500 1.0 R | 30.40 |
| 3968 Herpes virus typing: Monoclonal immunological 2004.00 350 20.690 1.0 R | 139.60 |
| 3969 Western blot technique 2004.00 350 74.000 1.0 R | 499.10 |
| 3970 Epstein-Barr virus antibody titer 2004.00 350 6.750 1.0 R | 45.50 |
| 3932 Antibodies to human immunodeficiency virus (HIV): ELISA 2004.00 350 14.100 1.0 R | 95.10 |
| 3933 IgE: Total: EMIT or ELISA 2004.00 350 11.700 1.0 R | 78.90 |
| 3934 Auto antibodies by labelled antibodies 2004.00 350 16.000 1.0 R | 107.90 |
| 3935 Sperm antibodies 2004.00 350 16.000 1.0 R | 107.90 |
| 3936 Virus neutralisation test: First antibody 2004.00 350 75.000 1.0 R | 505.90 |
| 3937 Virus neutralisation test: Each additional antibody 2004.00 350 15.000 1.0 R | 101.20 |
| 3938 Precipitation test per antigen 2004.00 350 4.500 1.0 R | 30.40 |
| 3939 Agglutination test per antigen 2004.00 350 5.500 1.0 R | 37.10 |
| 3940 Haemaggiutination test; Per antigen 2004.00 350 9.900 1.0 R | 66.80 |
| 3941 Modified Coombs' test for brucellosis 2004.00 350 4.500 1.0 R | 30.40 |
| 3943 Antibody titer to bacterial exotoxin 2004.00 350 3.600 1.0 R | 24.30 |
| 3944 IgE: Specific antibody titer: ELISA/EMIT: Per Ag 2004.00 350 12.400 1.0 R | 83.60 |
| 3945 Complement fixation test 2004.00 350 5.850 1.0 R | 39.50 |
| 3946 IgM: Specific antibody titer:ELISA/EMIT: Per Ag 2004.00 350 14.050 1.0 R | 94.80 |

35

| 3947 | C-reactive protein | 2004.00 | 350 | 10.840 1.0 R 73.10 |
|------|--|-----------|------|-----------------------|
| 3948 | IgG: Specific antibody titer: ELISA/EMIT: Per Ag | 2004.00 | 350 | 12.950 1.0 R 87.30 |
| 3949 | Qualitative Kahn, VDRL or other flocculation | 2004.00 | 350 | 2.250 1.0 R 15.20 |
| 3950 | Neutrophil phagocytosis | 2004.00 | 350 | 25.200 1.0 R 170.00 |
| 3951 | Quantitative Kahn, VDRL or other flocculation | 2004.00 | 350 | 3.600 1.0 R 24.30 |
| | Neutrophil chemotaxis | 2004.00 | 350 | 67.950 1.0 R 458.30 |
| | | | | |
| 3953 | Tube agglutination test | 2004.00 | 350 | 4.150 1.0 R 28.00 |
| | Paul Bunnell: Presumptive | 2004.00 | 350 | 2.250 1.0 R 15.20 |
| 3956 | Infectious mononucleosis latex slide test (Monospot or equivalent) | 2004,00 | 350 | 8.500 1.0 R 57.30 |
| | Paul Bunnell: Absorption | 2004.00 | 350 | 4.500 1.0 R 30.40 |
| 3971 | Immuno-diffusion test: Per antigen | 2004.00 | 350 | 3.150 1.0 R 21.20 |
| 3972 | Respiratory syncytlal virus (ELISA technique) | 2004.00 | 350 | 35.000 1.0 R 236.10 |
| 3973 | Immuno electrophoresis: Per immune serum | 2004.00 | 350 | 9,450 1.0 R 63.70 |
| 3974 | Polymerase chain reaction | 2004.00 | 350 | 75.000 1.0 R 505.90 |
| 3975 | Indirect immuno-fluorescence test (bacterial, viral, parasitic) | 2004.00 | 350 | 12.000 1.0 R 80.90 |
| 3977 | Counter immuno-electrophoresis | 2004.00 | 350 | 6.750 1.0 R 45.50 |
| 3978 | Lymphocyte transformation | 2004.00 | 350 | 51.700 1.0 R 348.70 |
| 4601 | Panel typing: Antibody detection: Class I | 2004.00 | 350 | 36.000 1.0 R 242.80 |
| 4602 | Panel typing: Antibody detection: Class ii | 2004.00 | 350 | 44.000 1.0 R 296.80 |
| 4603 | HLA test for specific locus/antigen - serology | 2004.00 | 350 | 27.000 1.0 R 182.10 |
| 4604 | HLA typing: Class I - serology | 2004.00 | 350 | 52.000 1.0 R 350.70 |
| 4605 | HLA typing: Class II - serology | 2004.00 | 350 | 52.000 1.0 R 350.70 |
| 4606 | HLA typing: Class I & II - serology | 2004.00 | 350 | 90.000 1.0 R 607.10 |
| 4607 | Cross matching T-cells (per tray) | 2004.00 | 350 | |
| 4608 | Cross matching B-cells | 2004.00 | 350 | 38.000 1.0 R 256.30 |
| 4609 | Cross matching T- & B-cells | 2004.00 | 350 | 48.000 1.0 R 323.80 |
| | Biochemical tests: Blood | | | |
| 3991 | Abnormal pigments: Qualitative | 2004.00 | 350 | 4.500 1.0 R 30.40 |
| 3993 | Abnormal pigments: Quantitative | 2004.00 | 350 | 9.000 1.0 R 60.70 |
| | Acid phosphate | 2004.00 | 350 | 5.180 1.0 R 34.90 |
| 3997 | Acid phosphatase fractionation | 2004.00 | 350 | 1.800 1.0 R 12.10 |
| | Amino acids Quantitative (Post derivatisation HPLC) | 2004.00 | 350 | 78.120 1.0 R 526.90 |
| | Albumin | 2004.00 | 350 | 4.800 1.0 R 32.40 |
| = | Alcohoi | 2004.00 | 350 | 12.400 1.0 R 83.60 |
| | Alkaline phosphatase | 2004.00 | 350 | 5.180 1.0 R 34.90 |
| | Alkaline phosphatase-isc-enzymes | 2004.00 | 350 | 11.700 1.0 R 78.90 |
| | Ammonia: Enzymatic | 2004.00 | 350 | 7.710 1.0 R 52.00 |
| _ | Ammonia: Monitor | 2004.00 | 350 | 4.500 1.0 R 30.40 |
| | Alpha-1-antitrypsin: Total | 2004.00 | 350 | 7.200 1.0 R 48.60 |
| | Amylase | 2004.00 | 350 | 5.180 1.0 R 34.90 |
| | Arsenic in blood, hair or nails | 2004.00 | 350 | 36.250 1.0 R 244.50 |
| | Bilirubin: Total | 2004.00 | 350 | 4.770 1.0 R 32.20 |
| | Bilirubin: Conjugated | 2004.00 | 350 | 3.620 1.0 R 24.40 |
| 4014 | Cadmium: Atomic absorption | 2004.00 | 350 | 18.120 1.0 R 122.20 |
| | Calcium: Ionized | 2004.00 | 350 | 6.750 1.0 R 45.50 |
| 7010 | anistici in ining | 12001.004 | 1000 | 4.1 00 1.0 11 TO.00 |

| 4017 | Calcium: Spectrophotometric | 2004.00 | 350 | 3.620 1.0 R | 24.40 |
|--------------|---|---------|-----|--------------|--------|
| 4018 | Calcium: Atomic absorption | 2004.00 | 350 | 7.250 1.0 R | 48.90 |
| 4019 | Carotene | 2004.00 | 350 | 2.250 1.0 R | 15.20 |
| | Carnitine (Total or free) in biological fluid: Each | 2004.00 | 350 | 11.690 1.0 R | 78.80 |
| 4021 | Carnitine (Total or free) in muscle: Each | 2004.00 | 350 | 23.380 1.0 R | 157.70 |
| 4022 | Acyl Carnitine | 2004.00 | 350 | 23.380 1.0 R | 157.70 |
| 4023 | Chloride | 2004.00 | 350 | 2.590 1.0 R | 17.50 |
| 4026 | LDL cholesterol (chemical determination) | 2004.00 | 350 | 6.900 1.0 R | 46.50 |
| 4027 | Cholesterol total | 2004.00 | 350 | 5.340 1.0 R | 36.00 |
| 4028 | HDL cholesteral | 2004.00 | 350 | 6.900 1.0 R | 46.50 |
| 4029 | Cholinesterase: Serum or erythrocyte: Each | 2004.00 | 350 | 7.480 1.0 R | 50.50 |
| | Cholinesterase phenotype (Dibucaine or fluoride each) | 2004.00 | 350 | 9.000 1.0 R | 60.70 |
| | Total CO2 | 2004.00 | 350 | 5.180 1.0 R | 34.90 |
| 4032 | Creatinine | 2004.00 | 350 | 3.620 1.0 R | 24.40 |
| 4040 | Homocysteine (random) | 2004.00 | 350 | 15.300 1.0 R | 103.20 |
| 4041 | Homocysteine (after Methionine load) | 2004.00 | 350 | 18.100 1.0 R | 122.10 |
| 4042 | D-Xylose absorption test: Two hours | 2004.00 | 350 | 13.150 1.0 R | 88.70 |
| 4045 | Fibrinogen: Quantitative | 2004.00 | 350 | 3.600 1.0 R | 24.30 |
| | Hollander test | 2004.00 | 350 | 24.750 1.0 R | 166.90 |
| 4049 | Glucose tolerance test (2 specimens) | 2004.00 | 350 | 8.970 1.0 R | 60.50 |
| | Glucose strip-test with photometric reading | 2004.00 | 350 | 1.800 1.0 R | 12.10 |
| 4051 | Galactose | 2004.00 | 350 | 11.250 1.0 R | 75.90 |
| 4052 | Glucose tolerance test (3 specimens) | 2004.00 | 350 | 13.170 1.0 R | 88.80 |
| 4053 | Glucose tolerance test (4 specimens) | 2004.00 | 350 | 17.370 1.0 R | 117.20 |
| 4057 | Glucose: Quantitative | 2004.00 | 350 | 3.620 1.0 R | 24.40 |
| 4061 | Glucose tolerance test (5 specimens) | 2004.00 | 350 | 21.560 1.0 R | 145.40 |
| 4062 | Galactose-1-phosphate uridyl transferase | 2004.00 | 350 | 16.000 1.0 R | 107.90 |
| 4063 | Fructosamine | 2004.00 | 350 | 7.200 1.0 R | 48.60 |
| 4064 | HbA1C | 2006.04 | 350 | 14.250 1.0 R | 96.10 |
| 4066 | Immunofixation: Total protein, IgG, IgA, IgM, Kappa, Lambda | 2004.00 | 350 | 46.880 1.0 R | 316.20 |
| 4067 | Lithlum: Flame ionisation | 2004.00 | 350 | 5.180 1.0 R | 34.90 |
| 4068 | Lithlum: Atomic absorption | 2004.00 | 350 | 7.480 1.0 R | 50.50 |
| 4071 | iron | 2004.00 | 350 | 6.750 1.0 R | 45.50 |
| | Iron-binding capacity | 2004.00 | 350 | 7.650 1.0 R | 51.60 |
| 4078 | Oximetry analysis: MetHb, COHb, O2Hb, RHb, SulfHb | 2004.11 | 350 | 6.750 1.0 R | 45.50 |
| 4079 | Ketones In plasma: Qualitative | 2004.00 | 350 | 2.250 1.0 R | 15.20 |
| 4081 | Drug level-biological fluid: Quantitative | 2004.00 | 350 | 10.800 1.0 R | 72.80 |
| 4083 | Lysosomal enzyme assay | 2004.00 | 350 | 36.560 1.0 R | 246.60 |
| 4085 | Lipase | 2004.00 | 350 | 5.180 1.0 R | 34.90 |
| | Lipoprotein electrophoresis | 2004.00 | 350 | 9.000 1.0 R | 60.70 |
| 4093 | Osmolality: Serum or urine | 2004.00 | 350 | 6.750 1.0 R | 45.50 |
| 4094 | Magneslum: Spectrophotometric | 2004.00 | 350 | 3.620 1.0 R | 24.40 |
| | Magnesium: Atomic absorption | 2004.00 | 350 | 7.250 1.0 R | 48.90 |
| 4096 | Mercury: Atomic absorption | 2004.00 | 350 | 18.120 1.0 R | 122.20 |
| <u>409</u> 8 | Copper: Atomic absorption | 2004.00 | 350 | 18.120 1.0 R | 122.20 |

| 4105 | Protein electrophoresis | 2004.00 | 350 | 9.000 | 1.0 | R | 60.70 | \neg |
|---------------|---|---------|------------|-----------------|-----|---|-----------------|---------------------|
| | IgG sub-class 1, 2, 3 or 4: Per sub-class | 2004.00 | 350 | 20.000 | 1.0 | R | 134.90 | \dashv |
| | Phosphate | 2004.00 | 350 | 3.620 | 1.0 | _ | 24.40 | \dashv |
| 4111 | Phospholipids | 2004.00 | 350 | 3.150 | 1.0 | R | 21.20 | \neg |
| | Potassium | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | - |
| 4114 | Sodium | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | - |
| | Protein: Total | 2004.00 | 350 | 3.110 | | | 21.00 | |
| | pH, pCO2 or pO2: Each | 2004.00 | 350 | 6.750 | 1.0 | | 45.50 | -1 |
| | Pyruvic acid | 2004.00 | 350 | 4.500 | 1.0 | R | 30.40 | -1 |
| | Salicylates | 2004.00 | 350 | 4.500 | | R | 30.40 | -1 |
| | Secretin-pancreozymin response | 2004.00 | 350 | 26.100 | | _ | 176.00 | - |
| 4127 | Caeruloplasmin | 2004.00 | 350 | 4.500 | 1.0 | | 30.40 | $\overline{}$ |
| | Phenylalanine: Quantitative | 2004.00 | 350 | 11.250 | 1.0 | | 75.90 | |
| _ | Glutamate dehydrogenase (GDH) | 2004.00 | 350 | 5.400 | 1.0 | R | 36.40 | - |
| $\overline{}$ | Aspartate aminotransferase (AST) | 2004.00 | 350 | 5.400 | | | 36.40 | |
| | Alanine aminotransferase (ALT) | 2004.00 | 350 | 5.400 | 1.0 | R | 36.40 | - |
| | Creatine kinase (CK) | 2004.00 | 350 | 5.400 | 1.0 | R | 36,40 | - |
| | Lactate dehidrogenase (LD) | 2004.00 | 350 | 5.400 | | | 36.40 | - |
| | Gamma glutamyl transferase (GGT) | 2004.00 | 350 | 5.400 | | | 36.40 | - |
| | Aldolase | 2004.00 | 350 | 5.400 | | _ | 36.40 | - |
| | Angiotensin converting enzyme (ACE) | 2004.00 | 350 | 9.000 | | | 60.70 | _ |
| | Lactate dehydrogenase isoenzyme | 2004.00 | 350 | 10.800 | | | 72.80 | |
| | CK-MB: Immunoinhibition/precipitation | 2004.00 | 350 | 10.800 | | | 72.80 | \vdash |
| | Adenosine deaminase | 2004.11 | 350 | 5.400 | | | 36.40 | |
| | Red cell enzymes: Each | 2004.00 | 350 | | | | 52.60 | - |
| | Serum/plasma enzymes | 2004.00 | 350 | | | | 36.40 | - |
| | | 2004.00 | 350 | | | | 78.90 | \vdash |
| | Transferrin | 2004.00 | 350 | | 1.0 | | 101.20 | — |
| | Lead: Atomic absorption | 2004.00 | 350 | | | | 53.50 | - |
| | Triglyceride | 2004.00 | 350 | | | | 78.90 | - |
| | Red ceil magnesium | 2004.00 | 350 | | 1.0 | | 24.40 | i |
| _ | Urea Constitution (Astronomy) | | 350 | | | _ | | \vdash |
| | CK-MB: Mass determination: Quantitative (Automated) | 2004.00 | 350 | | | | 83.60 117.80 | - |
| | CK-MB: Mass determination: Quantitative (Not automated) | | | | | | | Щ |
| | Myoglobin quantitative: Monoclonal immunological | 2004.00 | 350 | 12.400 | | | 83.60 | \vdash |
| | Uric acid | 2004.00 | 350 350 | 3.780 15.300 | | R | 25.50 103.20 | \vdash |
| 4157 | Vitamin A-saturation test | | | | | | | \vdash |
| 4158 | Vitamin E (tocopherol) | 2004.00 | 350 | | | | 24.30 | $\vdash \vdash$ |
| 4159 | Vitamin A | 2004.00 | 350 | | | R | 42.50 | \vdash |
| | Vitamin C (ascorbic acid) | 2004.00 | 350 | | | | 15.20 | $\vdash \vdash$ |
| | Troponin isoforms: Each | 2004.00 | 350 | | | R | 134.90 | $\vdash \vdash$ |
| | Apoprotein Al: Turbidometric method | 2004.00 | 350 | | | | 55.80 | $oldsymbol{\sqcup}$ |
| | Apoprotein All: Turbidometric method | 2004.00 | 350 | | | | 55.80 | $oldsymbol{\sqcup}$ |
| | Apoprotein B: Turbidometric method | 2004.00 | 350 | | | | 55,80 | oxdot |
| | Lipoprotein (a)(Lp(a)) assay | 2004.00 | 350 | | | | 83,80 | — — |
| 4171 | Sodium + potassium + chloride + CO2 + urea | 2004.00 | 350 | 15.840 | 1.0 | R | 106.80 | Ш |

| 4181 Qua | | 2004.00 | 350 | 12.420 1.0 F | 83.80 |
|-----------|---|---------|--------|----------------------|--------|
| 4101 July | antitative protein estimation: Mancini method | 2004.00 | 350 | 7.760 1.0 F | 52.30 |
| 4182 Qua | antitative protein estimation: Nephelometer or Turbidometeric method | 2004.00 | 350 | 8.280 1.0 F | 55.80 |
| 4183 Qua | antitative protein estimation: Labelled antibody | 2004.00 | 350 | 12.420 1.0 F | 83.80 |
| 4185 Lact | tose | 2004.00 | 350 | 10.800 1.0 F | 72.80 |
| 4187 Zinc | c: Atomic absorption | 2004.00 | 350 | 18.120 1.0 F | 122.20 |
| Bloc | chemical tests: Urine | | \Box | | |
| 4188 Urin | ne dipstick, per stick (irrespective of the number of tests on stick) | 2004.00 | 350 | 1.500 1.0 F | |
| 4189 Abn | normal pigments | 2004.00 | 350 | 4.500 1.0 F | 30.40 |
| 4193 Alka | apton test: Homogentisic acid | 2004.00 | 350 | 4.500 1.0 F | 30.40 |
| | Ino acids: Quantitative (Post derivatisation HPLC) | 2004.00 | 350 | 78.120 1.0 F | 526.90 |
| 4195 Amii | ino laevulinic acid | 2004.00 | 350 | 18.000 1.0 F | 121.40 |
| 4197 Amy | ylase | 2004.00 | 350 | 5.180 1.0 F | 34.90 |
| 4198 Arse | enic | 2004.00 | 350 | 18.120 1.0 F | |
| 4199 Asc | eorbic acid | 2004.00 | 350 | 2.250 1.0 F | 15.20 |
| 4201 Ben | ce-Jones protein | 2004.00 | 350 | 2.700 1.0 F | |
| 4203 Phe | enol | 2004.00 | 350 | 3.600 1.0 F | 24.30 |
| 4204 Calc | cium; Atomic absorption | 2004.00 | 350 | 7.250 1.0 F | 48.90 |
| 4205 Calc | cium: Spectrophotometric | 2004.00 | 350 | 3.620 1.0 F | 24.40 |
| 4206 Calc | cium: Absorption and excretion studies | 2004.00 | 350 | 25.000 1.0 F | 168.60 |
| 4209 Lead | d: Atomic absorption | 2004.00 | 350 | 15.000 1.0 F | 101.20 |
| 4211 Bile | pigments: Qualitative | 2004.00 | 350 | 2.250 1.0 F | 15.20 |
| 4213 Prot | tein: Quantitative | 2004.00 | 350 | 2.250 1.0 F | 15.20 |
| 4216 Muc | copolysaccharides: Qualitative | 2004.00 | 350 | 3.600 1.0 F | 24.30 |
| 4217 Oxa | elate | 2004.00 | 350 | 9.380 1.0 F | |
| 4218 Glud | cose: Quantitative | 2004.00 | 350 | 2.250 1.0 F | 15.20 |
| 4219 Ster | roids: Chromatography (each) | 2004.00 | 350 | 7.200 1.0 F | 48.60 |
| 4221 Crea | atinine | 2004.00 | 350 | 3.620 1.0 F | 24.40 |
| | atinine clearance | 2004.00 | 350 | 7. 65 0 1.0 F | |
| | ctrophoresis: Qualitative | 2004.00 | 350 | 4.500 1.0 F | |
| 4229 Uric | c acid clearance | 2004.00 | 350 | 7.650 1.0 F | 51.60 |
| | ydroxy-indole-acetic acid: Screen test | 2004.00 | 350 | 2.700 1.0 F | 18.20 |
| | ydroxy-indole-acetic acid: Quantitative | 2004.00 | 350 | 6.750 1.0 F | |
| | ones: Excluding dip-stick method | 2004.00 | 350 | 2.250 1.0 F | |
| | ducing substances | 2004.00 | 350 | | |
| | anephrines: Column chromatography | 2004.00 | 350 | | |
| 4253 Aror | matic amines (gas chromatography/mass spectrophotometry) | 2004.00 | 350 | 27.000 1.0 F | 182.10 |
| | osonaphtol test for tyrosine | 2004.00 | 350 | 2.250 1.0 F | |
| | Excluding dip-stick method | 2004.00 | 350 | | |
| | n layer chromatography: One way | 2004.00 | 350 | | |
| 4266 Thir | n layer chromatography: Two way | 2004.00 | 350 | | |
| | al organic matter screen: Infrared | 2004.00 | 350 | | |
| 4268 Org | anic acids; Quantitative; GCMS | 2004.00 | 350 | | |
| 4269 Phe | enylpyruvic acid: Ferric chloride | 2004.00 | 350 | 2.250 1.0 F | |
| 4271 Pho | psphate excretion index | 2004.00 | 350 | 22.050 1.0 F | 148.70 |

| 4272 | Porphobilinogen qualitative screen: Urine | 0004 00 | 250 | E 000 | <i>-</i> \sim | _ | 20.70 | $\overline{}$ |
|------|--|---------|-----|--------|-----------------|----|---------------|-----------------------|
| | | 2004.00 | 350 | 5.000 | | | 33.70 | - |
| | Porphobilinogen/ALA: Quantitative each | 2004.00 | 350 | 15.000 | | | 101.20 | |
| | Magnesium: Spectrophotometric | 2004.00 | 350 | | 1.0 | | 24.40 | |
| 4284 | Magnesium: Atomic absorption | 2004.00 | 350 | | 1.0 | | 48.90 | _ |
| | Identification of carbohydrate | 2004.00 | 350 | | 1.0 | | 51.60 | _ |
| | identification of drug: Qualitative | 2004.00 | 350 | | 1.0 | _ | 30.40 | _ |
| 4288 | Identification of drug: Quantitative | 2004.00 | 350 | | 1.0 | | 72.80 | _ |
| 4293 | Urea clearance | 2004.00 | 350 | | 1.0 | | 36.40 | |
| 4297 | Copper: Spectrophotometric | 2004.00 | 350 | | 1.0 | | 24.40 | |
| 4298 | Copper: Atomic absorption | 2004.00 | 350 | 18.120 | | | 122.20 | |
| | Indican or Indole: Qualitative | 2004.00 | 350 | | 1.0 | | 21.20 | |
| | Chloride | 2004.00 | 350 | 2.590 | | | 17.50 | |
| | Ammonium chloride loading test | 2004.00 | 350 | 22.050 | | | 148.70 | |
| | Urobilinogen: Quantitative | 2004.00 | 350 | | 1.0 | | 45.50 | |
| | Phosphates | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| | Potassium | 2004.00 | 350 | | 1.0 | | 24.40 | |
| | Sodium | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| | Urea | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| 4321 | Uric acid | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| 4322 | Fluoride | 2004.00 | 350 | 5.180 | 1.0 | R | 34.90 | \neg |
| 4323 | Total protein and protein electrophoresis | 2004.00 | 350 | 11.250 | 1.0 | R | 75.90 | |
| 4325 | VMA: Quantitative | 2004.00 | 350 | | 1.0 | | 75.90 | \neg |
| 4326 | Catecholamines (HPLC) | 2004.00 | 350 | | 1.0 | R | 526.90 | \neg |
| 4327 | Immunofixation: Total protein, IgG, IgA, IgM, Kappa, Lambda | 2004.11 | 350 | | 1.0 | | 316.20 | \neg |
| | Cystine: Quantitative | 2004.00 | 350 | 12.600 | 1.0 | R | 85.00 | \neg |
| | Dinitrophenol hydrazine test: Ketoacids | 2004.00 | 350 | 2.250 | | | 15.20 | \neg |
| | Hydroxyproline: Quantitative | 2004.00 | 350 | | 1.0 | | 127.50 | |
| | Blochemical tests: Faeces | | | | _ | | | \neg |
| 4339 | Chloride | 2004.00 | 350 | 2.590 | 1.0 | R | 17.50 | \neg |
| | Fat: Qualitative | 2004.00 | 350 | 3.150 | | | 21.20 | \neg |
| | Fat: Quantitative | 2004.00 | 350 | 22.050 | | | 148.70 | \neg |
| | Ph | 2004.00 | 350 | 0.900 | | | 6.07 | \neg |
| 4351 | Occult blood: Chemical test | 2004.00 | 350 | | 1.0 | | 15.20 | \neg |
| | Occult blood: Monoclonal antibodies | 2004.00 | 350 | | 1.0 | | 67.50 | \neg |
| | Potassium | 2004.00 | 350 | | 1.0 | | 24.40 | \dashv |
| 4358 | Sodium | 2004.00 | 350 | | 1.0 | | 24.40 | \dashv |
| | Stercobilin | 2004.00 | 350 | 2.250 | | | 15.20 | - |
| | Elastase quantitative ELISA | 2004.00 | 350 | | 1.0 | | 317.00 | \dashv |
| | Stercobilinogen: Quantitative | 2004.00 | 350 | | 1.0 | | 45.50 | -1 |
| | Chymotrypsin determination: Enzymatic | 2004.00 | 350 | 7.470 | | | 50.40 | \dashv |
| | Blochemical tests: Miscellaneous | 2007.04 | | 7.770 | ' | 11 | 30.40 | |
| | Porphyrin screen qualitative: Urine, stool, red blood cells: Each | 2004.00 | 350 | 5.000 | 4 1 | ь | 33.70 | - |
| | Porphyrin galitative analysis by TLC: Urine, stool, red blood cells: Each | 2004.00 | 350 | 20.000 | | | 134.90 | - |
| _ | Porphyrin: Total quantisation: Urine, stool, red blood cells: Each | 2004.00 | 350 | 20.000 | | | 134.90 | - |
| | | | 350 | | | | | $\boldsymbol{\dashv}$ |
| +308 | Porphyrin quantitative analysis by TLC/HPLC: Urine, stool, red blood cells: Each | 2004.00 | 330 | 30.000 | 1.0 | π_ | <u>202.40</u> | |

| 4370 | Drug level in biological fluid: Monoclonal immunological | 2004.00 | 350 | 12.400 | 1.0 | R | 83,60 | \neg |
|------|---|---------|-----|--------|-----|---|----------|--------|
| | Amylase in exudate | 2004.00 | 350 | 5.180 | | | 34.90 | |
| 4372 | Fluoride in biological fluids and water | 2004.00 | 350 | 15.620 | | | 105.40 | |
| | Breast milk analysis | 2004.00 | 350 | 6.750 | | | 45.50 | |
| | Trace metals in biological fluid: Atomic absorption | 2004.00 | 350 | 18.130 | | | 122,30 | |
| | Calcium in fluid: Spectrophotometric | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| | Calcium in fluid: Atomic absorption | 2004.00 | 350 | 7.250 | | | 48.90 | |
| | Gallstone analysis: (Bilirubin, Ca, P, Oxalate, Cholesterol) | 2004.11 | 350 | | | | 147.60 | |
| | Lecithin in amniotic fluid: L/S ratio | 2004.00 | 350 | | | | 182.10 | |
| | Bilirubin in amniotic fluid: Spectrophotometric essay | 2004.00 | 350 | 9.450 | 1.0 | R | 63.70 | |
| | Oestrogen/Progesterone receptors: Fluorescent method | 2004.00 | 350 | 20.700 | | | 139.60 | |
| | Oestrogen/Progesterone receptors: Cytosol radio-isotope technique | 2004.00 | 350 | | | | 1 551,40 | |
| | Gastric contents: Maximal stimulation test | 2004.00 | 350 | 27.000 | | | 182.10 | |
| | Gastric fluid: Total acid per specimen | 2004.00 | 350 | 2.250 | 1.0 | R | 15.20 | |
| | Foam test: Amniotic fluid | 2004.00 | 350 | 3.150 | | | 21.20 | |
| | Renai calculus: Chemistry | 2004.00 | 350 | 5.400 | | | 36.40 | |
| 4392 | Renal calculus: Crystallography | 2004.00 | 350 | 16.250 | 1.0 | R | 109,60 | |
| | Sallva: Potassium | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| 4394 | Saliva: Sodium | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| 4395 | Sweat: Sodium | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| 4396 | Sweat: Potassium | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| 4397 | Sweat: Chloride | 2004.00 | 350 | 2.590 | 1.0 | R | 17.50 | |
| 4399 | Sweat collection by lontophoresis (excluding collection material) | 2004.00 | 350 | 4.500 | 1.0 | R | 30.40 | |
| | Tryptophane loading test | 2004.00 | 350 | 22.050 | 1.0 | R | 148.70 | ╗ |
| | Cerebrospinal fluid | | | | | | | |
| 4401 | Cell count | 2004.00 | 350 | 3.450 | 1.0 | R | 23.30 | |
| 4407 | Cell count, protein, glucose and chloride | 2004.00 | 350 | 7.650 | 1.0 | R | 51.60 | |
| 4409 | Chloride | 2004.00 | 350 | 2.590 | 1.0 | R | 17.50 | |
| 4415 | Potassium | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | \neg |
| 4416 | Sodium | 2004.00 | 350 | 3.620 | 1.0 | R | 24.40 | |
| 4417 | Protein: Qualitative | 2004.00 | 350 | 0.900 | 1.0 | R | 6.07 | |
| 4419 | Protein: Quantitative | 2004.00 | 350 | 3.110 | 1.0 | R | 21.00 | |
| 4421 | Glucose | 2004.00 | 350 | 3.620 | | R | 24.40 | |
| | Urea | 2004.00 | 350 | 3.620 | | | 24.40 | |
| 4425 | Protein electrophoresis | 2004.00 | 350 | 12.600 | 1.0 | R | 85.00 | |
| | RNA/DNA based tests and andrology | | | | | | | |
| | RNA/DNA based tests and andrology: RNA/DNA based tests | | | | | | | |
| | Recombinant DNA technique | 2004.00 | 350 | | | | 168.60 | |
| 4431 | Ribosomal RNA targeting for bacteriological identification | 2004.00 | 350 | 35.000 | | | 236.10 | |
| | Ribosomal RNA amplification for bacteriological identification | 2004.00 | 350 | | | | 505.90 | |
| 4433 | Bacteriological DNA identification (LCR) | 2004.00 | 350 | 25.000 | | | 168.60 | |
| | Bacteriological DNA Identification (PCR) | 2004.00 | 350 | 75.000 | 1.0 | R | 505.90 | |
| | RNA/DNA based tests and andrology: Andrology | | | | | | | |
| 4435 | Mixed antiglobulin reaction: Semen | 2004.00 | 350 | 6,600 | | | 44.50 | |
| 4436 | Friberg test: Semen | 2004.00 | 350 | 14.500 | 1.0 | R | 97.80 | |

| Semen analysis: Cell count | 4437 | Kremer test: Semen | 2004.00 | 350 | 3.600 | 1.0 | R | 24.30 | |
|---|------|---|---------|--------|---------|-----|---|----------|--------|
| | | | | 350 | | | | 51.60 | П |
| Semen analysis: Viability + motility - 6 hours 2004.00 350 6.000 1.0 R 40.50 | | | 2004.00 | 350 | 7.200 | 1.0 | R | 48.60 | |
| Seminal Fluid: Alpha glucosidase 2004.00 350 5.440 1,0 R 36.70 | | | 2004.00 | 350 | 6.000 | 1.0 | R | 40.50 | |
| Seminal fluick Alpha glucosidase 2004.00 350 20.000 1.0 R 134.90 | | | 2004.00 | 350 | 5.440 | 1.0 | R | 36.70 | |
| Seminal fluid fructose 2004.00 350 3.150 1.0 R 21.20 | | | 2004.00 | 350 | 20.000 | 1.0 | R | 134.90 | |
| | | | 2004.00 | 350 | 3.150 | 1.0 | R | 21.20 | |
| Immunology | | | | | | | | 34.90 | \Box |
| HCG: Latex aggiutination: Qualitative (side room) 2004.00 350 4000 1.0 R 27.00 1.4449 HCG: Latex aggiutination: Semi-quantitative (side room) 2004.00 350 9.310 1.0 R 67.50 1.0 K | | | \top | | | | | |
| HCG: Latex aggiulination: Semi-quantitative (side room) 2004.00 350 3.10 1.0 R 62.80 HCG: Monoclonal immunological: Qualitative 2004.00 350 10.000 1.0 R 67.50 4451 HCG: Monoclonal immunological: Qualitative 2004.00 350 12.400 1.0 R 83.80 4452 Anti IgE receptor antibody test (10 samples and dilution) 2004.00 350 16.1500 1.0 R 10.99.70 4458 Easinghil cathoric protein 2004.00 350 27.810 1.0 R 176.60 4459 Mast cell tryptase 2004.00 350 28.810 1.0 R 187.60 4458 Micro-albuminuria: Radic-isotope method 2004.00 350 12.420 1.0 R 187.60 4459 Acety Choline receptor antibody 2004.00 350 158.120 1.0 R 168.50 4469 Acety Choline receptor antibody 2004.00 350 158.120 1.0 R 168.50 4460 CA-199 tumour marker 2004.00 350 20.000 1.0 R 134.90 4461 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4462 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4463 Complement functional essay 2004.00 350 20.000 1.0 R 137.00 4468 Edsez-eurooglobulin 2004.00 350 20.000 1.0 R 137.00 4469 CA-496 2004.00 350 20.000 1.0 R 134.90 4470 CA-195 tumour marker 2004.00 350 20.000 1.0 R 134.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4478 Neopterin 2004.00 350 20.000 1.0 R 134.90 4479 Marin B12-absorption: Shilling teet 2004.00 350 20.000 1.0 R 134.90 4479 Marin B12-absorption: Shilling teet 2004.00 350 20.000 1.0 R 33.80 4489 Tere browner essay 2004.00 350 20.000 1.0 R 33.80 4490 Marin B12-absorption: Shilling teet 2004.00 350 20.000 1.0 R 33.80 4491 Marin B12 2004.00 350 20.000 1.0 R 33.80 4492 Marin B12 2004.00 350 20.000 1.0 R | 4448 | | 2004.00 | 350 | 4.000 | 1.0 | R | 27.00 | \Box |
| HCG: Monoclonal immunological: Qualitative 2004.00 350 10.000 1.0 R 67.50 4451 HCG: Monoclonal immunological: Quantitative 2004.00 350 12.400 1.0 R 83.80 4455 Artl IgE receptor artibody test (10 samples and dilution) 2004.00 350 12.7810 1.0 R 109.70 4456 Artl IgE receptor artibody test (10 samples and dilution) 2004.00 350 27.810 1.0 R 109.70 4458 Micro-albuminuria: Radio-laotope method 2004.00 350 96.870 1.0 R 635.40 4458 Micro-albuminuria: Radio-laotope method 2004.00 350 15.420 1.0 R 363.80 4459 Acetyl choline receptor artibody 2004.00 350 158.120 1.0 R 10.65.50 4450 Acetyl choline receptor artibody 2004.00 350 20.000 1.0 R 134.90 4462 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4463 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4463 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4468 CA-549 2004.00 350 20.000 1.0 R 134.90 4470 Acron-embryonic artigen 2004.00 350 20.000 1.0 R 134.90 4470 Acron-embryonic artigen 2004.00 350 20.000 1.0 R 134.90 4471 Carcin-embryonic artigen 2004.00 350 20.000 1.0 R 134.90 4478 Arrivor specific enolase 2004.00 350 20.000 1.0 R 134.90 4478 Arrivor specific enolase 2004.00 350 20.000 1.0 R 134.90 4479 4470 Acron-embryonic artigen 2004.00 350 20.000 1.0 R 134.90 4479 4470 4000 350 20.000 1.0 R 33.80 4490 4470 4000 4000 350 4000 350 4000 350 4000 4000 350 4000 | | | 2004.00 | 350 | 9.310 | 1.0 | R | 62.80 | |
| HCG: Monoclonal immunological: Quantitative 2004.00 350 12.400 1.0 R 83.60 4455 Anti IgE receptor artibody test (10 samples and dilution) 2004.00 350 12.7810 1.0 R 1089.70 4456 Eosinophil cationic protein 2004.00 350 27.810 1.0 R 167.60 4457 Mast cell tryptase 2004.00 350 98.870 1.0 R 653.40 4458 Micro-albuminuria: Radio-isotope method 2004.00 350 12.420 1.0 R 83.80 4458 Micro-albuminuria: Radio-isotope method 2004.00 350 158.120 1.0 R 10.86.50 4458 Micro-albuminuria: Radio-isotope method 2004.00 350 158.120 1.0 R 10.86.50 4459 Acety choline receptor artibody 2004.00 350 12.420 1.0 R 33.80 4469 Acety choline receptor artibody 2004.00 350 20.000 1.0 R 134.90 4462 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4463 Ca-125 tumour marker 2004.00 350 20.000 1.0 R 303.50 4464 House dust mitle antigen ELIZA 2004.00 350 20.301 1.0 R 303.50 4468 Beta-2-microglobulin 2004.00 350 20.301 1.0 R 33.80 4468 CA-549 Acety Ca-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4470 CA-159 tumour marker 2004.00 350 20.000 1.0 R 134.90 4470 CA-159 tumour marker 2004.00 350 20.000 1.0 R 134.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 4472 CA-159 tumour marker 2004.00 350 20.000 1.0 R 134.90 4473 Neuron specific enclase 2004.00 350 20.000 1.0 R 134.90 4478 Neopherin 2004.00 350 20.000 1.0 R 134.90 4478 Neopherin 2004.00 350 20.000 1.0 R 134.90 4478 Neopherin 2004.00 350 20.000 1.0 R 334.90 4478 Neopherin 2004.00 350 20.000 1.0 R 334.90 4478 Neopherin 2004.00 350 20.000 1.0 R 334.90 4488 Ere thyroxine (FT4) 2004.00 350 12.420 1.0 R 33.80 4489 Releasing hormone response 2004.00 350 12.420 1.0 R 33.80 | 4450 | | 2004.00 | 350 | 10.000 | 1.0 | R | | |
| Ad55 | | | 2004.00 | 350 | 12.400 | 1.0 | | | |
| 4456 Ecsinophil cationic protein 2004.00 350 27.810 1.0 R 187.60 4457 Mast cell tryptase 2004.00 350 96.870 1.0 R 633.40 4458 Micro-albuminuris: Radio-isotope method 2004.00 350 12.420 1.0 R 83.80 4459 Acatyl choline receptor antibody 2004.00 350 158.120 1.0 R 108.50 4460 CA-195 tumour marker 2004.00 350 20.000 1.0 R 134.90 4462 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4463 Ca-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4464 House dust mite antigen ELIZA 2004.00 350 20.000 1.0 R 303.50 4464 House dust mite antigen ELIZA 2004.00 350 20.000 1.0 R 334.90 4468 Beta-2-microglobulin 2004.00 350 20.000 1.0 R 334.90 4469 Tumour markers: Monoclonal immunological (each) 2004.00 350 20.000 1.0 R 334.90 4470 CA-195 tumour marker 2004.00 350 20.000 1.0 R 334.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 334.90 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 334.90 4478 Neopterin 2004.00 350 20.000 1.0 R 334.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 20.000 1.0 R 334.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 20.000 1.0 R 334.90 4485 Insulin B12-absorption: Shilling test 2004.00 350 20.000 1.0 R 334.90 4485 Insulin B12-absorption: Shilling test 2004.00 350 20.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 20.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 20.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 20.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 20.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 20.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 20.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 20.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 | | | 2004.00 | 350 | 161.560 | 1.0 | R | 1 089.70 | |
| Mast cell tryptase | | | 2004.00 | | | 1.0 | R | | |
| 4458 Micro-albuminuria: Radio-isotope method 2004.00 350 12.420 1.0 R 83.80 4459 Acetyl choline receptor antibody 2004.00 350 158.120 1.0 R 1086.50 4460 CA-195 tumour marker 2004.00 350 20.000 1.0 R 134.90 4462 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4463 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4463 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4463 CA-125 tumour marker 2004.00 350 45.000 1.0 R 303.50 4464 House dust mite antigen ELIZA 2004.00 350 20.310 1.0 R 337.00 4466 Beta-2-microglobulin 2004.00 350 20.000 1.0 R 134.90 4468 Each-2-microglobulin 2004.00 350 20.000 1.0 R 134.90 4469 Tumour markers: Monoclonal immunological (each) 2004.00 350 20.000 1.0 R 134.90 4470 CA-195 tumour marker 2004.00 350 20.000 1.0 R 134.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4478 Neopterin 2004.00 350 20.000 1.0 R 134.90 4479 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 79.90 4485 Insulin 812-absorption: Shilling test 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 12.420 1.0 R 83.80 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4491 Free hormone assay 2004.00 350 12.420 1.0 R 83.80 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 | 4457 | Mast cell tryptase | 2004.00 | 350 | 96.870 | 1.0 | R | 653.40 | |
| Acetyl choline receptor antibody 2004.00 350 158.120 1.0 R 1 066.50 1 | | Micro-albuminuria: Radio-isotope method | | 350 | 12.420 | | | | |
| 4462 CA-199 tumour marker 2004.00 350 20.000 1.0 R 134.90 4462 CA-125 tumour marker 2004.00 350 20.000 1.0 R 303.50 4463 C6 complement functional essay 2004.00 350 45.000 1.0 R 303.50 4464 House dust mitte antigen ELIZA 2004.00 350 20.310 1.0 R 33.90 4468 Eda-2-microglobulin 2004.00 350 20.000 1.0 R 33.90 4469 Tumour markers: Monocional immunological (each) 2004.00 350 20.000 1.0 R 134.90 4470 CA-195 tumour marker 2004.00 350 20.000 1.0 R 134.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4478 Neopterin 2004.00 350 20.000 1.0 R 134.90 4477 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 20.000 1.0 R 34.90 4480 Serotonin 2004.00 350 17.00 1.0 R 33.90 4480 Serotonin 2004.00 350 17.00 1.0 R 33.90 4481 Fee thyroxine (FT4) 2004.00 350 17.480 1.0 R 17.90 4482 Fee thyroxine (FT4) 2004.00 350 17.480 1.0 R 33.80 4492 Vitamin B12 2004.00 350 12.420 1.0 R 33.80 4493 Vitamin B12 2004.00 350 12.420 1.0 R 33.80 4494 Free hormone assay 2004.00 350 12.420 1.0 R 83.80 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quartitative 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quartitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 12.420 1.0 R 83.80 4498 Cortisol 4499 Cortisol 4490 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 12.420 1.0 R 83.80 4498 Cortisol 4490 2004.00 350 12.420 1.0 R 83.80 4498 | | | 2004.00 | 350 | | | R | 1 066.50 | |
| 4462 CA-125 tumour marker 2004.00 350 20.000 1.0 R 134.90 4463 C6 complement functional essay 2004.00 350 45.000 1.0 R 303.50 4464 House dust mite antigen ELIZA 2004.00 350 12.420 1.0 R 83.80 4465 Beta-2-microglobulin 2004.00 350 12.420 1.0 R 83.80 4466 Beta-2-microglobulin 2004.00 350 12.420 1.0 R 83.80 4469 Tumour markers: Monoclonal immunological (each) 2004.00 350 20.000 1.0 R 134.90 4470 CA-195 tumour marker 2004.00 350 20.000 1.0 R 134.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4473 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4474 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 17.00 1.0 R 78.90 4480 Serotonin 2004.00 350 17.480 1.0 R 126.50 4481 Free thyroxine (FT4) 2004.00 350 12.420 1.0 R 33.80 4491 Vitamin B12 2004.00 350 12.420 1.0 R 33.80 4492 Vitamin B12 2004.00 350 12.420 1.0 R 33.80 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 33.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 12.420 1.0 R 83.80 4498 Cortisol 2004.00 350 12.420 1.0 R 83.80 4498 Cortisol 2004.00 350 12.420 1.0 R 83.80 4498 Cortisol 2004.00 350 12.420 1.0 R 83.80 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4490 Cortisol 2004.00 350 12.420 1.0 R 83.80 | | | 2004.00 | 350 | 20.000 | 1.0 | R | | |
| House dust mite antigen ELIZA 2004.00 350 20.310 1.0 R 137.00 4466 Beta-2-microglobulin 2004.00 350 12.420 1.0 R 83.80 4468 CA-549 2004.00 350 20.000 1.0 R 134.90 4470 CA-195 tumour markers: Monoclonal immunological (each) 2004.00 350 20.000 1.0 R 134.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4473 McA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4474 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4475 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4476 Vitamin B12-absorption: Shilling test 2004.00 350 20.000 1.0 R 134.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 78.90 4480 Serotonin 2004.00 350 17.480 1.0 R 17.90 4485 Insulin 2004.00 350 17.480 1.0 R 17.90 4485 Insulin 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 12.420 1.0 R 83.80 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4492 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 12.420 1.0 R 83.80 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 12.420 1.0 R 83.80 4498 Cortisol 2004.00 350 12.420 1.0 R 83.80 4498 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | | | 2004.00 | 350 | | | | | |
| House dust mite antigen ELIZA 2004.00 350 20.310 1.0 R 137.00 1466 Beta-2-microglobulin 2004.00 350 12.420 1.0 R 83.80 14668 CA-549 2004.00 350 20.000 1.0 R 134.90 1470 CA-195 tumour markers: Monocional immunological (each) 2004.00 350 20.000 1.0 R 134.90 1471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 1472 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 1472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 1476 Neopterin 2004.00 350 20.000 1.0 R 134.90 1476 Neopterin 2004.00 350 20.000 1.0 R 134.90 1476 Neopterin 2004.00 350 20.000 1.0 R 134.90 1477 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 1479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 78.90 1480 Serotonin 2004.00 350 17.480 1.0 R 17.90 1482 Free thyroxine (FT4) 2004.00 350 17.480 1.0 R 17.90 1485 Insulin 2004.00 350 12.420 1.0 R 33.80 1490 1490 Vitamin B12 2004.00 350 12.420 1.0 R 33.80 1490 | 4463 | C6 complement functional essay | 2004.00 | 350 | | | R | 303,50 | |
| 4466 Beta-2-microglobulin 2004.00 350 12.420 1.0 R 83.80 4468 CA-549 2004.00 350 20.000 1.0 R 134.90 4470 CA-195 tumour marker 2004.00 350 20.000 1.0 R 134.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4478 Neopterin 2004.00 350 20.000 1.0 R 134.90 4477 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4478 Neopterin 2004.00 350 20.000 1.0 R 134.90 4477 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4477 Neuron specific enolase 2004.00 350 11.700 1.0 R 78.90 4480 Serotonin 2004.00 | | | 2004.00 | | | | R | | |
| 4468 CA-549 2004.00 350 20.000 1.0 R 134.90 | | | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | |
| 4470 CA-195 tumour marker 2004.00 350 20.000 1.0 R 134.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4478 Neopterin 2004.00 350 20.000 1.0 R 134.90 4477 Neuron specific enclase 2004.00 350 20.000 1.0 R 134.90 4478 Neuron specific enclase 2004.00 350 10.00 1.0 R 134.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 78.90 4480 Serotonin 2004.00 350 18.750 1.0 R 126.50 4481 Free thyroxine (FT4) 2004.00 350 17.480 1.0 R 117.90 4485 Insulin 2004.00 350 12.420 1.0 R 83.80 4491 Vitamin B12 200 | | | | | | | R | | |
| 4470 CA-195 turnour marker 2004.00 350 20.000 1.0 R 134.90 4471 Carcino-embryonic antigen 2004.00 350 20.000 1.0 R 134.90 4472 MCA antigen turnour marker 2004.00 350 20.000 1.0 R 134.90 4476 Neopterin 2004.00 350 20.000 1.0 R 134.90 4477 Neuron specific enclase 2004.00 350 20.000 1.0 R 134.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 78.90 4480 Serotonin 2004.00 350 18.750 1.0 R 126.50 4482 Free thyroxine (FT4) 2004.00 350 17.480 1.0 R 117.90 4485 Insulin 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 12.420 1.0 R 83.80 4491 Vitamin B12 <t< td=""><td>4469</td><td>Tumour markers: Monoclonal immunological (each)</td><td>2004.00</td><td></td><td></td><td></td><td>R</td><td></td><td></td></t<> | 4469 | Tumour markers: Monoclonal immunological (each) | 2004.00 | | | | R | | |
| 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4476 Neopterin 2004.00 350 20.000 1.0 R 134.90 4477 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 78.90 4480 Serotonin 2004.00 350 18.750 1.0 R 126.50 4482 Free thyroxine (FT4) 2004.00 350 17.480 1.0 R 117.90 4485 Insulin 2004.00 350 12.420 1.0 R 33.80 4490 Releasing hormone response 2004.00 350 50.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 50.000 1.0 R 33.80 4492 Vitamin D3: Calcitroii (RIA) 2004.00 350 75.000 1.0 R 83.80 4493 Drug concentration: Quantitative </td <td></td> <td></td> <td>2004.00</td> <td></td> <td></td> <td>10</td> <td>R</td> <td></td> <td></td> | | | 2004.00 | | | 10 | R | | |
| 4472 MCA antigen tumour marker 2004.00 350 20.000 1.0 R 134.90 4478 Neopterin 2004.00 350 20.000 1.0 R 134.90 4477 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 78.90 4480 Serotonlin 2004.00 350 11.700 1.0 R 126.50 4482 Free thyroxine (FT4) 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 50.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 50.000 1.0 R 83.80 4492 Vitamin D3: Calcitroii (RIA) 2004.00 350 75.000 1.0 R 83.80 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4495 Growth ho | 4471 | Carcino-embryonic antigen | 2004.00 | | | | | | |
| 4476 Neopterin 2004.00 350 20.000 1.0 R 134.90 4477 Neuron specific enolase 2004.00 350 20.000 1.0 R 134.90 4479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 78.90 4480 Serotonin 2004.00 350 18.750 1.0 R 126.50 4482 Free thyroxine (FT4) 2004.00 350 17.480 1.0 R 117.90 4485 Insulin 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 50.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4492 Vitamin D3: Calcitroil (RIA) 2004.00 350 12.420 1.0 R 505.90 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay | 4472 | MCA antigen tumour marker | 2004.00 | | | 1.0 | R | 134.90 | |
| 4479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 78.90 4480 Serotonin 2004.00 350 18.750 1.0 R 126.50 4482 Free thyroxine (FT4) 2004.00 350 17.480 1.0 R 117.90 4485 Insulin 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 50.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4492 Vitamin D3: Calcitroil (RIA) 2004.00 350 75.000 1.0 R 505.90 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quant | | | | | | | R | | |
| 4479 Vitamin B12-absorption: Shilling test 2004.00 350 11.700 1.0 R 78.90 4480 Serotonin 2004.00 350 18.750 1.0 R 126.50 4482 Free thyroxine (FT4) 2004.00 350 17.480 1.0 R 117.90 4485 Insulin 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 50.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4492 Vitamin D3: Calcitroil (RIA) 2004.00 350 75.000 1.0 R 505.90 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quant | 4477 | Neuron specific enolase | 2004.00 | | | | R | | |
| 4482 Free thyroxine (FT4) 2004.00 350 17.480 1.0 R 117.90 4485 Insulin 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 50.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4492 Vitamin D3: Calcitroil (RIA) 2004.00 350 75.000 1.0 R 505.90 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 12.420 1.0 R 83.80 4500 DHEA s | | | 2004.00 | | | | | | |
| 4485 Insulin 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 50.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4492 Vitamin D3: Calcitroil (RIA) 2004.00 350 75.000 1.0 R 505.90 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 12.420 1.0 R 83.80 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate | | | 2004.00 | | | | ĸ | | |
| 4485 Insulin 2004.00 350 12.420 1.0 R 83.80 4490 Releasing hormone response 2004.00 350 50.000 1.0 R 337.30 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4492 Vitamin D3: Calcitroil (RIA) 2004.00 350 75.000 1.0 R 505.90 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 12.420 1.0 R 83.80 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | 4482 | Free thyroxine (FT4) | 2004.00 | | | 1.0 | æ | | |
| 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4492 Vitamin D3: Calcitroil (RIA) 2004.00 350 75.000 1.0 R 505.90 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 12.420 1.0 R 83.80 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | | | 2004.00 | | | | | | |
| 4491 Vitamin B12 2004.00 350 12.420 1.0 R 83.80 4492 Vitamin D3: Calcitroil (RIA) 2004.00 350 75.000 1.0 R 505.90 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 12.420 1.0 R 83.80 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | 4490 | Releasing hormone response | | | | | | | |
| 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 29.080 1.0 R 196.00 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | | | | | | | | | |
| 4493 Drug concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 29.080 1.0 R 196.00 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | 4492 | Vitamin D3: Calcitroil (RIA) | | | | | | | |
| 4494 Free hormone assay 2004.00 350 17.480 1.0 R 117.90 4495 Growth hormone 2004.00 350 12.420 1.0 R 83.80 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 29.080 1.0 R 196.00 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | 4493 | | | | | | | | |
| 4496 Hormone concentration: Quantitative 2004.00 350 12.420 1.0 R 83.80 4497 Carbohydrate deficient transferrin 2004.00 350 29.060 1.0 R 196.00 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | 4494 | | 2004.00 | | | | | | |
| 4497 Carbohydrate deficient transferrin 2004.00 350 29.060 1.0 R 196.00 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | 4495 | Growth hormone | | | | | | | |
| 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | 4496 | Hormone concentration: Quantitative | | | | | | | |
| 4499 Cortisol 2004.00 350 12.420 1.0 R 83.80 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | 4497 | Carbohydrate deficient transferrin | 2004.00 | | | | R | | |
| 4500 DHEA sulphate 2004.00 350 12.420 1.0 R 83.80 | | | 2004.00 | | | | | | |
| | | DHEA sulphate | 2004.00 | | | | | | |
| | 4501 | | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | |

| 4502 | Free testosterone | 2004.00 | 350 | 17.480 | 1.0 | R | 117.90 | \neg |
|------|--|---------|-----|---------|-----|---|--------|---------------|
| 4503 | Oestradiol | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | П |
| 4505 | Oestrio | 2004.00 | 350 | 10.800 | | | 72.80 | ヿ |
| 4506 | Multiple antigen specific IgE screening test for Atopy | 2004.00 | 350 | | | | 251.30 | ヿ |
| 4507 | Thyrotropin (TSH) | 2004.00 | 350 | | | | 132.20 | \neg |
| 4508 | Combined antigen specific IgE | 2004.00 | 350 | 24.480 | 1.0 | R | 165.10 | \neg |
| 4509 | Free tri-iodothyronine (FT3) | 2004.00 | 350 | 17.480 | 1.0 | R | 117.90 | ヿ |
| 4512 | Parathormone | 2004.00 | 350 | 17.080 | | | 115.20 | \neg |
| 4513 | IgE: Total | 2004.00 | 350 | 12,420 | | | 83.80 | |
| 4514 | Antigen specific IgE | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | \neg |
| 4515 | Aldosterone | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | \neg |
| 4516 | Follitropin (FSH) | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | \neg |
| 4517 | Lutropin (LH) | 2004.00 | 350 | 12.420 | | | 83.80 | \neg |
| 4519 | Prostate specific antigen | 2004.00 | 350 | 14.490 | 1.0 | R | 97.70 | \neg |
| 4520 | 17 Hydroxy progesterone | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | |
| | Progesterone | 2004.00 | 350 | | | | 83.80 | |
| 4522 | Alpha-feto protein | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | \neg |
| 4523 | ACTH | 2004.00 | 350 | 21.740 | 1.0 | R | 146,60 | \neg |
| 4526 | Sex hormone binding globulin | 2004.00 | 350 | 12.420 | | | 83.80 | |
| 4527 | Gastrin | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | |
| 4528 | Ferritin | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | |
| 4529 | Anti-DNA antibodies | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | \neg |
| 4530 | Antiplatelet antibodies | 2004.00 | 350 | 15,300 | 1.0 | R | 103.20 | \neg |
| 4531 | Hepatitis: Per antigen or antibody | 2004.00 | 350 | 14.490 | 1.0 | R | 97.70 | |
| 4532 | Transcobalamine | 2004.00 | 350 | 12.420 | 1.0 | Ŕ | 83.80 | |
| 4533 | Folic acid | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | |
| 4534 | Prostatic acid phosphatase | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | $\overline{}$ |
| 4536 | Erythrocyte folate | 2004.00 | 350 | 17.480 | 1.0 | R | 117.90 | |
| 4537 | Prolactin | 2004.00 | 350 | 12.420 | 1.0 | R | 83.80 | \neg |
| 4540 | HCG: Quantitative as used for Down's screen | 2004.00 | 350 | 15.000 | 1.0 | R | 101.20 | |
| | Clinical pathology: Miscellaneous | | | | | | | |
| 4544 | Attendance in theatre | 2004.00 | 350 | 27.000 | 1.0 | R | 182.10 | |
| | Exfoliative cytology | | | | | | = $=$ | |
| | Sputum, all body fluids and tumour aspirates: First unit | 2004.00 | 351 | 13.400 | | | 104.20 | |
| | Sputum, all body fluids and tumour aspirates: Each additional unit | 2004.00 | 351 | 7.800 | | | 60.70 | |
| | Performance of fine-needle aspiration for cytology | 2004.00 | 351 | 15.000 | 1.0 | R | 116.70 | |
| 4565 | Examination of fine needle aspiration in theatre | 2004.00 | 351 | 90,000 | 1.0 | R | 700.10 | |
| 4566 | Vaginal or cervical smears, each | 2004.00 | 351 | 11.000 | 1.0 | R | 85.60 | |
| | Human Genetics | | | | | | | |
| | Cytogenito | | | | | | | |
| 4750 | Cell culture: Lymphocytes, cord blood | 2004.00 | 352 | 15.000 | 1.0 | R | 103.60 | |
| | Cell culture: Amniotic fluid, fibroblasts, leukaemia bloods, bone marrow, other specialised cultures | | | | | | | |
| 4751 | | 2004.00 | 352 | | | | 310.80 | |
| | Cell culture: Chorionic villi | 2004.00 | 352 | 60,000 | | | 414.40 | |
| | Cytogenetic analysis: Lymphocytes: Idiograms, karyotyping, one staining technique | 2004.00 | 352 | 135.000 | | | 932.40 | |

| | Cytogenetic analysis: Armniotic fluid, fibroblasts, chorionic villi, products of conception, bone marrow, leukamia bloods: Idiograms, karyotyping, one straining technique | 2004.00 | 352 | 270.000 | 1.0 | R | 1 864.90 | |
|------|--|---------|-----|---------|-----|---|----------|----------|
| 4757 | Specified additional analysis e.g. mosalcism, Fanconi anaemia, Fra X, additional staining techniques | 2004.00 | 352 | 70.000 | 1.0 | R | 483.50 | |
| 4760 | FISH procedure, including cell culture | 2004.00 | 352 | 115.000 | 1.0 | R | 794.30 | \sqcup |
| 4761 | FISH analysis per probe system | 2004.00 | 352 | 35.000 | 1.0 | R | 241.70 | Ш |
| | DNA-testing | | | | | | | \sqcup |
| 4763 | Blood: DNA extraction | 2004.00 | 352 | 45.000 | 1.0 | R | 310.80 | Ш |
| 4764 | Blood: Genotype per person: Southern blotting | 2004.00 | 352 | 89,000 | 1.0 | R | 614.70 | Ш |
| | Blood: Genotype per person: PCR | 2004.00 | 352 | 60.000 | 1.0 | R | 414.40 | \sqcup |
| 4767 | Prenatal diagnosis: Amniotic fluid or chorionic tissue: DNA extraction | 2004.00 | 352 | 90.000 | 1.0 | R | 621.60 | |
| | Prenatal diagnosis: Amniotic fluid or chorionic tissue: Genotype per person: Southern blotting | 2004.00 | 352 | 188.000 | 1.0 | R | 1 298.50 | Ш |
| | Prenatal diagnosis: Amniotic fluid or chorlonic tissue: Genotype per person: PCR | 2004.00 | 352 | 120.000 | 1.0 | R | 828.80 | |

| Code | Description |
|-------|--------------------|
| 37600 | Medical Technology |

| Code | Description | RCF |
|------|---|-------|
| 350 | Medical Technology - Clinical Pathology | 6.745 |
| 351 | Medical Technology - Cytology | 7.779 |
| 352 | Medical Technology - Genetics | 6.907 |

| No | 30 | 11 | Ω | 47 |
|-----|-----|----|---|----|
| NO. | .30 | 41 | u | 41 |

MENTAL HEALTH INSTITUTIONS

| | | | | | 55500 | | | | | | | |
|-----|---|---------|----------|---------------|--------------|----------|-------|---------|--|--|--|--|
| | NATIONAL REFERENCE PRICE LIST IN RESPECT OF MENTAL HEALTH CARE FACILITIES | l | l | - | | | | | | | | |
| | | Version | Add | CF | Units | BF | Value | Flag | | | | |
| | The following reference price list is not a set of tariffs that must be applied by medical schemes | | 1 | | | i l | | 1 1 | | | | |
| | and/or providers. It is rather intended to serve as a baseline against which medical schemes can | | | | | l | | | | | | |
| | Individually determine benefit levels and health service providers can individually determine fees | l | l | | | ΙI | | 1 | | | | |
| | charged to patients. Medical schemes may, for example, determine in their rules that their benefit in | ļ . | | | | ΙI | | 1 | | | | |
| | respect of a particular health service is equivalent to a specified percentage of the national health | | | | | | | 1 1 | | | | |
| | reference price list. It is especially intended to serve as a basis for negotiation between individual | l | | l | | l | | 1 1 | | | | |
| | funders and individual health care providers with a view to facilitating agreements which will minimise | | | | | | | 1 1 | | | | |
| | balance billing against members of medical schemes. Should Individual medical schemes wish to | | | | | | | ΙI | | | | |
| | determine benefit structures, and individual providers determine fee structures, on some other basis | | | | | | | 1 1 | | | | |
| | without reference to this list, they may do so as well.□ | | | | | | | 1 1 | | | | |
| | in calculating the prices in this schedule, the following rounding method is used: Values R10 and | | | | | | | | | | | |
| | below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded | 2004.00 | | | | | | | | | | |
| | GENERAL RULES | | | | | | | | | | | |
| | It is recommended that, when such benefits are granted, drugs, consumables and disposable items | | | | | | | 7 1 | | | | |
| | used during a procedure or issued to a patient on discharge will only be reimbursed by a medical | 1 | | | | | | 1 ! | | | | |
| a I | scheme if the appropriate code is supplied on the account. | 2004.00 | | | | | | \perp | | | | |
| | All accounts submitted by mental health institutions shall comply with all of the requirements in terms | | | | | | | 1 1 | | | | |
| | of the Medical Schemes Act, Act No. 131 of 1999. Where possible, such accounts shall also reflect | | l | | | | | 1 1 | | | | |
| | the practice code numbers and names of the surgeon, the anaesthetist and of any assistant surgeon | | l | | | | | 1 1 | | | | |
| С | who may have been present during the course of an operation. | 2004.00 | _ | _ | | | | ╨ | | | | |
| 1 | All accounts shall be accompanied by a copy of the relevant theatre accounts specifying all details of | | | | | | | | | | | |
| | items charged, as well as all the procedures performed. Photocopies of all other documents | | | | | ı | | 1 1 | | | | |
| | pertaining to the patients account must be provided on request. Medical schemes shall have the right | | | 1 | | ı | | 1 1 | | | | |
| | | 2004.00 |] | | | ı | | 1 1 | | | | |
| ם | to inspect the original source documents at the rehabilitation hospital concerned. | 2004.00 | ┪ | | - | \vdash | | + | | | | |
| | All accounts containing items which are subject to a discount in terms of the recommended benefit | 1 | l | | | | | | | | | |
| Ę | shall indicate such items individually and shall show separately the gross amount of the discount. | 2004.00 | <u> </u> | <u> </u> | | | | 4— | | | | |
| | Mental Institutions refers to all institutions registered with the Department of Health in terms of the | | | | | | | | | | | |
| | Mental Health Care Act 17 of 2002 having practice code numbers commencing with the digits 55. | 2006.04 | d | | | | | | | | | |
| J.J | Mential Fledial Care Act 17 of 2002 having practice code numbers continuently with the digits 55. | L000.04 | | $\overline{}$ | | 1 | | | | | | |

| | | | | | _ | | | | |
|-----|--|---------|--------|-----|--------|-----|---|--------|----|
| | Accommodation fees includes the services listed below: | | | | | | | | |
| | A.□The minimum services that are required are items 3, 5 and 6. | | | | | | | | |
| | B. If managed care organisations or medical schemes request any of the other services included in this list, no additional charge may be levied by the hospital. | | | | | | | | |
| | 1 □ Pre-authorisation (up to the date of admission) of: - length of stay | | | | | | | | |
| l | level of care | | - 1 | - 1 | | | | | [|
| | · theatre procedures | | | | | | | | |
| | 2□Provision of ICD-10 and CPT-4 codes when requesting pre-authorisation | | | | | | | | |
| | 3⊡Notification of admission | | ĺ | | | | | | |
| | 4□Immediate notification of changes to: | | | | | | | | |
| | · length of stay | | | | | | | | |
| | ievel of care | | - 1 | | l | | İ | | 1 |
| | · theatre procedures | | | - | | | | | |
| | 5⊡Reporting of length of stay and level of care | | | - | | | | | |
| | In standard format for purposes of creating a minimum dataset of information to be used in defining | 1 1 | | | | | | | 1 |
| | an alternative reimbursement system. | | - 1 | | | | | | |
| | 6□Discharge ICD-10 and CPT-4 coding | | ı | | | | | | H |
| | In standard format for purposes of creating a minimum dataset of information to be used in defining | | - 1 | | | | | | |
| | an alternative reimbursement system. | | - 1 | - 1 | | | | | ΙI |
| F | Including coding of complications and co-morbidity. To be done as accurately as practically | 2004.00 | J | ļ | | | | | ļļ |
| | SCHEDULE | | | ▔▔ | | | | | М |
| | INSTITUTIONS REGISTERED IN TERMS OF THE MENTAL HEALTH ACT 1973 WITH A | | \neg | ╗ | | | | | П |
| 8 | PRACTICE NUMBER COMMENCING WITH "55" | | - [| | | | | | |
| 004 | General ward fee: with overnight stay | 2004.00 | | 470 | 10.000 | | | 838.60 | |
| | General ward fee: without overnight stay | 2004.00 | | 470 | 7.355 | | | 616.80 | |
| 006 | General ward fee: under 5 hours stay | 2004.00 | | 470 | 3.808 | 1.0 | R | 319.40 | |
| | Ward and dispensary drugs. The amount charged in respect of dispensed medicines and | | | | | | | | |
| | scheduled substances shall not exceed the limits prescribed in the Regulations Relating to a | | | | | | | | |
| | Transparent Pricing System for Medicines and Scheduled Substances, dated 30 April 2004, made | | | - 1 | | | | | |
| | in terms of the Medicines and Related Substances Act, 1965 (Act No 101 of 1965). | | | | | | | | |
| | In relation to other ward stock (materials and/or medicines), the amount charged shall not exceed the | | | | | | | | |
| | net acquisition price (inclusive of VAT) or the exit price as determined in terms of Act No 101 of | | | | | | | | |
| 045 | 1965 | 2005.03 | | 470 | | 1.0 | R | - | |
| 055 | Electroconvulsive therapy (ECT) (No theatre fee chargeable) | 2004.00 | | 470 | | 1.0 | | 419.10 | |
| 231 | Monitors | 2006.04 | | 470 | 1.463 | 1.0 | R | 122.70 | Z |

| | | | | | | | | П |
|---|-----|---|---------|-----|---|-----|---|-----|
| | | To take out. Dispensed items including ampoules, over the counter and proprietary items issued to | | | | | | 1 |
| | | patients. All items must be shown on accounts. Dispensed items including ampoules, over the | | | | | | 1 1 |
| Ŀ | 273 | counter and proprietary items issued to patients. The same principles as in code 045 apply. | 2004.00 | 470 | - | 1.0 | R | |

5

| Code | Description |
|-------|----------------------------|
| 55500 | Mental Health Institutions |

| | | | L | | | 55 | 500 | |
|----------|---|---------|----------|----------|--------------|----|-------|----------|
| | NATIONAL REFERENCE PRICE LIST IN RESPECT OF MENTAL HEALTH CARE FACILITIES | | | | | | | |
| <u> </u> | WITH EFFECT FROM 1 JANUARY 2008 | Version | Add | CF | <u>Units</u> | BF | Value | Flag |
| | The following reference price list is not a set of tariffs that must be applied by medical schemes | | | | | | | 1 I |
| i | and/or providers. It is rather intended to serve as a baseline against which medical schemes can | | | | | | | 1 1 |
| | Individually determine benefit levels and health service providers can individually determine fees | | | | | | | 1 1 |
| | charged to patients. Medical schemes may, for example, determine in their rules that their benefit in | | | | | | | 1 1 |
| | respect of a particular health service is equivalent to a specified percentage of the national health | | | | | | | 1 ! |
| i | reference price list. It is especially intended to serve as a basis for negotiation between individual | | 1 | | | | | 1 1 |
| l . | funders and individual health care providers with a view to facilitating agreements which will minimise | | | | | | | 1 1 |
| l | balance billing against members of medical schemes. Should individual medical schemes wish to | | | | | | | 1 1 |
| l | determine benefit structures, and individual providers determine fee structures, on some other basis | | | | | | | 1 1 |
| l | without reference to this list, they may do so as well.□ | | l | | | | | 1 1 |
| l | In calculating the prices in this schedule, the following rounding method is used: Values R10 and | | l | | | | | 1 1 |
| | below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifler values are rounded | | ! | | | | | 1 1 |
| <u> </u> | VAT EXCLUSIVE PRICES APPEAR IN BRACKETS. | 2004.00 | | | _ | | | ↓ |
| Ь— | GENERAL RULES | | <u> </u> | | | | | 4 |
| | It is recommended that, when such benefits are granted, drugs, consumables and disposable items | | | | | | | 1 1 |
| l | used during a procedure or issued to a patient on discharge will only be reimbursed by a medical | | | | | | | 1 1 |
| Α | scheme if the appropriate code is supplied on the account. | 2004.00 | | | | Ь. | | \bot |
| l . | All accounts submitted by mental health institutions shall comply with all of the requirements in terms | | | | | | | 1 1 |
| | of the Medical Schemes Act, Act No. 131 of 1999. Where possible, such accounts shall also reflect | | | | | | | 1 1 |
| | the practice code numbers and names of the surgeon, the anaesthetist and of any assistant surgeon | | | | | | | 1 1 |
| С | who may have been present during the course of an operation. | 2004.00 | | | | | | + |
| | All accounts shall be accompanied by a copy of the relevant theatre accounts specifying all details of | | | | | | | 1 1 |
| | items charged, as well as all the procedures performed. Photocopies of all other documents | | | | | | | |
| | pertaining to the patients account must be provided on request. Medical schemes shall have the right | | 1 | | | | | 1 1 |
| n . | , | 2004.00 | | | |] | | 1 1 |
| D | to inspect the original source documents at the rehabilitation hospital concerned. | 2004.00 | \vdash | \vdash | | ⊢ | | + |
| | All accounts containing items which are subject to a discount in terms of the recommended benefit | | ١., | | | | | |
| E | shall indicate such items individually and shall show separately the gross amount of the discount. | 2004.00 | | | | | | |
| | | | | | | | | |
| | Mental institutions refers to all institutions registered with the Department of Health in terms of the | 0000 5 | | | | | | |
| E.3.3 | Mental Health Care Act 17 of 2002 having practice code numbers commencing with the digits 55. | 2006.04 | | | | | | |

| | Accommodation fees includes the services listed below: | | | | | | | | |
|-----|--|---------|---|-----|--------|-----|---|--------|----------|
| | A. □The minimum services that are required are items 3, 5 and 6. | | | | | | | | |
| | B. If managed care organisations or medical schemes request any of the other services included in this list, no additional charge may be levied by the hospital. | | | | | | | | |
| | 1 □ Pre-authorisation (up to the date of admission) of: · length of stay | | | | | | | | |
| l | level of care | | | - 1 | | | | | 1 1 |
| 1 | | | | . 1 | | | | | |
| | · theatre procedures | | | | | | | | ΙI |
| | 2□Provision of ICD-10 and CPT-4 codes when requesting pre-authorisation | | | | | | | | |
| : | 3□Notification of admission | | | | | | | | |
| | 4□Immediate notification of changes to: | | | | | | | | $ \ $ |
| | length of stay | | 1 | 1 | | | | | 1 1 |
| l | level of care | | | | | . ! | | | |
| | · theatre procedures | | | | | | | | Ιł |
| | 5⊡Reporting of length of stay and level of care | | | 1 | | | | | |
| l | In standard format for purposes of creating a minimum dataset of information to be used in defining | | | | | | | | |
| | an alternative reimbursement system. | | | | | | | | |
| | an another of our war well with a yacture. | | | | | 1 | | | |
| İ | 6□Discharge ICD-10 and CPT-4 coding | | | | | | | | ΙI |
| | · In standard format for purposes of creating a minimum dataset of information to be used in defining | | | | | | | | I 1 |
| | an alternative reimbursement system. | | | | | | | | ΙI |
| F | | 2004.00 | | | | | | | Ιl |
| | SCHEDULE | | | | | | | | \vdash |
| | INSTITUTIONS REGISTERED IN TERMS OF THE MENTAL HEALTH ACT 1973 WITH A | | | | | | | | М |
| 8 | PRACTICE NUMBER COMMENCING WITH "55" | | | | | | | | |
| 004 | General ward fee: with overnight stay | 2004.00 | | 470 | 10.000 | 1.0 | R | 838.60 | |
| 005 | General ward fee: without overnight stay | 2004.00 | | 470 | 7.355 | 1.0 | | 616.80 | |
| 006 | | 2004.00 | | 470 | 3.808 | 1.0 | R | 319.40 | |
| | Ward and dispensary drugs. The amount charged in respect of dispensed medicines and | | | | | | | | |
| | scheduled substances shall not exceed the limits prescribed in the Regulations Relating to a | | | | | | | | |
| | Transparent Pricing System for Medicines and Scheduled Substances, dated 30 April 2004, made | | | | | | | | |
| | In terms of the Medicines and Related Substances Act, 1965 (Act No 101 of 1965). | | | | | | | | |
| | In relation to other ward stock (materials and/or medicines), the amount charged shall not exceed the | , | | | | | | | |
| | net acquisition price (inclusive of VAT) or the exit price as determined in terms of Act No 101 of | | | | | | | | |
| 045 | | 2005.03 | | 470 | _ | 1.0 | R | - | |
| 055 | Electroconvulsive therapy (ECT) (No theatre fee chargeable) | 2004.00 | | 470 | | 1.0 | | 419.10 | |
| 231 | Monitors | 2006,04 | | 470 | 1.463 | | | 122.70 | z |
| | | | | | | | | | - |

| 1 | | | | | | | | ı |
|-----|-----|---|---------|-----|---|-----|-----|---|
| ı | | To take out. Dispensed items including ampoules, over the counter and proprietary items issued to | | | | | | ı |
| - 1 | | patients. All items must be shown on accounts. Dispensed items including ampoules, over the | | | | l | | ı |
| L | 273 | counter and proprietary items issued to patients. The same principles as in code 045 apply. | 2004.00 | 470 | - | 1.0 | R - | ı |

55

| Code | Description | |
|-------|----------------------------|--|
| 55500 | Mental Health Institutions | |

| Code | Description | RCF |
|--------------------------------|-------------|------------|
| 470 Mental Health Institutions | | 83.864 |

OPTOMETRISTS

Optometrists 2008

NATIONAL REFERENCE PRICE LIST FOR SERVICES BY OPTOMETRISTS EFFECTIVE FROM 1 JANUARY 2008

The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees a baseline against which interleas a colorine can individually determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well.

In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+

rounded to the nearest 10cent. Modifier values are rounded to the nearest cent. When new item prices are calculated, e.g. when applying a modifier, the same rounding scheme should be followed.

| VAT EX | CLUSIVE PRICES APPEAR IN BRACKETS. | | | |
|--------|--|---------|-------------|-------------------------|
| RUI ES | [발발: [1] 12 [1] 12 [1] 12 [1] 12 [12 [12 [12 [12 [12 [12 [12 [12 [12 | | 1. May 1. | |
| MODIF | ERS: | | | |
| ITEMS | | | | 27 Nov. 18 at 2 2 2 2 2 |
| | tations: | | 7.4 / 2.1 / | |
| Code | | Ver Add | | metry |
| 2 2 | | | RVU | Fee |
| 11001 | Optometric Examination (incl Tonometry) | 06.02 | 30.000 | 195.90 (171.80) |
| 11081 | Optometric Examination & Visual Fields | 06.02 | 35.000 | 228.60 (200.50) |
| 11021 | Optometric-Re-examination | 06.02 | 20.000 | 130.60 (114.60) |
| 11041 | Consultation :15 min. without performing Optometric Exam. | 06.02 | 15.000 | 98.00 (86.00) |
| Diagno | stic Procedures: | | 1.1 | N. W. S. |
| 11303 | Cycloplegic Refraction | 06.02 | 15.000 | 98.00 (86.00) |
| 11323 | Preferential Looking (Infants < Two Years) | 06.02 | 15.000 | 98.00 (86.00) |
| 11346 | Comeal Topography | 06.02 | 20.000 | 130.60 (114.60) |
| 11356 | Gonioscopy | 06.02 | 10.000 | 65.30 (57.30) |
| 11366 | Dilated Fundus Examination / BIO | 06.02 | 10.000 | 65.30 (57.30) |
| 11423 | Visual Field | 06.02 | 15.000 | 98.00 (86.00) |
| 11443 | Threshold Visual Fields | 06.02 | 25.000 | 163.30 (143.20) |
| 11246 | Revaluation of Colour Vision | 06.02 | 15.000 | 98.00 (86.00) |
| 11265 | Evaluation of Contrast Sensitivity | 06.02 | 10.000 | 65.30 (57.30) |
| 11283 | Evaluation of Lacrimal System | 06.02 | 10.000 | 65.30 (57.30) |
| 11604 | Photography of Anterior Segment | 06.02 | 10.000 | 65.30 (57.30) |
| 11624 | Photography of Fundus | 06.02 | 10.000 | 65.30 (57.30) |
| 11644 | Photographic Materials | 06.02 | - | - |
| Proced | ures done in isolation | | | |
| 11141 | Evaluation of Refractive Status | 06.02 | 20.000 | 130.60 (114.60) |
| 11161 | Screening for Pathology | 06.02 | 15.000 | 98.00 (86.00) |
| 11183 | Keratometry | 06.02 | 10.000 | 65.30 (57.30) |
| 11202 | Tonometry (Non-contact) | 06.02 | 10.000 | 65.30 (57.30) |
| 11212 | Tonometry (Aplanation) | 06.02 | 10.000 | 65.30 (57.30) |
| 11221 | Screening of Colour Vision | 06.02 | 5.000 | 32.70 (28.70) |
| 11402 | Screening of Visual Fields | 06.02 | 10.000 | 65.30 (57.30) |
| 12503 | Assessment of CL Related Problems - Monocular | 06.02 | 10.000 | 65.30 (57.30) |
| 12523 | Assessment of CL Related Problems - Binocular | 06.02 | 15.000 | 98.00 (86.00) |

| Code | Description | Ver | Add Op | tometry Fee |
|----------|---|-------------------|---------------------|---|
| <u> </u> | | | 1 1 1 K 1 2 8 2 9 1 | H. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. |
| 12533 | CL Instruction | 06.02 | 15.000 | 98.00 (86.00) |
| Dispen | sing Fees | 11111 | | 4747 787 |
| 11501 | Dispensing Fee - Single Vision | 06.02 | 5.000 | 32.70 (28.70) |
| 11521 | Dispensing Fee - Bifocals | 06.02 | 10.000 | 65.30 (57.30) |
| 11541 | Dispensing Fee - Varifocals | 06.02 | 10.000 | 65.30 (57.30) |
| 11707 | Night/Weekend/Public Holiday Visit | 06.02 | 15.000 | 98.00 |
| 11729 | Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 06.02 | - | , |
| 11809 | Screening School (per hour) | 06.02 | 60.000 | 391.90 (343.80) |
| 11829 | Screening Industrial (per hour) | 06.02 | 60.000 | 391.90 (343.80 |
| Contac | t Lens Procedures | , # Jan 117 | - 4 - 4 - 4 - 4 | |
| 12012 | Basic - per visit | 06.02 | 30.000 | 195.90 (171.80 |
| 12032 | Complex - per visit | 06.02 | 30.000 | 195.90 (171.80) |
| 12052 | Advanced - per visit | 06.02 | 30.000 | 195.90 (171.80) |
| 12072 | CL Dispensing and/or Assessment | 06.02 | 15.000 | 98.00 |
| Pinocu | lar Vision/Orthoptics | Paragraphy | 1- 9: 4170 ag | |
| 13003 | Evaluation of Binocular Instability Simple Case | 06.02 | 30.000 | 195.90 (171.80 |
| 13023 | Evaluation of Binocular Instability Complex Case | 06.02 | 60.000 | 391.90 (343.80) |
| Vienali | Related Disorders | 1 1 1 1 1 1 1 1 1 | VI. (1972) | |
| 13105 | Evaluation of Visually Related Learning Disorders | 06.02 | 90.000 | 587.80 (515.60) |
| 13125 | Evaluation of Eye Movements (e.g. Visigraph) | 06.02 | 30.000 | 195.90 (171.80 |
| Colorin | netry Codes | | De Laberto | |
| 13509 | Screening - Rate of Reading Test | 06.02 | 15.000 | 98.00 (86.00) |
| 13529 | Evaluation - Ortho-Didactical Reading Skills | 06.02 | 45.000 | 293.90 (257.80 |
| 13549 | Evaluation - Intuitive Colorimetry | 06.02 | 60.000 | 391.90 (343.80 |
| Visual | Therapy/Orthoptics Training | | | ola ala |
| 13403 | Training Home Therapy Instruction | 06.02 | 10.000 | 65.30 (57.30 |
| 13423 | Training Individual (per 15 minutes) | 06.02 | 15.000 | 98.00 |
| 13445 | Training Individual (per 30minutes) | 06.02 | 30.000 | 195.90 (171.80 |
| 13463 | Training Group per Patient (per 15 minutes) | 06.02 | 3.750 | 24.50 (21.50 |
| 13489 | Training Away from Practice | 06.02 | 30.000 | 195.90 (171.80 |
| Low Vi | sion Assessment & Training (per Half hour) | 2.72 | 製を製造され | PYRK |
| 16013 | Simple LV Assessment | 06.02 | 30.000 | 195.90 (171.80 |
| 16033 | Complex LV Assessment | 06.02 | 30.000 | (171.80 |
| 16053 | Advanced LV Assessment | 06.02 | 30.000 | 195.90 (171.80 |
| 16073 | Simple LV Training | 06.02 | 30.000 | 195.90 (171.80 |
| 16093 | Complex LV Training | 06.02 | 30.000 | 195.90 (171.80 |
| 16113 | Advanced LV Training | 06.02 | 30.000 | (171.80 |
| Sports | Vision - In Office Procedures | 703.5 | | 1 |
| | Screening Sports Vision Individual | 06.02 | 20.000 | 130.60 |

85012

84000

99999 All other codes

Varifocal Distance to near

Varifocal Intermediate to Near

98.00

24.50 (21.50)

57.10

24.50

195.90

98.00

40.80

(35.80)

(71.60)

81.60

24.50

98.00 (86.00)

163.30

32.70

176.90

829.30 (727.50)

829.30 (727.50)

06.02

06.05

06.02

11,128

11.128

61

| | | | | | | 37 | 000 | |
|-------|---|-------------|-----|----------------------|--------|-----|---------------|--------|
| | NATIONAL REFERENCE PRICE LIST FOR SERVICES BY OPTOMETRISTS EFFECTIVE FROM 1 JANUARY 2008 | Version | Add | CF | Units | 8F | Va <u>lue</u> | Flag |
| | The following reference price list is not a set of tariffs that must be applied by medical schemes | | | | | | | Т |
| | and/or providers. It is rather intended to serve as a baseline against which medical schemes can | 1 1 | 1 | | | | | 1 |
| | individually determine benefit levels and health service providers can individually determine fees | | | | | | | 1 |
| | charged to pattents. Medical schemes may, for example, determine in their rules that their benefit in | | | | | | | |
| | respect of a particular health service is equivalent to a specified percentage of the national health | | | | | ! | | 1 |
| | reference price list. It is especially intended to serve as a basis for negotiation between individual | | | | | | | |
| | funders and individual health care providers with a view to facilitating agreements which will minimise | | | | | | | 1 |
| | balance billing against members of medical schemes. Should individual medical schemes wish to | | | | | | | 1 |
| | determine benefit structures, and individual providers determine fee structures, on some other basis | ' | | | | | | 1 |
| | without reference to this list, they may do so as well.□ | | | | | | | 1 |
| | in calculating the prices in this schedule, the following rounding method is used: Values R10 and | | | | | | | |
| | below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded | 1 1 | | | | | | |
| | VAT EXCLUSIVE PRICES APPEAR IN BRACKETS. | 2006.02 | | | | | | +- |
| | RULES | | | - | | | | +- |
| | ITEMS | | | $\vdash\vdash\vdash$ | | | | +- |
| | Consultations: | | - | - | | | | ┿ |
| 1001 | Optometric Examination (incl Tonometry) | 2006.02 | | 490 | 30.000 | 1.0 | R 195.90 | + |
| | Optometric Examination & Visual Fields | 2006.02 | | 490 | 35.000 | | | |
| | Optometric-Re-examination | 2006.02 | - | 490 | 20.000 | | | _ |
| | Consultation :15 min. without performing Optometric Exam. | 2006.02 | | 490 | 15.000 | | | _ |
| | Diagnostic Procedures: | 2000.02 | - | 700 | 10.000 | 1.0 | 10 30.00 | ┰ |
| | Cycloplegic Refraction | 2006.02 | | 490 | 15.000 | 1.0 | R 98.00 | + |
| | Preferential Looking (Infants < Two Years) | 2006.02 | | 490 | 15.000 | | | _ |
| | Corneal Topography | 2006.02 | _ | 490 | 20.000 | | _ | _ |
| | Gonioscopy | 2006.02 | | 490 | 10.000 | | | |
| | Dilated Fundus Examination / BIO | 2006.02 | _ | 490 | 10.000 | | | |
| 11423 | Visual Field | 2006.02 | _ | 490 | 15.000 | | | |
| | Threshold Visual Fields | 2006.02 | | 490 | 25.000 | | | _ |
| 1246 | Revaluation of Colour Vision | 2006.02 | | 490 | 15.000 | 1.0 | R 98.00 | \top |
| 1265 | Evaluation of Contrast Sensitivity | 2006.02 | | 490 | 10.000 | 1.0 | R 65.30 | |
| 11283 | Evaluation of Lacrimal System | 2006.02 | | 490 | 10.000 | 1.0 | R 65.30 | 1 |
| 1604 | Photography of Anterior Segment | 2006.02 | Ì | 490 | 10.000 | 1.0 | R 65.30 | \top |
| 1624 | Photography of Fundus | 2006.02 | | 490 | 10.000 | 1.0 | R 65.30 | |
| 1644 | Photographic Materials | 2006.02 | | 490 | | 1.0 | R | |
| | Procedures done in isolation | | | | | | | |
| | Evaluation of Refractive Status | 2006.02 | | 490 | 20,000 | | | |
| | Screening for Pathology | 2006.02 | | 490 | 15.000 | | | |
| _ | Keratometry | 2006.02 | | 490 | 10.000 | | | |
| | Tonometry (Non-contact) | 2006.02 | | 490 | 10.000 | 1.0 | | |
| | Tonometry (Aplanation) | 2006.02 | | 490 | 10.000 | | | |
| 11221 | Screening of Colour Vision | 2006.02 | | 490 | 5.000 | 1.0 | R 32.70 | |

| 11402 Screening of Visual Fields 2006.02 490 10,000 1,0 R 65,30 12523 Assessment of CL Related Problems - Monocular 2006.02 490 10,000 1,0 R 98,00 12523 Assessment of CL Related Problems - Binocular 2006.02 490 15,000 1,0 R 98,00 12523 Assessment of CL Related Problems - Binocular 2006.02 490 15,000 1,0 R 98,00 12523 CL Instruction 2006.02 490 15,000 1,0 R 98,00 1500 Disparating Fee - Birocular 2006.02 490 15,000 1,0 R 98,00 1500 Disparating Fee - Birocular 2006.02 490 10,000 1,0 R 65,30 11541 Disparating Fee - Birocular 2006.02 490 10,000 1,0 R 65,30 11541 Disparating Fee - Birocular 2006.02 490 10,000 1,0 R 65,30 11707 Right/Websand/Public Holdsy Visit 2006.02 490 15,000 1,0 R 98,00 11707 Right/Websand/Public Holdsy Visit 2006.02 490 15,000 1,0 R 98,00 11707 Right/Websand/Public Holdsy Visit 2006.02 490 15,000 1,0 R 98,00 11509 Screening School (ger hour) 2006.07 490 20 | 44.455 | A 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 000000 | 14001 | 40.000 4.0 | 1 5 | 65.40 | \neg |
|--|--------|---|----------|--------|------------|----------------|--------|-----------------------|
| 18523 Assessment of CL Related Problems - Binocular 2006.02 490 15.000 1.0 R 98.00 | | | | | | | | \dashv |
| 18533 CL Instruction 2006.02 490 15,000 1.0 R 98.00 | 12503 | Assessment of CL Related Problems - Monocular | | | | | | \dashv |
| Disparsing Fees Disparsing Fees Single Vision 2006.02 490 5.000 1.0 R 32.70 | | | | | | | | $\boldsymbol{\dashv}$ |
| 1500 Dispensing Fee - Single Vision | 12533 | | 2006.02 | 490 | 15.000 1.0 |) R | 98.00 | — |
| 11521 Dispensing Fee - Varifocals 2006.02 490 10.000 1.0 R 65.30 11541 Dispensing Fee - Varifocals 2006.02 490 15.000 1.0 R 85.30 11770 NigirWeekend/Public Holiday Visit Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall 11729 Into the "By arrangement with the scheme" or "Patient own account" category). 2006.02 490 60.000 1.0 R 391.90 11809 Screening School (per hour) 2006.02 490 60.000 1.0 R 391.90 11809 Screening Industrial (per hour) 2006.02 490 60.000 1.0 R 391.90 12012 Basic - per visit 2006.02 490 30.000 1.0 R 195.90 12012 Basic - per visit 2006.02 490 30.000 1.0 R 195.90 12022 Complex - per visit 2006.02 490 30.000 1.0 R 195.90 12072 C.D. Dispensing and/or Assessment 2006.02 490 30.000 1.0 R 195.90 12072 C.D. Dispensing and/or Assessment 2006.02 490 30.000 1.0 R 195.90 13003 Evaluation of Binocular Instability Complex Case 2006.02 490 30.000 1.0 R 195.90 13125 Evaluation of Visually Related Disorders 2006.02 490 30.000 1.0 R 195.90 13125 Evaluation of Visually Related Disorders 2006.02 490 30.000 1.0 R 195.90 13509 Evaluation of Visually Related Disorders 2006.02 490 30.000 1.0 R 195.90 13629 Evaluation of Orthocol Relating Skills 2006.02 490 30.000 1.0 R 195.90 13629 Evaluation of Orthocol Relating Skills 2006.02 490 30.000 1.0 R 195.90 13629 Evaluation of Orthocol Relating Skills 2006.02 490 30.000 1.0 R 195.90 13629 Evaluation of Orthocol Relating Skills 2006.02 490 30.000 1.0 R 195.90 13629 Evaluation of Orthocol Relating Skills 2006.02 490 30.000 1.0 R 195.90 13629 13629 13629 13629 13629 13629 13629 13629 13629 13629 13629 13629 13629 13629 13629 13629 13629 13629 1 | | | | + | | ↓_ | | _ |
| 15451 Disparaing Fee - Varifocals 2006.02 490 10.000 1.0 R 65.30 | 11501 | Dispensing Fee - Single Vision | | | | | | |
| 11707 Night/Weekend/Public Hoilday Visit | 11521 | Dispensing Fee - Bifocals | | _ | | | | _ |
| Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall 11723 Into the "By arrangement with the scheme" or "Petient own account" category). 2006.02 490 60.000 1.0 R 391.90 11829 Screening Inclustrial (per hour) 2006.02 490 60.000 1.0 R 391.90 11829 Screening Industrial (per hour) 2006.02 490 60.000 1.0 R 391.90 12032 Contact Lens Procedures 2006.02 490 30.000 1.0 R 195.90 12032 Complex - per visit 2006.02 490 30.000 1.0 R 195.90 12032 Complex - per visit 2006.02 490 30.000 1.0 R 195.90 12072 C. Dispensing and/or Assessment 2008.02 490 30.000 1.0 R 195.90 12072 C. Dispensing and/or Assessment 2008.02 490 30.000 1.0 R 195.90 13032 Evaluation of Binocular Instability Complex Case 2008.02 490 30.000 1.0 R 195.90 13032 Evaluation of Binocular Instability Complex Case 2008.02 490 30.000 1.0 R 391.90 13125 Evaluation of Visually Related Disorders 2006.02 490 30.000 1.0 R 391.90 13125 Evaluation of Visually Related Closorders 2006.02 490 30.000 1.0 R 195.90 13529 Evaluation - Tortho-Dictackae Reading Skills 2006.02 490 30.000 1.0 R 98.00 13529 Evaluation - Tortho-Dictackae Reading Skills 2006.02 490 45.000 1.0 R 98.00 13549 Evaluation - Tortho-Dictackae Reading Skills 2006.02 490 490.00 1.0 R 98.00 13549 Evaluation - Tortho-Dictackae Reading Skills 2006.02 490 40.000 1.0 R 98.00 13445 Training Individual (per 15 minutes) 2006.02 490 30.000 1.0 R 195.90 13445 Training Individual (per 15 minutes) 2006.02 490 30.000 1.0 R 195.90 13445 Training Individual (per 15 minutes) 2006.02 490 30.000 1.0 R 195.90 150.03 30.000 1.0 R 195.90 150.03 30.000 1.0 R 195.90 150.03 30.000 1.0 R 195.90 150.03 30.000 30.000 30.000 30.000 30.000 30.000 | 11541 | Dispensing Fee - Varifocals | | | | | | _ |
| 11729 Into the "By arrangement with the scheme" or "Patient own account" category). 2006.02 490 60.000 1.0 R 391.90 11829 Screening School (per hour) 2006.02 490 60.000 1.0 R 391.90 12020 2006.02 490 60.000 1.0 R 391.90 12022 Sales or privalst 2006.02 490 30.000 1.0 R 195.90 12022 Sales or per visit 2006.02 490 30.000 1.0 R 195.90 12032 Complex - per visit 2006.02 490 30.000 1.0 R 195.90 12032 Advanced - per visit 2006.02 490 30.000 1.0 R 195.90 12032 Advanced - per visit 2006.02 490 30.000 1.0 R 195.90 12072 CI. Dispensing and/or Assessment 2006.02 490 50.000 1.0 R 195.90 13003 Evaluation of Binocular Instability Simple Case 2006.02 490 30.000 1.0 R 391.90 13003 Evaluation of Binocular Instability Complex Case 2006.02 490 490.000 1.0 R 391.90 13105 Evaluation of Visually Related Learning Disorders 2006.02 490 30.000 1.0 R 391.90 13105 Evaluation of Visually Related Learning Disorders 2006.02 490 30.000 1.0 R 195.90 13529 Evaluation - Intuitive Colorimetry 2006.02 490 490.000 1.0 R 98.00 13529 Evaluation - Intuitive Colorimetry 2006.02 490 45.000 1.0 R 293.90 13549 Evaluation - Intuitive Colorimetry 2006.02 490 45.000 1.0 R 293.90 13443 Training Individual (per 5 minutes) 2006.02 490 30.000 1.0 R 195.90 13443 Training Individual (per 5 minutes) 2006.02 490 30.000 1.0 R 195.90 13443 Training Individual (per 15 minutes) 2006.02 490 30.000 1.0 R 195.90 15033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 15033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 15033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 15033 Sortevity Storing Individual (per 15 minutes) 2006.02 490 30.000 1.0 R 195.90 15033 Sortevity Storing Individual (per 15 min | | | 2006.02 | 490 | 15.000 1.0 |) R | 98.00 | |
| 1609 Screening School (per hour) 2006.02 450 60.000 1.0 R 391.90 | | Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall | | 1 1 | | 1 | 1 | |
| 11829 Screening Industrial (per hour) 2006.02 490 60.000 1.0 R 391.90 | 11729 | into the "By arrangement with the scheme" or "Patient own account" category). | | _ | 1.0 |) R | - | |
| Contact Lens Procedures 2006.02 490 30.000 1.0 R 195.90 | 11809 | Screening School (per hour) | 2006.02 | | | | | |
| 12012 Basic - per visit 2006.02 490 30,000 1.0 R 195.90 12032 Complex - per visit 2006.02 490 30,000 1.0 R 195.90 12032 Advanced - per visit 2006.02 490 30,000 1.0 R 195.90 12072 CL Dispensing and/or Assessment 2006.02 490 30,000 1.0 R 98.00 12073 CL Dispensing and/or Assessment 2006.02 490 30,000 1.0 R 98.00 13073 Evaluation of Binocular Instability Simple Case 2006.02 490 30,000 1.0 R 195.90 13073 Evaluation of Binocular Instability Complex Case 2008.02 490 60,000 1.0 R 391.90 13083 Evaluation of Visually Related Clearning Disorders 2006.02 490 90,000 1.0 R 391.90 13105 Evaluation of Visually Related Learning Disorders 2006.02 490 90,000 1.0 R 195.90 13125 Evaluation of Eye Movements (e.g. Visigraph) 2006.02 490 30,000 1.0 R 195.90 13509 Screening - Rate of Reading Test 2006.02 490 45,000 1.0 R 293.90 13543 Evaluation - Intuitive Colorimetry 2006.02 490 60,000 1.0 R 293.90 13543 Training Individual (per 15 minutes) 2006.02 490 60,000 1.0 R 391.90 13443 Training Individual (per 15 minutes) 2006.02 490 30,000 1.0 R 98.00 13443 Training Individual (per 30minutes) 2006.02 490 30,000 1.0 R 195.90 13443 Training Individual (per 30minutes) 2006.02 490 30,000 1.0 R 195.90 13443 Training Individual (per 30minutes) 2006.02 490 30,000 1.0 R 195.90 13443 Training Individual (per 40minutes) 2006.02 490 30,000 1.0 R 195.90 13443 Training Individual (per 30minutes) 2006.02 490 30,000 1.0 R 195.90 13443 Training Individual (per 30minutes) 2006.02 490 30,000 1.0 R 195.90 13443 Training Individual (per 30minutes) 2006.02 490 30,000 1.0 R 195.90 13453 Training Individual (per 30minutes) 2006.02 490 30,000 1.0 R 195.90 13463 Training Individual (per 30minutes) 2006.02 490 3 | 11829 | Screening Industrial (per hour) | 2006.02 | 490 | 60.000 1. |) R | 391.90 | |
| 12032 Complex - per visit 2006.02 490 30,000 1,0 R 195,90 | | Contact Lens Procedures | | \neg | | | | |
| 12032 Complex - per visit 2006.02 490 30,000 1.0 R 195.90 | 12012 | Basic - per visit | 2006.02 | 490 | 30.000 1.0 | R | 195.90 | |
| 12052 Advanced - per visit 2006.02 490 30.000 1.0 R 195.90 12072 CL Dispensing and/or Assessment 2006.02 490 15.000 1.0 R 98.00 13003 Evaluation of Binocular Instability Simple Case 2006.02 490 30.000 1.0 R 195.90 13003 Evaluation of Binocular Instability Complex Case 2006.02 490 40.000 1.0 R 391.90 13105 Evaluation of Visually Related Disorders 2006.02 490 90.000 1.0 R 195.90 13105 Evaluation of Eye Movements (e.g. Visigraph) 2006.02 490 90.000 1.0 R 195.90 13105 Evaluation of Eye Movements (e.g. Visigraph) 2006.02 490 90.000 1.0 R 195.90 13509 Screening - Rate of Reading Test 2006.02 490 15.000 1.0 R 98.00 13509 Screening - Rate of Reading Test 2006.02 490 15.000 1.0 R 293.90 13549 Evaluation - Intuitive Colorimetry 2006.02 490 490.00 1.0 R 293.90 13445 Training Individual (per 15 minutes) 2006.02 490 15.000 1.0 R 65.30 13445 Training Individual (per 15 minutes) 2006.02 490 30.000 1.0 R 195.90 13448 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 13469 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment & Training (per Hall hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment & Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16034 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Tr | | | 2006,02 | 490 | | | 195.90 | |
| 12072 CL Dispensing and/or Assessment 2006.02 490 15.000 1.0 R 98.00 | | | 2006.02 | 490 | 30.000 1.4 | R | 195.90 | |
| Binocular Vision/Orthoptics 2006.02 490 30.000 1.0 R 195.90 | | | 2006.02 | 490 | 15.000 1.0 | R | 98.00 | |
| 13003 Evaluation of Binocular Instability Simple Case 2006.02 490 30.000 1.0 R 195.90 | | | | | | Т | | |
| 13023 Evaluation of Binocular Instability Complex Case 2006.02 490 60.000 1.0 R 391.90 | | | 2006.02 | 490 | 30,000 1.0 | R | 195.90 | |
| Visually Related Disorders 2006.02 490 90.000 1.0 R 587.80 | | | | 490 | | | 391.90 | |
| 13105 Evaluation of Visually Related Learning Disorders 2006.02 490 90.000 1.0 R 587.80 13125 Evaluation of Eye Movements (e.g. Visigraph) 2006.02 490 30.000 1.0 R 195.90 13609 Screening - Rate of Reading Test 2006.02 490 15.000 1.0 R 293.90 13629 Evaluation - Ortho-Didactical Reading Skills 2006.02 490 45.000 1.0 R 293.90 13649 Evaluation - Intuitive Colorimetry 2006.02 490 60.000 1.0 R 391.90 13403 Training Individual (per 15 minutes) 2006.02 490 15.000 1.0 R 65.30 13423 Training Individual (per 15 minutes) 2006.02 490 30.000 1.0 R 98.00 13445 Training Away from Practice 2006.02 490 3.750 1.0 R 24.50 13489 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 13490 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 13490 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 16013 Simple LV Assessment & Training (per Half hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment & Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 | 10020 | | 1 1 | | | \top | | |
| 13125 Evaluation of Eye Movements (e.g. Visigraph) 2006.02 490 30.000 1.0 R 195.90 | 13105 | | 2006.02 | 490 | 90.000 1. |) R | 587.80 | |
| Colorimetry Codes 2006.02 490 15.000 1.0 R 98.00 13509 Screening - Rate of Reading Test 2006.02 490 45.000 1.0 R 293.90 13549 Evaluation - Ortho-Didactical Reading Skills 2006.02 490 45.000 1.0 R 293.90 13549 Evaluation - Intuitive Colorimetry 2006.02 490 60.000 1.0 R 391.90 13403 Training Home Therapy / Orthoptics Training 2006.02 490 10.000 1.0 R 65.30 13423 Training Individual (per 15 minutes) 2006.02 490 15.000 1.0 R 98.00 13445 Training Individual (per 30minutes) 2006.02 490 30.000 1.0 R 195.90 13445 Training Group per Patient (per 15 minutes) 2006.02 490 30.000 1.0 R 195.90 13445 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 16033 Simple LV Assessment & Training (per Half hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV | | | | 490 | | | 195.90 | |
| 13509 Screening - Rate of Reading Test 2006.02 490 15.000 1.0 R 98.00 13529 Evaluation - Ortho-Didactical Reading Skills 2006.02 490 45.000 1.0 R 293.90 13549 Evaluation - Intuitive Colorimetry 2006.02 490 60.000 1.0 R 391.90 Visual Therapy/Orthoptics Training 2006.02 490 10.000 1.0 R 65.30 13423 Training Individual (per 15 minutes) 2006.02 490 15.000 1.0 R 98.00 13445 Training Individual (per 30minutes) 2006.02 490 30.000 1.0 R 195.90 13463 Training Group per Patient (per 15 minutes) 2006.02 490 3.750 1.0 R 24.50 13489 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 16013 Simple LV Assessment & Training (per Half hour) 2006.02 490 30.000 1.0 R 195.90 16053 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 | .0.20 | | | | | \top | | |
| 13529 Evaluation - Ortho-Didactical Reading Skills 2006.02 490 45.000 1.0 R 293.90 13549 Evaluation - Intuitive Colorimetry 2006.02 490 60.000 1.0 R 391.90 13403 Training Home Therapy Instruction 2006.02 490 10.000 1.0 R 65.30 13423 Training Individual (per 15 minutes) 2006.02 490 15.000 1.0 R 98.00 13445 Training Individual (per 30minutes) 2006.02 490 30.000 1.0 R 195.90 13463 Training Group per Patient (per 15 minutes) 2006.02 490 3.750 1.0 R 24.50 13489 Training Group per Patient (per 15 minutes) 2006.02 490 30.000 1.0 R 195.90 13489 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 16013 Simple LV Assessment & Training (per Haif hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Sports Vision - in Office Procedures 1408 Screening Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 393.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 14218 Evaluation Sports | 13509 | | 2006.02 | 490 | 15.000 1. | I R | 98.00 | |
| 13549 Evaluation - Intuitive Colorimetry 2006.02 490 60.000 1.0 R 391.90 | 13529 | Evaluation - Ortho-Didactical Reading Skills | | | | | 293.90 | |
| Visual Therapy/Orthoptics Training 2006.02 490 10.000 1.0 R 65.30 13423 Training Individual (per 15 minutes) 2006.02 490 15.000 1.0 R 98.00 13445 Training Individual (per 30minutes) 2006.02 490 30.000 1.0 R 195.90 13463 Training Group per Patient (per 15 minutes) 2006.02 490 3.750 1.0 R 24.50 13489 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 16013 Simple LV Assessment & Training (per Half hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16033 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Sports Vision - in Office Procedures 14008 Screening Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | | | | | | | | |
| 13403 Training Home Therapy Instruction 2006.02 490 10.000 1.0 R 65.30 13423 Training Individual (per 15 minutes) 2006.02 490 15.000 1.0 R 98.00 13445 Training Individual (per 30minutes) 2006.02 490 30.000 1.0 R 195.90 13463 Training Group per Patient (per 15 minutes) 2006.02 490 3.750 1.0 R 24.50 13489 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 Low Vision Assessment & Training (per Half hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 Sports Vision - in Office Procedures 2006.02 490 20.000 1.0 R 195.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | 100 10 | | 1-200.00 | 1 | | 1 | | |
| 13423 Training Individual (per 15 minutes) 2006.02 490 15.000 1.0 R 98.00 13445 Training Individual (per 30minutes) 2006.02 490 30.000 1.0 R 195.90 13463 Training Group per Patient (per 15 minutes) 2006.02 490 3.750 1.0 R 24.50 13489 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 Low Vision Assessment & Training (per Half hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16053 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 Sports Vision - in Office Procedures 2006.02 490 30.000 1.0 R 195.90 14218 Evaluation Sports Vision Individual 2006.02 < | 13403 | | 2006.02 | 490 | 10,000 1 | l R | 65.30 | |
| 13445 Training Individual (per 30minutes) 2006.02 490 30.000 1.0 R 195.90 13463 Training Group per Patient (per 15 minutes) 2006.02 490 3.750 1.0 R 24.50 13489 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 16013 Simple LV Assessment & Training (per Half hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16053 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16108 Screening Sports Vision - in Office Procedures 2006.02 490 20.000 1.0 R 195.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | | | | | | | | _ |
| 13463 Training Group per Patient (per 15 minutes) 2006.02 490 3.750 1.0 R 24.50 13489 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 16013 Simple LV Assessment & Training (per Half hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16053 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16108 Screening Sports Vision - in Office Procedures 2006.02 490 20.000 1.0 R 195.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | | | | | | | | |
| 13489 Training Away from Practice 2006.02 490 30.000 1.0 R 195.90 16013 Simple LV Assessment & Training (per Half hour) 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16053 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 14008 Screening Sports Vision Individual 2006.02 490 20.000 1.0 R 130.60 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 14218 2006.02 490 45.000 1.0 R 293.90 14218 2006.02 490 45.000 1.0 R 293.90 14218 2006.02 490 45.000 1.0 R 293.90 14218 2006.02 490 45.000 1.0 R 293.90 14218 2006.02 490 45.000 1.0 R 293.90 14218 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R 2006.02 490 45.000 1.0 R | | | | | | | | |
| Low Vision Assessment & Training (per Half hour) 16013 Simple LV Assessment 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16053 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 14008 Screening Sports Vision - in Office Procedures 14008 Screening Sports Vision Individual 2006.02 490 20.000 1.0 R 130.60 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | 13480 | Training Stoup per Facetice | | | | | | |
| 16013 Simple LV Assessment 2006.02 490 30.000 1.0 R 195.90 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16053 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 Sports Vision - in Office Procedures 2006.02 490 30.000 1.0 R 195.90 14008 Screening Sports Vision Individual 2006.02 490 20.000 1.0 R 130.60 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | 13409 | i nu Vielan Accecement & Training (ner Half hour) | 12500.07 | 1,00 | 1. | ''' | 100.00 | |
| 16033 Complex LV Assessment 2006.02 490 30.000 1.0 R 195.90 16053 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 Sports Vision - in Office Procedures 14008 Screening Sports Vision Individual 2006.02 490 20.000 1.0 R 130.60 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | 46012 | Cimple i V Accessment | 2006.02 | 490 | 30 000 1 | ol R | 195 90 | |
| 16053 Advanced LV Assessment 2006.02 490 30.000 1.0 R 195.90 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 Sports Vision - in Office Procedures 14008 Screening Sports Vision Individual 2006.02 490 20.000 1.0 R 130.60 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | 16013 | Complex I V Accedenant | | | | | | |
| 16073 Simple LV Training 2006.02 490 30.000 1.0 R 195.90 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 Sports Vision - in Office Procedures 14008 Screening Sports Vision Individual 2006.02 490 20.000 1.0 R 130.60 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | | | | | | | | |
| 16093 Complex LV Training 2006.02 490 30.000 1.0 R 195.90 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 195.90 195.90 195.90 195. | | | | _ | | | | |
| 16113 Advanced LV Training 2006.02 490 30.000 1.0 R 195.90 Sports Vision - in Office Procedures 14008 Screening Sports Vision Individual 2006.02 490 20.000 1.0 R 130.60 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | | | | | | | | |
| Sports Vision - in Office Procedures 14008 Screening Sports Vision Individual 2006.02 490 20.000 1.0 R 130.60 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | | | | | | | | _ |
| 14008 Screening Sports Vision Individual 2006.02 490 20.000 1.0 R 130.60 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | 16113 | | 2000.02 | 450 | 30,000 1. | 4^ | 100.00 | — |
| 14218 Evaluation Sports Vision Individual 2006.02 490 45.000 1.0 R 293.90 | 1.1555 | | 2006 00 | 400 | 20 000 4 | 4 5 | 130.60 | \vdash |
| | | | | | | | | _ |
| [14238] Training Sports vision individual (per 15 minutes) [2005.02] [490] 15.000 [1.0] R 98.00 [| 14218 | Evaluation Sports Vision Individual | | | | | | |
| | 14238 | Training Sports vision individual (per 15 minutes) | 2000.02 | 490 | 15,000 1. | אוט | 30.00 | |

| | Group fees are per individual member of the group | 2006.02 | | | | | | |
|-------|---|---------|--------|--------|-----|---|--------|--------|
| 14268 | Screening Sports Vision Group | 2006.02 | 490 | 3.750 | 1.0 | R | 24.50 | \Box |
| | Evaluation Sports Vision Group | 2006.02 | 490 | 8.750 | | | 57.10 | \Box |
| 14288 | Training Sports Vision Group (per 15 minutes) | 2006.02 | 490 | 3.750 | | | 24.50 | \Box |
| | Sports Vision - Procedures done in the Field | | \Box | | | | | |
| 14309 | Screening Sports Vision Individual | 2006.02 | 490 | 30.000 | 1.0 | R | 195.90 | |
| 14319 | Evaluation Sports Vision Individual | 2006.02 | 490 | 60.000 | 1.0 | R | 391.90 | |
| 14329 | Training Sports Vision Individual (per 15 minutes) | 2006.02 | 490 | 15.000 | 1.0 | R | 98.00 | |
| | Group fees are per Individual member of the group | 2006.02 | \Box | | | | | |
| 14369 | Screening Sports Vision Group | 2006.02 | 490 | 6.250 | 1.0 | R | 40.80 | |
| 14379 | Evaluation Sports Vision Group | 2006.02 | 490 | 12.500 | 1.0 | R | 81.60 | |
| 14389 | Training Sports Vision Group (per 15 minutes) | 2006.02 | 490 | 3.750 | 1.0 | R | 24.50 | |
| | Reports etc | | | | | | | |
| 19001 | Report at request of Medical Aid | 2006.02 | 490 | 15.000 | 1.0 | R | 98.00 | |
| 19021 | Report at Patient's request | 2006.02 | 490 | 25.000 | 1.0 | R | 163.30 | |
| 19081 | Confirming Med. Aid Benefit by tel. or fax (per 10 minutes) | 2006.02 | 490 | 5.000 | 1.0 | R | 32.70 | |
| | Generic Lenses | | 1 | | | | | |
| | Frames | 2006.02 | 491 | - | 1.0 | R | - | |
| 70011 | Single Vision lens (up to 6.00Sph) | 2006.02 | 491 | 2.374 | 1.0 | R | 176.90 | |
| 70021 | Special Vision High Powers | 2006.02 | 491 | 5.786 | 1.0 | R | 431.20 | |
| 70712 | Bifocal-Round/flat/top Seg 68*28 Seg | 2006.02 | 491 | 7.567 | 1.0 | R | 563.90 | |
| 75012 | Varifocal Distance to near | 2006.02 | 491 | 11.869 | 1.0 | R | 884.50 | |
| 80011 | Single Vision lens | 2006.02 | 491 | 2.374 | 1.0 | R | 176.90 | |
| | Special Vision High Powers | 2006.02 | 491 | 5.104 | 1.0 | R | 380.40 | |
| 80812 | Bifocal-Round/flat/top Seg 74*28 Seg | 2006.02 | 491 | 5.727 | 1.0 | R | 426.80 | |
| | Varifocal Distance to near | 2006.02 | 491 | 11.128 | 1.0 | R | 829.30 | |
| 84000 | Varifocal Intermediate to Near | 2006.05 | 491 | 11.128 | 1.0 | R | 829.30 | |
| 99999 | All other codes | 2006.02 | 491 | | 1.0 | R | | |

| _ | | | _ | |
|---|-----|-------|-------|-------------|
| O | ntn | met | riete | 2008 |
| _ | ,,, | 11161 | 100 | _UUU |

| Code | Description | ٦ |
|-------|-------------|---|
| 37000 | Optometry | ┪ |

65

| Code | Description | RCF |
|------|-----------------|--------|
| 490 | Optometry | 6.531 |
| 491 | Optometry Goods | 74.521 |
| | | |

| ١. | 30 | 41 | O | 6 |
|----|----|----|---|---|
| | | | | |

ORTHOPTIST

Orthoptists 2008

NATIONAL REFERENCE PRICE LIST IN RESPECT OF ORTHOPTISTS WITH EFFECT FROM 1 JANUARY 2008

The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures,

on some other basis without reference to this list, they may do so as well.

In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded to the nearest cent. When new item prices are calculated, e.g. when applying a modifier, the same rounding scheme should be followed.

VAT EXCLUSIVE PRICES APPEAR IN BRACKETS.

| ITEMS | · 100 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | | ٠. | | |
|-------|---|-------|-----|--------|--------------------|
| Code | Description | Ver | Add | Orth | optists |
| 1.0 | | | - 4 | RVU | Fee |
| 001 | Orthoptic consultation (Ocular motility assessment, comprehensive examination) | 04.00 | | 10.000 | 86.00 (75.40) |
| 003 | Orthoptic treatment (Ocular motility imbalance) | 04.00 | | 8.700 | 74.80 (65.60) |
| 005 | Orthoptic consultation (Hess chart) | 04.00 | | 11.100 | 95.50 (83.80) |
| 007 | Orthoptic visual fields charting or field of binocular single vision | 04.00 | | 21.700 | 186.70 (163.80) |
| 107 | Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 04.00 | | - | - |

69

Orthoptists 2008

| | | | | 3740 | 00 | | | |
|-----|---|-------------|---------|------|-------|----|-------|-----|
| | NATIONAL REFERENCE PRICE LIST IN RESPECT OF ORTHOPTISTS WITH EFFECT FROM 1 JANUARY 2008 | Versio n | Ad d | CF | Units | BF | Value | Fla |
| | The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well. In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded ITEMS | | | | | | | |
| 001 | Orthoptic consultation (Ocular motility assessment, comprehensive examination) | 2004.0 0 | | 330 | 10 | 1 | 86 | ŝ |
| 003 | Orthoptic treatment (Ocular motility imbalance) | 2004.0 0 | | 330 | 8.7 | 1 | 74.8 | 1 |
| 005 | Orthoptic consultation (Hess chart) | 2004.0 0 | | 330 | 11.1 | 1 | 95.5 | 5 |
| 007 | Orthoptic visual fields charting or field of binocular single vision | 2004.0 0 | | 330 | 21.7 | 1 | 186.7 | |
| 107 | Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 2004.0 0 | | 330 | 0 | 0 |) 7 | 7 |

Orthoptists 2008

| Code | | Description | |
|-------|-------------|-----------------|--|
| 37400 | Orthoptists | | |

Orthoptists 2008

| Code | Description | RCF |
|------|-------------|-------|
| 330 | Orthoptists | 8.602 |

OSTEOPATHY

Osteopathy 2008

NATIONAL REFERENCE PRICE LIST FOR SERVICES BY OSTEOPATHS EFFECTIVE FROM 1 JANUARY 2008

The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well.

In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+rounded to the nearest 10cent. Modifier values are rounded to the nearest cent. When new item prices are calculated, e.g. when applying a modifier, the same rounding scheme should be followed.

| | er, the same rounding scheme should be followed. XCLUSIVE PRICES APPEAR IN BRACKETS. | | |
|--------------------------|--|----------------------------------|-----------|
| | #2018.1 T | 2 | :: T |
| 01 | All accounts must be presented with the following information clearly stated: - name of osteopath - qualifications of the osteopath - BHF practice number - Postal address and telephone number - Date on which the service(s) were provided - Applicable item codes - The nature of the treatment - The surname and initials of the member - The first name of the patient - The name of the medical scheme - The membership number of the patient - The name and practice number of the referring practitioner | | 06.02 |
| 02 | The fee of more than one procedure performed at the same consultation or visit, shall be the fee for the major procedure perfection in respect of each additional procedure, but under no circumstances will additional fees be charged for more than three additional procedures carried out in the treatment of any one condition. | lus the | 06.02 |
| 03 | After a series of 10 treatments in respect of one patient for the same condition, the practitioner concerned shall report to the scheme as soon as possible if further treatment is necessary. Payment for treatment in excess of the stipulated number migranted by the scheme after receipt of a letter from the practitioner concerned, motivating the need for such treatment. | | 06.02 |
| 04 | It is recommended that, when such benefits are granted, drugs, consumables and disposable items used during a procedu issued to a patient on discharge will only be reimbursed if the correct NAPPI code is supplied on the account. | re or | 06.02 |
| ITEMS | | | - 1 Z F |
| 1: | Consultation, Spinal or Joint Manipulation | | . : ^ : : |
| Code | Description | Ver | Add |
| 001 | Initial consultation/manipulation (fee covering history, examination and treatment) | 06.02 | T |
| 001 | COIDS - Full case history, physical exam & use of diagnostic equipment, but excluding remedies, immobilisation, and manipulative procedure | 06.02 | _ |
| 002 | Subsequent manipulation/examination (fee covering subsequent examination and treatment / manipulation for the same condition) | 06.02 | : |
| | COIDS - Subsequent consultation & examination not requiring treatment | 06.02 | : |
| 003 | Consultation/examination where not treatment is required | 06.02 | ! |
| | COIDS - Spinal or extra-spinal joint manipulation ONLY. | 06.02 | ! |
| 2. | Modalities/Adjunctive Therapy | A 10 15 | 1300 |
| Soft T | ssue Mantputation | | 3.90 |
| 101 | Massage | 06.02 | ! |
| 103 | Myofacial pain therapy | 06.02 | ! |
| Deep ! | Heating Radiation | 45 1 1 4 | |
| 111 | Short wave diathermy | 06.02 | ! |
| 113 | Microwave diathermy | 06.02 | ! |
| Super | ficial Heating Therapy | John Story | 14.00 |
| 121 | Hydrocollator/lice pack - Hot or cold packs | 06.02 | ! |
| 123 | Infra-red | 06.02 | |
| 125 | Ultra-violet | 06.02 | |
| 127 | Parrafin bath/wax unit | 06.02 | |
| 129 | Whirlpool/Hubbard tank immersion | 06.02 | |
| 131 | Fluidotherapy | 06.02 | |
| 133 | Sitz bath | 06.02 | |
| A1 | | | |
| | The second of th | _ | |
| 141 | Galvanism/Faradic & Sine wave | 06.02 | |
| 141 143 | Galvanism/Faradic & Sine wave Low voltage galvanic iontophoresis | 06.02 06.02 | ! |
| 141 143 145 | Galvanism/Faradic & Sine wave Low voltage galvanic iontophoresis Ultrasound | 06.02 06.02 06.02 | |
| 141 143 145 147 | Galvanism/Faradic & Sine wave Low voltage galvanic iontophoresis Ultrasound Combined ultrasound & electric stimulation | 06.02 06.02 06.02 06.02 | |
| 141 143 145 | Galvanism/Faradic & Sine wave Low voltage galvanic iontophoresis Ultrasound | 06.02 06.02 06.02 | |

| Code | Description | Ver | Add |
|--------|---|----------|-----|
| | | | |
| 155 | Vibration therapy | 06.02 | |
| 157 | High voltage pulse direct current | 06.02 | |
| 159 | Electro-Stim 180 | 06.02 | |
| 161 | TENS | 06.02 | |
| 163 | Micro current modalities | 06.02 | |
| 165 | Traction: Mechanical/Static, etc. | 06.02 | |
| 167 | Laser therapy | 06.02 | |
| Cold A | pplications | an reigi | |
| 171 | Cryomatic/Cryotherapy | 06.02 | |
| 173 | Cold packs | 06.02 | |
| Therap | eutic Exercise | 7.70 | |
| 187 | Proprioceptive neuromuscular facilitation | 06.02 | |
| 189 | Gait training | 06.02 | |
| 191 | Prosthetic fitting and training | 06.02 | |
| Immob | lisatio f | | |
| 201 | Hard and soft immobilisation | 06.02 | |
| 203 | Supportive strapping, bracing, splinting and taping | 06.02 | |
| 205 | Supportive devices | 06.02 | |

Osteopathy 2008

| Code | Description | Practice Type | 2007 |
|------|--|---------------|-------|
| 001 | Initial consultation/manipulation (fee covering history, examination and treatment) | Osteopathy | 0.000 |
| | Subsequent manipulation/examination (fee covering subsequent examination and treatment / manipulation for the same | | |
| 002 | condition) | Osteopathy | 0.000 |
| 003_ | Consultation/examination where not treatment is required | Osteopathy | 0.000 |
| 101 | Massage | Osteopathy | 0.000 |
| 103 | Myofacial pain therapy | Osteopathy | 0.000 |
| | Short wave diathermy | Osteopathy | 0,000 |
| 113 | Microwave diathermy | Osteopathy | 0.000 |
| 121 | Hydrocollator/Ice pack - Hot or cold packs | Osteopathy | 0,000 |
| 123 | Infra-red | Osteopathy | 0.000 |
| 125 | Ultra-violet | Osteopathy | 0.000 |
| 127 | Parrafin bath/wax unit | Osteopathy | 0,000 |
| 129 | Whirlpool/Hubbard tank immersion | Osteopathy | 0,000 |
| | Fluidotherapy | Osteopathy | 0.000 |
| | Sitz bath | Osteopathy | 0.000 |
| 141 | Galvanism/Faradic & Sine wave | Osteopathy | 0.000 |
| | Low voltage galvanic iontophoresis | Osteopathy | 0.000 |
| | Ultrasound | Osteopathy | 0.000 |
| | Combined ultrasound & electric stimulation | Osteopathy | 0,000 |
| | Inteferential | Osteopathy | 0.000 |
| | Vacutron/Vasopneumatic devices | Osteopathy | 0.000 |
| | Vacutron plus inteferential | Osteopathy | 0.000 |
| | Vibration therapy | Osteopathy | 0.000 |
| | High voltage pulse direct current | Osteopathy | 0.000 |
| | Electro-Stim 180 | Osteopathy | 0.000 |
| | TENS | Osteopathy | 0.000 |
| | Micro current modalities | Osteopathy | 0.000 |
| 165 | Traction: Mechanical/Static, etc. | Osteopathy | 0.000 |
| 167 | Laser therapy | Osteopathy | 0.000 |
| | Cryomatic/Cryotherapy | Osteopathy | 0.000 |
| | Cold packs | Osteopathy | 0.000 |
| | Proprioceptive neuromuscular facilitation | Osteopathy | 0.000 |
| | Gait training | Osteopathy | 0.000 |
| | Prosthetic fitting and training | Osteopathy | 0.000 |
| | Hard and soft immobilisation | Osteopathy | 0.000 |
| | Supportive strapping, bracing, splinting and taping | Osteopathy | 0.000 |
| | Supportive devices | Osteopathy | 0.000 |

No. 30410

Osteopathy 2008

| | | | 1 | |
|-----|--|-------------|-----------------|--|
| | NATIONAL REFERENCE PRICE LIST FOR SERVICES BY OSTEOPATHS EFFECTIVE FROM 1 JANUARY 2008 | Versio n | Add | |
| | The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well. | 2006.0 2 | | |
| | In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded | | | |
| | RULES | | | |
| | All accounts must be presented with the following information clearly stated: - name of osteopath - qualifications of the osteopath | 2006.0 2 | | |
| | - BHF practice number - Postal address and telephone number - Date on which the service(s) Were provided | | | |
| | - Applicable item codes - The nature of the treatment | | | |
| | - The surname and initials of the member - The first name of the patient | | | |
|)1 | - The name of the medical scheme - The membership number of the patient - The name and practice number of the referring practitioner | | | |
|)2 | The fee of more than one procedure performed at the same consultation or visit, shall be the fee for the major procedure plus the fee in respect of each additional procedure, but under no circumstances will additional fees be charged for more than three additional procedures carried out in the treatment of any one condition. | 2006.0 2 | | |
| _ | After a series of 10 treatments in respect of one patient for the same condition, the practitioner concerned shall report to the scheme as soon as possible if further treatment is necessary. Payment for treatment in excess of the stipulated number may be granted by the scheme after receipt of a letter from the practitioner concerned, motivating the need for such treatment. | 2006.0 2 | | |
|)3 | | | | |
| 04 | it is recommended that, when such benefits are granted, drugs, consumables and disposable items used during a procedure or issued to a patient on discharge will only be reimbursed if the correct NAPPI code is supplied on the account. | 2006.0 2 | | |
| | ITEMS | | $\vdash \vdash$ | |
| | Consultation, Spinal or Joint Manipulation | | \vdash | |
| 001 | Initial consultation/manipulation (fee covering history, examination and treatment) | 2006.0 2 | П | |

Osteopathy 2008

| | COIDS - Full case history, physical exam & use of diagnostic equipment, but excluding remedies, immobilisation, and manipulative procedure | 2006.0 | |
|-----|--|--------|--|
| 002 | Subsequent manipulation/examination (fee covering subsequent examination and treatment / manipulation for the same condition) | 2006.0 | |
| | COIDS - Subsequent consultation & examination not requiring treatment | 2006.0 | |
| 003 | Consultation/examination where not treatment is required | 2006.0 | |
| | COIDS - Spinal or extra-spinal joint manipulation ONLY. | 2006.0 | |
| 2. | Modalitles/Adjunctive Therapy | | |
| | Soft Tissue Manipulation | | |
| 101 | Massage | 2006.0 | |
| | Myofacial pain therapy | 2006.0 | |
| 103 | <u> </u> | 2 | |
| | Deep Heating Radiation | | |
| 111 | Short wave diathermy | 2006.0 | |
| 113 | Microwave diathermy | 2006.0 | |
| | Superficial Heating Therapy | | |
| 121 | Hydrocollator/ice pack - Hot or cold packs | 2006.0 | |
| 123 | infra-red | 2006.0 | |
| 125 | Ultra-violet | 2006.0 | |
| 127 | Parrafin bath√wax unit | 2006.0 | |
| 129 | Whirlpool/Hubbard tank immersion | 2006.0 | |
| 131 | Fluidotherapy | 2006.0 | |
| 133 | Sitz bath | 2006.0 | |
| | Non-heating Modalities | | |
| 141 | Galvanism/Faradic & Sine wave | 2006.0 | |
| 143 | Low voltage galvanic iontophoresis | 2006.0 | |
| -70 | Ultrasound | 2006.0 | |
| 145 | | 2006.0 | |
| 147 | Combined ultrasound & electric stimulation | 2 | |

No. 30410

Osteopathy 2008

| | Inteferential | 2006.0 |
|------|---|-------------|
| 149 | | 2 |
| | Vacutron/Vasopneumatic devices | 2006.0 |
| 151 | | 2 |
| | Vacutron plus Inteferential | 2006.0 |
| 153 | | 2 |
| | Vibration therapy | 2006.0 |
| 155 | | 2 |
| | High voltage pulse direct current | 2006.0 |
| 157 | Plantes Office 400 | 2 |
| 159 | Electro-Stim 180 | 2006.0 |
| 109 | TENS | 2006.0 |
| 161 | TENS | 2000.0 |
| 101 | Micro current modalities | 2006.0 |
| 163 | Tribito outre (L'Irioquinios | 2 |
| ,,,, | Traction: Mechanical/Static, etc. | 2006.0 |
| 165 | ,,,,,,, | 2 |
| | Laser therapy | 2006.0 |
| 167 | ·· | 2 |
| | Cold Applications | |
| | Cryomatic/Cryotherapy | 2006.0 |
| 171 | <u> </u> | 2 |
| | Cold packs | 2006.0 |
| 173 | | 2 |
| | Therapeutic Exercise | |
| | Proprioceptive neuromuscular facilitation | 2006,0 |
| 187 | Cott to July 2 | 2006.0 |
| 189 | Gait training | 2000.0 |
| 109 | Prosthetic fitting and training | 2006.0 |
| 191 | Prostrette many and dalining | 2 |
| ۳ | Immobilisation | |
| _ | Hard and soft immobilisation | 2006.0 |
| 201 | | 2 |
| | Supportive strapping, bracing, splinting and taping | 2006.0 |
| 203 | | |
| | Supportive devices | 2006.0 |
| 205 | | 2 |

| STAATSKOERANT, 16 NOVEMBER 2007 | No. 30410 | 0.1 |
|----------------------------------|------------|-----|
| STATISTOPHANT, TO NOVEWIBER 2007 | 140. 30410 | 01 |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| • | | |
| | | |
| | | |
| | | |
| PHYSICAL REHABILITATION | | |
| | | |
| | | |
| | | |
| | | |
| | | |

NATIONAL REFERENCE PRICE LIST IN RESPECT OF REHABILITATION HOSPITALS WITH A PRACTICE NUMBER COMMENCING WITH "59" WITH EFFECT FROM 1 JANUARY 2008

The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well.

| in calcu | e other basis without reference to this list, they may do so as well. lating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10- lating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10- | |
|--------------|--|--|
| modifier | to the nearest 10cent. Modifier values are rounded to the nearest cent. When new item prices are calculated, e.g. when applying r, the same rounding scheme should be followed. ICLUSIVE PRICES APPEAR IN BRACKETS. | a |
| | AL RULES CONTROL OF THE CONTROL OF T | <u> </u> |
| A | It is recommended that, when such benefits are granted, drugs, consumables and disposable items used during a procedure or issued to a patient on discharge will only be reimbursed by a medical scheme if the appropriate code is supplied on the account. | 04.00 |
| B.1 | Procedure for the classification of hospitals: | 04.00 |
| B.1.1 | Inspections of sub-acute facilities, private hospitals, rehabilitation hospitals or sub-acute facilities having practice code numbers commencing with the digits 059 will be conducted by an independent agency on behalf of BHF. Applications to be addressed in writing to BHF. | 04.00 |
| C | All accounts submitted by rehabilitation hospitals shall comply with all of the requirements in terms of the Medical Schemes Act, Act No. 131 of 1999. Where possible, such accounts shall also reflect the practice code numbers and names of the surgeon, the anaesthetist and of any assistant surgeon who may have been present during the course of an operation. | 04.00 |
| D | All accounts shall be accompanied by a copy of the relevant theatre accounts specifying all details of items charged, as well as all the procedures performed. Photocopies of all other documents pertaining to the patients account must be provided on request. Medical schemes shall have the right to inspect the original source documents at the rehabilitation hospital concerned. | 04.00 |
| E | All accounts containing items which are subject to a discount in terms of the recommended benefit shall indicate such items individually and shall show separately the gross amount of the discount. | 04.00 |
| F | Accommodation fees includes the services listed below: | 04.00 |
| | A. The minimum services that are required are items 3, 5 and 6. | |
| | A. The minimum services that are required are items 3, 5 and 6. | |
| | B. If managed care organisations or medical schemes request any of the other services included in this list, no additional charge may be levied by the hospital. | |
| | 1 Pre-authorisation (up to the date of admission) of: - length of stay - level of care | |
| | - theatre procedures | |
| | Provision of ICD-10 and CPT-4 codes when requesting pre-authorisation | |
| | 3 Notification of admission | |
| | 4 immediate notification of changes to: length of stay level of care | |
| | · theatre procedures | |
| | 5 Reporting of length of stay and level of care In standard format for purposes of creating a minimum dataset of information to be used in defining an alternative reimbursement system. | |
| | 6 Discharge ICD-10 and CPT-4 coding In standard format for purposes of creating a minimum dataset of information to be used in defining an alternative reimbursement system. | |
| | Including coding of complications and co-morbidity. To be done as accurately as practically possible by the hospital. | |
| | 7 Case management by means of standard documentation and liaison between scheme and hospital appointed case managers Liaison means communication and sharing of information between case managers, but does not include active case management by the hospital. | |
| SCHED | | .: 211. |
| (was | GLOBAL FEE FOR REHABILITATION WITH A PRACTICE NUMBER COMMENCING WITH "59" | <u>, </u> |
| | The following rehabilitation categories will be treated in recognised and accredited rehabilitation hospitals: Stroke, Brain dysfunction (traumatic and non-traumatic), Spinal cord dysfunction (traumatic and non-traumatic), Orthopaedic (lower joint replacements), Amputation (lower extremity), Cardiac, Pulmonary, Major multiple trauma. Other neurological or orthopaedic impairments will require specific letters of motivation. | 04.00 |
| | This section is only applicable to facilities registered as Physical Rehabilitation Hospitals and not Sub-acute facilities. | 04.00 |
| Rehabil | Itation: | <u> </u> |
| Code | Description Ver Add Physics Rehabilitar | ion |
| 70 9 9 | | B 0 |

| Code | Description | Ver | Add | Reha | iysical bilitation spitals |
|------|---|-------|-----|--------|----------------------------------|
| | | | | RVU | Fee |
| 100 | Out patients, 3 hours per day (maximum 18 days) | 04.00 | | 10.000 | 409.90 (359.60) |
| 101 | Out patients, 6 hours per day (maximum 18 days) | 04.00 | | 21.103 | 865.00 (758.80) |
| 105 | General care (maximum 27 days) | 04.00 | | 42.013 | 1722.10 (1510.60) |
| 107 | High care (maximum 36 days) | 04.00 | | 49.522 | 2029.90 (1780.60) |
| 109 | Rehabilitation ICU (maximum 7 days) | 04.00 | | 89.005 | 3648.30 (3200.30) |

| | | 55900 | | | | | | |
|-------|--|--------|----------|----|----------|----------|-------|--------|
| | NATIONAL REFERENCE PRICE LIST IN RESPECT OF REHABILITATION HOSPITALS WITH | Versio | Ad | CF | Units | 8F | Value | Fla |
| | A PRACTICE NUMBER COMMENCING WITH "59" WITH EFFECT FROM 1 JANUARY 2008 | n | đ | | | | | g |
| | The following reference price list is not a set of tariffs that must be applied by medical schemes | 2004.0 | | П | | | | |
| | and/or providers, it is rather intended to serve as a baseline against which medical schemes can | 0 | l | l | | | | |
| | individually determine benefit levels and health service providers can individually determine fees | | l | 1 | | 1 | 1 | |
| | charged to patients. Medical schemes may, for example, determine in their rules that their benefit in | | l | i | | 1 | 1 | |
| | respect of a particular health service is equivalent to a specified percentage of the national health | | l | 1 | | 1 | 1 | |
| | reference price list. It is especially intended to serve as a basis for negotiation between individual | | l | l | | | | |
| | funders and individual health care providers with a view to facilitating agreements which will minimise | | l | l | | 1 | | |
| | balance billing against members of medical schemes. Should individual medical schemes wish to | | l | ı | | 1 | | - [|
| | determine benefit structures, and individual providers determine fee structures, on some other basis | | l | | | | | 1 |
| | without reference to this list, they may do so as well. □ | | l | l | | 1 | | |
| | In calculating the prices in this schedule, the following rounding method is used: Values R10 and | | l | ļ | | | | |
| | below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded | | l | Ì | | i | 1 | |
| | GENERAL RULES | | | | | 1 | | \neg |
| Α | | 2004.0 | | | | Т | | |
| | used during a procedure or issued to a patient on discharge will only be reimbursed by a medical | 0 | l | |] | 1 | | 1 |
| | scheme if the appropriate code is supplied on the account. | | | | | | | - 1 |
| B.1 | Procedure for the classification of hospitals: | 2004.0 | | | | Т | | \neg |
| | | 0 | | | <u> </u> | | | |
| B.1.1 | Inspections of sub-acute facilities, private hospitals, rehabilitation hospitals or sub-acute facilities | 2004.0 | | | | | | |
| | having practice code numbers commencing with the digits 059 will be conducted by an independent | 0 | | | | | 1 | - 1 |
| | agency on behalf of BHF. Applications to be addressed in writing to BHF. | | <u> </u> | | | | | |
| С | All accounts submitted by rehabilitation hospitals shall comply with all of the requirements in terms of | 2004.0 | | | | Т | | |
| | the Medical Schemes Act, Act No. 131 of 1999. Where possible, such accounts shall also reflect | 0 | 1 | | | 1 | | |
| | the practice code numbers and names of the surgeon, the anaesthetist and of any assistant surgeon | | 1 | | | 1 | | |
| | who may have been present during the course of an operation. | | | | | | | |
| D | All accounts shall be accompanied by a copy of the relevant theatre accounts specifying all details of | 2004.0 | | | | T | | |
| | items charged, as well as all the procedures performed. Photocopies of all other documents | 0 | ĺ | | | | | |
| | pertaining to the patients account must be provided on request. Medical schemes shall have the right | | l | | | 1 | | |
| | to inspect the original source documents at the rehabilitation hospital concerned. | | | | | 1 | | |
| É | All accounts containing items which are subject to a discount in terms of the recommended benefit | 2004.0 | | | | \vdash | | + |
| | shall indicate such items individually and shall show separately the gross amount of the discount. | lo . | | 1 | | 1 | 1 | 1 |

| | | | | <u> </u> | | | | | |
|--|--|-------------|----------|----------------|--------|-----|----------|----------|----------|
| F | Accommodation fees includes the services listed below: | 2004.0 | | | | | | | |
| | | lo | | | | | l | | |
| | A.DThe minimum services that are required are items 3, 5 and 6. | | | | | | | | |
| | B. [] If managed care organisations or medical schemes request any of the other services included in | | | | | | | | |
| | this list, no additional charge may be levied by the hospital. | | | | | | | | |
| | | | | | | | | | |
| | 1 Pre-authorisation (up to the date of admission) of: | | | | | | l | | |
| | · length of stay | | | | | | | | |
| | · level of care | | | | | | 1 | | |
| | · theatre procedures | 1 | | ΙI | | | | | |
| | 2□Provision of ICD-10 and CPT-4 codes when requesting pre-authorisation | | | | | | | | |
| | 3□Notification of admission | | | | | | | | |
| | 4□Immediate notification of changes to: | | | | | | | | |
| | · length of stay | | | | | | | | |
| <u> </u> | level of care |] | | ļļ | ļ | | ļ | | - 1 |
| | - theatre procedures | | | | | | | | |
| l | 5□Reporting of length of stay and level of care | | | | | | | | |
| | · In standard format for purposes of creating a minimum dataset of information to be used in defining | | 1 | ΙI | | | l | | |
| | an alternative reimbursement system. | | | | | | | | |
| | 8□Discharge ICD-10 and CPT-4 coding | | | | | | | | |
| | In standard format for purposes of creating a minimum dataset of information to be used in defining | | | | | | | | |
| | an alternative reimbursement system. | | | l I | | | | | |
| | Including coding of complications and co-morbidity. To be done as accurately as practically | | | | | | | | |
| | SCHEDULE | | | | | | | | |
| 7 | GLOBAL FEE FOR REHABILITATION WITH A PRACTICE NUMBER COMMENCING WITH | | | | | | | | |
| | The following rehabilitation categories will be treated in recognised and accredited rehabilitation | 2004.0 | | | | | l | | |
| | hospitals: Stroke, Brain dysfunction (traumatic and non-traumatic), Spinal cord dysfunction | lo | | | | | l | | |
| | (traumatic and non-traumatic), Orthopaedic (lower joint replacements), Amputation (lower extremity), | | | | | | | | |
| | Cardiac, Pulmonary, Major multiple trauma. Other neurological or orthopaedic impairments will | | | | | | | | |
| | require specific letters of motivation. This section is only applicable to facilities registered as Physical Rehabilitation Hospitals and not | 2004.0 | \vdash | $\vdash\vdash$ | | | \vdash | | - |
| | Sub-acute facilities. | 0 | | | | | | | |
| | Rehabilitation | Ť | \vdash | \square | . — | - | \vdash | | \vdash |
| 100 | Out patients, 3 hours per day (maximum 18 days) | 2004.0 | | 530 | 10.000 | 1.0 | R | 409.90 | \Box |
| 101 | | 0 | | | 21.12 | 1.5 | <u> </u> | 200.00 | |
| 101 | Out patients, 6 hours per day (maximum 18 days) | 2004.0 0 | | 530 | 21.103 | 1.0 | R | 865.00 | |
| 105 | General care (maximum 27 days) | 2004.0 | | 530 | 42.013 | 1.0 | R | 1 722.10 | |
| L | | 0 | L. | | | | | | |
| | | | | | | | | | |

| 107 | High care (maximum 36 days) | 2004.0 | | 530 | 49.522 | 1.0 | R : | 2 029,90 | П |
|-----|-------------------------------------|--------|--|-----|--------|-----|-----|----------|---|
| | | 0 | | | | | | | |
| 109 | Rehabilitation ICU (maximum 7 days) | 2004.0 | | 530 | 89.005 | 1.0 | R : | 3 648.30 | |
| | | 0 | | | | | | | |

| Code | Description | П |
|-------|-----------------------------------|---|
| 55900 | Physical Rehabilitation Hospitals | П |

| Code | Description | RCF |
|---------------------------------------|-------------|--------|
| 530 Physical Rehabilitation Hospitals | | 40.990 |

PHYSIOTHERAPY

012

Physiotherapy 2008

NATIONAL REFERENCE PRICE LIST IN RESPECT OF PHYSIOTHERAPISTS WITH EFFECT FROM 1 JANUARY 2008 The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well. In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded to the nearest cent. When new item prices are calculated, e.g. when applying a modifier, the same rounding scheme should be followed. VAT EXCLUSIVE PRICES APPEAR IN BRACKETS. REGULATIONS DEFINING THE SCOPE OF THE PROFESSION OF PHYSIOTHERAPY (R2301 - 3 December 1976) SCHEDULE General rules governing the scale of benefits 04.00 Unless timely steps (i.e. 24 hours prior to the appointment) are taken to cancel an appointment the relevant fee may be charged, 001 but shall not be payable by medical schemes. Each case shall, however, be considered on merit and, if circumstances warrant, no fee shall be charged. Modifier 0001 to be quoted 002 In exceptional cases where the fee is disproportionately low in relation to the actual services rendered by the practitioner, the 04.00 practitioner shall provide motivation for a higher fee and such higher fee as may be agreed upon between the practitioner and the scheme may be charged 04.00 003 Where a practitioner uses equipment which is not owned by that practitioner, a reduction of 15% of the relevant rate will be applicable. Modifier 0003 must be quoted when this rule is applied 04.00 004 In the case of prolonged or costly treatment, the practitioner should first ascertain from the scheme concerned whether it will accept financial responsibility in respect of such treatment, since the member may be subject to maximum annual benefits 04.00 005 After a series of 20 treatments in respect of one patient for the same condition, the practitioner concerned shall report to the scheme as soon as possible if further treatment is necessary. Payment for treatments in excess of the stipulated number may be granted by the scheme after receipt of a letter from the practitioner concerned, motivating the need for such treatment 04.00 006 Where emergency treatment is provided: a. during working hours, and the provision of such treatment requires the practitioner to leave her or his practice to attend to the patient in hospital; or b. after working hours the fee for such visits shall be the total fee plus 50%. For purposes of this rule: a. "emergency treatment" means a bona fide, justifiable emergency physiotherapy procedure, where failure to provide the procedure immediately would result in serious impairment to bodily functions or serious dysfunction of a bodily organ or part, or would place the person's life in serious jeopardy; and b. "working hours" means 8h00 to 17h00, Monday to Friday. Modifier 0006 must be quoted after the appropriate code number(s) to indicate that this rule is applicable. 007 Practitioners are reminded that a lower fee than that appearing in the scale of benefits shall be charged if the customary fee in the 04.00 area is less than that charged. Reduced fees shall also be charged where the practitioner would have reduced his/her fee in private practice in particular cases. Prolonged treatment or exceptional cases should also receive special consideration in accordance with the usual medical practice 008 The fee in respect of more than one procedure (excluding evaluation and visiting items 407, 501, 502, 503, 507, 509, 701, 702, 05.05 703, 704, 705, 706, 707, 708, 801, 803, 901 and 903) performed at the same consultation or visit, shall be the fee for the major procedure plus half the fee in respect of each additional procedure, but under no circumstances may fees be charged for more than three procedures carried out in the treatment of any one condition. Modifier 0008 must then be quoted after the appropriate code numbers for the additional code numbers for the additional procedures to indicate that this rule is applicable 009 When more than one condition requires tractment and each of these conditions necessitates an individual treatment, they shall be 04.00 charged as individual treatments. Full details of the nature of the treatments and the diagnosis or diagnostic codes shall be stated. Modifier 0009 must then be quoted after the appropriate code number to indicate that this rule is applicable. 010 When the treatment times of two completely separate and different conditions overlap, the fee shall be the full fee for one 04.00 condition and 50% of the fee for the other condition. Both conditions must be specified. Modifier 0010 must then be quoted after the appropriate code number to indicate that this rule is applicable. Every physiotherapist must acquaint himself with the provisions of the Medical Schemes Act, 1998 and the regulations 011 04.00 promulgated under the Act in connection with the rendering of accounts. Every account shall contain the following particulars: The name and practice code number of the referring practitioner (where applicable). The name of the member. The name of the patient. The name of the medical scheme The membership number of the member. The practice code number end name of practitioner The nature and cost of the treatment. The date on which the service was rendered. The relevant diagnostic codes and NHRPL item code numbers relating to the health service rendered.

04.00

NB: Rounding off does not apply to amounts occurring once the modifiers are used.

| Code | Description | Ver Add | Physioth | erapy |
|-----------------|--|-----------------------------------|--------------|--------------------------|
| | | | RVU | Fee |
| 013 | Where the physiotherapist performs treatment away from the treatment rooms, travelling costs bein total) to be charged according to the AA-rate. Modifier 0013 must be quoted after the appropriate or rule is applicable. Please note that although only some medical schemes accept responsibility for the expenses, others do so in exceptional cases only. | ode numbers to he payment of t | show that th | n 04.00 |
| 014 | Physiotherapy services rendered in a nursing home or hospital. Modifier 0014 must be quoted after | each code. | | 04.00 |
| 016 | It is recommended that, when such benefits are granted, drugs, consumables and disposable items issued to a patient on discharge will only be reimbursed by a medical scheme if the appropriate code | used during a | procedure or | 04.00 |
| Modifie | | | | |
| 0001 | Appointment not kept | | | 04.00 |
| 0003 | 15% of the relevant rate to be deducted where equipment used is not owned by the practitioner | | | 04.00 |
| 0006 | Add 50% of the total fee for the treatment | | | 04.00 |
| 8000 | Only 50% of the fee for these additional procedures may be charged | | | 04.00 |
| 0009 | The full fee for the additional condition may be charged | | | 04.00 |
| 0010 | Only 50% of the fee for the second condition may be charged | | | 04.00 |
| 0013 | Travelling costs (being more than 16 kilometres in total) according to AA-rate. Please note that alth schemes accept responsibility for the payment of transport expenses, others do so in exceptional contents. | ough only some ases only. | e medical | 04.00 |
| 0014 | Physiotherapy services rendered to an in-patient in a nursing home or hospital. | | | 04.00 |
| 1 | RADIATION THERAPY / MOIST HEAT / CRYOTHERAPY | Charlet | | i |
| Code | Description | Ver Add | Physioth | егару |
| Ţ | | | RVU | Fee |
| 001 | Infra-red, Radiant heat, Wax therapy Hot packs | 04.00 | 5.000 | 26.70 (23.40) |
| 005 | Ultraviolet light | 04.00 | 10.000 | 53.30 |
| 006 | Laser beam | 04.00 | 15.000 | 80.00 (70.20) |
| 007 | Cryotherapy | 04.00 | 5.000 | 26.70 (23.40) |
| 2 | LOW FREQUENCY CURRENTS | | | |
| 103 | Galvanism, Diodynamic current, Tens. | 04.00 | 10.000 | 53.30 (46.80) |
| 105 | Muscle and nerve stimulating currents. | 04.00 | 12.000 | 64.00 |
| 107 | Interferential Therapy. | 04.00 | 10.000 | 53.30 |
| | HIGH EREQUENCY CURRENTS | | 1 2 2 2 3 | (46.80) |
| <u>3</u> 201 | HIGH FREQUENCY CURRENTS STATE OF THE STATE O | 04.00 | 5.000 | 26.70 (23.40) |
| 203 | Ultrasound. | 04.00 | 10.000 | 53.30 (46.80) |
| 205 | Microwave. | 04.00 | 5.000 | 26.70 (23.40) |
| 4 | PHYSICAL MODALITIES | Salelli, a | | Σ |
| 300 | Vibration | 04.00 | 10.000 | 53.30 (46.80) |
| 301 | Percussion | 04.00 | 16.100 | 85.80 (75.30 |
| 302 | Massage | 04.00 | 10.000 | 53.30 (46.80 |
| 303 | Myofacial release/soft tissue mobilisation, one or more body parts | 04.00 | 20.090 | 107.10 |
| 304 | Acupuncture | 04.00 | 15.000 | 80.00 (70.20 |
| 305 | Re-education of movement/Exercises (excluding ante- and post-natal exercises) | 04.00 | 10.000 | 53.30 (46.80 |
| 307 | Pre- and post-operative exercises and/or breathing exercises | 04.00 | 10.000 | 53.30 (46.80 |
| 308 | Group exercises (excluding ante- and post-natal exercises - maximum of 10 in a group) | 04.00 | 10.000 | 53.30 (46.80 53.30 |
| 309 310 | Isokinetic treatment. Neural tissue mobilisation | 04.00 | 20.000 | (46.80 106.60 |
| 313 | Ante and post natal exercises/counselling | 04.00 | 10.000 | (93.50 |
| 314 | Lymph drainage | 04.00 | 5.000 | (46.80 26.70 |
| | 1 | | | (23.40 |

| Code | Description | Ver | Add | | iotherapy |
|-------------|---|-------|---------|--------|--------------------|
| | | | <u></u> | RVU | Fee |
| 317 | Traction. | 04.00 | | 10.000 | 53.30 (46.80) |
| 318 | Upper respiratory nebulisation and/or lavage | 04.00 | | 10.000 | 53.30 (46.80) |
| 319 | Nebulisation | 04.00 | | 10.000 | 53.30 (46.80) |
| 321 | Intermittent positive pressure ventilation. | 04.00 | | 10.000 | 53.30 (46.80) |
| 323 | Suction: Level 1 (including sputum specimen taken by suction) | 04.00 | | 5.000 | 26.70 (23.40) |
| 325 | Suction: Level 2 (Suction with involvement of lavage as a treatment in a special unit situation or in the respiratory compromised patient) | 04.00 | | 20.090 | 107.10 (93.90 |
| 327 | Bagging (used on the intubated unconscious patient or in the severely respiratory distressed patient). | 04.00 | | 5.000 | 26.70 (23.40 |
| 328 | Dry needling | 04.00 | | 15.000 | 80.00 (70.20 |
| 5 | MANIPULATION/MOBILISATION OF JOINTS OR IMMOBILISATION | · | 33.5 | 10.00 | |
| 401 | Spinal. | 04.00 | | 15.000 | 80.00 (70.20) |
| 402 | Pre meditated manipulation | 04.00 | | 10.000 | 53.30 (46.80) |
| 405 | All other joints. | 04.00 | | 15.000 | 80.00 (70.20 |
| 407 | Immobilisation (excluding materials). Rule 008 does not apply. | 04.00 | | 15.000 | 80.00 (70.20 |
| 6 | REHABILITATION | | | | |
| 501 | Rehabilitation where the pathology requires the undivided attention of the physiotherapist. Rule 008 does not apply. Duration: 30min, | 04.00 | | 25.000 | 133.30 (116.90) |
| 502 | Hydrotherapy where the pathology requires the undivided attention of the physiotherapist. Rule 008 does not apply. Duration: 30min. | 04.00 | | 25.000 | 133.30 (116.90 |
| 503 | Rehabilitation for Central Nervous System disorders - condition to be clearly stated and fully documented (No other treatment modality may be charged in conjunction with this). Duration: 60min. | 04.00 | | 55.000 | 293.20 (257.20 |
| 504 | EMG Biofeedback treatment | 04.00 | | 15.000 | |
| 505 | Group rehabilitation. Treatment of a patient with disabling pathology in an appropriate facility requiring specific equipment and supervision, without individual attention for the whole treatment session, no charge may be levied by facility | 05.05 | | 12.000 | |
| 506 | Stress management | 04.00 | | 20.000 | 106.60 |
| 507 | Respiratory Re-education and Training. Duration: 30min. | 04.00 | | 15.000 | |
| 509 | Rehabilitation. Each additional full 15 mins. Where the pathology requires the undivided attention of the physiotherapist. (Rule 0008 does not apply.) Can only be used with codes 501, 502, 507 or 503 to indicate the completion of an additional 15 minutes. A maximum of two instances of this code may be charged per session. | 06.02 | | 15.000 | 80.00 (70.20) |
| 7 | EVALUATION | 1.5. | | -13.31 | |
| 701 | Evaluation/counselling at the first visit only (to be fully documented) | 04.00 | | 15.000 | 80.00 (70.20 |
| 702 | Complex evaluation/counselling at the first visit only (to be fully documented). | 04.00 | | 30.000 | 159.90 (140.30 |
| 703 | One complete re-assessment of a patient's condition during the course of treatment. To be used only once per episode of care. | 04.00 | | 15.000 | 80.00 (70.20 |
| 704 | Lung function: Peak flow (once per treatment). | 04.00 | | 5.000 | 26.70 (23.40 |
| 705 | Computerised/Electronic test for lung pathology | 04.00 | | 15.000 | 80.00 (70.20 |
| 706 | Reports. To be used to motivate for therapy and/or give a progress report and/or a pre-authorisation report, where such a report is specifically required by the medical scheme. | 05.03 | | 15.000 | 80.00 (70.20 |
| 7 07 | Physical Performance test. Must be fully documented. | 04.00 | | 20.000 | 106.60 |
| 708 | Interview, guidance or consultation with the patient or his family. To be used only once per episode of care. | 05.02 | | 15.000 | 80.00 (70.20) |
| 801 | Electrical test for diagnostic purposes (including IT curve and Isokinetic tests) for a specific medical condition | 04.00 | | 35.000 | 186.60 (163.70 |
| 803 | Effort test - multistage treadmill. | 04.00 | | 35.000 | 186.60 (163.70) |
| 8 | VISITING CODES | (A T | | 8 1 | |
| 901 | Treatment at a nursing home : Relevant fee plus (to be charged only once per day and not with every hospital visit | 04.00 | | 10.000 | 53.30 (46.80) |

| Code | Description | Ver | Add | Phys | iotherapy |
|------|---|-----------|-----|--------|------------------|
| 5 ji | | · · · · · | , ; | RVU | Fee |
| 903 | Domicilliary treatments : Relevant fee plus. | 04.00 | | 20.000 | 106.60 |
| 10 | OTHER | | | | |
| 117 | Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 04.00 | | - | • |
| 937 | Bird or equivalent freestanding nebuliser excluding oxygen at hospital per day. | 04.00 | | 10.000 | 53.30 (46.80) |
| 938 | Bird or equivalent freestanding nebuliser excluding oxygen domicilliary per day. | 04.00 | | 10.000 | 53.30 (46.80) |
| 939 | Cost of material: Items to be charged (exclusive of VAT) at net acquisition price plus - 26% of the net acquisition price where the net acquisition price of that material is less than one hundred rands; a maximum of twenty six rands where the net acquisition price of that material is greater than or equal to one hundred rands. | 04.00 | | - | - |
| 940 | Cost of appliances: Items to be charged (exclusive of VAT) at net acquisition price plus- 26% of the net acquisition price where the net acquisition price of that appliance is less than one hundred rands; a maximum of twenty six rands where the net acquisition price of that appliance is greater than or equal to one hundred rands. | 04.00 | | - | • |
| 941 | Hiring equipment: 1% of the current replacement value of the equipment per day. Total charge not to exceed 50% of replacement value. Description of equipment to be supplied. | 04.00 | | | |
| | Payment of this item is at the discretion of medical scheme concerned, and should be considered in instances where cost savings can be achieved. By prior arrangement with the medical scheme. | 05.03 | | | |

| | | | П | 372 | 00 | | | |
|-----|--|-------------|---------|-----|-------|----|-------|----------|
| | NATIONAL REFERÊNCE PRICE LIST IN RESPECT OF PHYSIOTHERAPISTS WITH EFFECT FROM 1 JANUARY 2008 | Versio n | Ad đ | CF | Units | BF | Value | Fla g |
| | The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well. | | or . | | | | | 9 |
| | below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded REGULATIONS DEFINING THE SCOPE OF THE PROFESSION OF PHYSIOTHERAPY (R2301 - 3 December 1976) SCHEDULE | | | | | 上 | | 丰 |
| | General rules governing the scale of benefits | | ⊢ | ⊢ | - | + | - | + |
| 001 | Unless timely steps (i.e. 24 hours prior to the appointment) are taken to cancel an appointment the relevant fee may be charged, but shall not be payable by medical schemes. Each case shall, however, be considered on merit and, if circumstances warrant, no fee shall be charged. Modifier 0001 to be quoted | 2004.0 0 | | | | | | |
| 002 | In exceptional cases where the fee is disproportionately low in relation to the actual services rendered by the practitioner, the practitioner shall provide motivation for a higher fee and such higher fee as may be agreed upon between the practitioner and the scheme may be charged | 2004.0 0 | | | | | | |
| 003 | Where a practitioner uses equipment which is not owned by that practitioner, a reduction of 15% of the relevant rate will be applicable. Modifier 0003 must be quoted when this rule is applied | 2004.0 0 | | | | | | |
| 004 | in the case of prolonged or costly treatment, the practitioner should first ascertain from the scheme concerned whether it will accept financial responsibility in respect of such treatment, since the member may be subject to maximum annual benefits | 2004.0 0 | | | | | | |
| 005 | After a series of 20 treatments in respect of one patient for the same condition, the practitioner concerned shall report to the scheme as soon as possible if further treatment is necessary. Payment for treatments in excess of the stipulated number may be granted by the scheme after receipt of a letter from the practitioner concerned, motivating the need for such treatment | 2004.0 0 | | | | | | |

| 006 | Where emergency treatment is provided: a. during working hours, and the provision of such treatment requires the practitioner to leave her or his practice to attend to the patient in hospital; or b. after working hours the fee for such visits shall be the total fee plus 50%. For purposes of this rule: a. "emergency treatment" means a bona fide, justifiable emergency physiotherapy procedure, where failure to provide the procedure immediately would result in serious impairment to bodily functions or serious dysfunction of a bodily organ or part, or would place the person's life in serious jeopardy; and b. "working hours" means 8h00 to 17h00, Monday to Friday. Modifier 0006 must be quoted after the appropriate code number(s) to indicate that this rule is | 2004.0 | | | |
|-----|--|-------------|--|--|--|
| | applicable. | | | | |
| 007 | Practitioners are reminded that a lower fee than that appearing in the scale of benefits shall be charged if the customary fee in the area is less than that charged. Reduced fees shall also be charged where the practitioner would have reduced his/her fee in private practice in particular cases. Prolonged treatment or exceptional cases should also receive special consideration in accordance with the usual medical practice | 2004.0 | | | |
| 008 | The fee in respect of more than one procedure (excluding evaluation and visiting items 407, 501, 502, 503, 507, 509, 701, 702, 703, 704, 705, 706, 707, 708, 801, 803, 901 and 903) performed at the same consultation or visit, shall be the fee for the major procedure plus half the fee in respect of each additional procedure, but under no circumstances may fees be charged for more than three procedures carried out in the treatment of any one condition. Modifier 0008 must then be quoted after the appropriate code numbers for the additional code numbers for the additional procedures to indicate that this rule is applicable. | 2005.0 | | | |
| 009 | When more than one condition requires treatment and each of these conditions necessitates an individual treatment, they shall be charged as individual treatments. Full details of the nature of the treatments and the diagnosis or diagnostic codes shall be stated. Modifier 0009 must then be quoted after the appropriate code number to indicate that this rule is applicable. | 2004.0 0 | | | |
| 010 | When the treatment times of two completely separate and different conditions overlap, the fee shall be the full fee for one condition and 50% of the fee for the other condition. Both conditions must be specified. Modifier 0010 must then be quoted after the appropriate code number to indicate that this rule is applicable. | 2004.0 0 | | | |

| 011 | Every physiotherapist must acquaint himself with the provisions of the Medical Schemes Act, 1998 | 2004.0 | | $\overline{}$ | Т_ | | $\overline{}$ |
|-------|---|--------|----------|---------------|--------|---|---------------|
| ' ' ' | and the regulations promulgated under the Act in connection with the rendering of accounts. | 0 | | | | 1 | ı |
| 1 | and the regulation profitaigated and of the Net in confinection with the reflecting of accounts. | ا | | | | | ı |
| | Every account shall contain the following particulars: | | | | | | |
| | The name and practice code number of the referring practitioner (where applicable). The name of the member. | | | | | | |
| | · The name of the patient. | | | | | | |
| l | · The name of the medical scheme. | 1 | | | | | 1 |
| | · The membership number of the member. | | | | | 1 | ı |
| | · The practice code number and name of practitioner | | - 1 | | | 1 | ı |
| 1 | The nature and cost of the treatment. | | | | 1 | 1 | ı |
| l | · The date on which the service was rendered. | | | | | [| ı |
| | · The relevant diagnostic codes and NHRPL item code numbers relating to the health service rendered. | | | | | | |
| 012 | ND Downline off door not contain a constant | 00040 | \dashv | | + | | ₩ |
| 012 | NB: Rounding off does not apply to amounts occurring once the modifiers are used. | 2004.0 | | | | | |
| 040 | | 0 | _ | | _ | | ╙ |
| 013 | Where the physiotherapist performs treatment away from the treatment rooms, travelling costs being | 2004.0 | | | | | 1 |
| | more than 16 kilometres in total) to be charged according to the AA-rate. Modifier 0013 must be | lo l | | | | | 1 |
| ľ | quoted after the appropriate code numbers to show that this rule is applicable. Please note that | | | | | 1 | 1 |
| | although only some medical schemes accept responsibility for the payment of transport expenses, | | | | | ļ | |
| | others do so in exceptional cases only. | | | | | | _ |
| 014 | Physiotherapy services rendered in a nursing home or hospital. Modifier 0014 must be quoted after | 2004.0 | | | | | 1 |
| | each code. | 0 | | | _ | | ↓_ |
| 016 | It is recommended that, when such benefits are granted, drugs, consumables and disposable items | 2004.0 | | | 1 | | 1 |
| | used during a procedure or issued to a patient on discharge will only be reimbursed by a medical | 0 | | | | | 1 |
| | scheme if the appropriate code is supplied on the account. | | | | | | |
| | Modifiers | | | | | | |
| 0001 | Appointment not kept | 2004.0 | | | | | |
| | | 0 | | | | | |
| 0003 | 15% of the relevant rate to be deducted where equipment used is not owned by the practitioner | 2004.0 | ١. | | | | |
| | | 0 | | | | | |
| 0006 | Add 50% of the total fee for the treatment | 2004.0 | | | | | |
| | | 0 | | | | | |
| 0008 | Only 50% of the fee for these additional procedures may be charged | 2004.0 | | | | | |
| | | 0 | | | | | |
| 0009 | The full fee for the additional condition may be charged | 2004.0 | | | | | Г |
| | | 0 | | i | | | |
| 0010 | Only 50% of the fee for the second condition may be charged | 2004.0 | | | | | \top |
| | 1 | 0 | | | | | i |
| 0013 | Travelling costs (being more than 16 kilometres in total) according to AA-rate. Please note that | 2004.0 | | | \top | | T |
| | although only some medical schemes accept responsibility for the payment of transport expenses, | 0 | | | | | 1 |
| | | | | | | | |

| 0014 | Physiotherapy services rendered to an in-patient in a nursing home or hospital. | 2004.0 | T | | | | | |
|------|---|-------------|-----|--------|-----|----------|--------|---|
| | | 0 | + | | | | | |
| 1 | RADIATION THERAPY / MOIST HEAT / CRYOTHERAPY | - | 260 | 5.000 | 1.0 | <u> </u> | 26.70 | |
| 001 | Infra-red, Radiant heat, Wax therapy Hot packs | 2004.0 0 | 260 | 5.000 | 1.0 | ĸ | 26.70 | |
| 005 | Ultraviolet light | 2004.0 | 260 | 10.000 | 1.0 | R | 53.30 | |
| 006 | Laser beam | 2004.0 | 260 | 15.000 | 1.0 | R | 80.00 | |
| 007 | Cryotherapy | 2004.0 | 260 | 5.000 | 1.0 | R | 26.70 | |
| 2 | LOW FREQUENCY CURRENTS | | 1 | | _ | | | |
| 103 | Galvanism, Diodynamic current, Tens. | 2004.0 | 260 | 10.000 | 1.0 | R | 53.30 | |
| 105 | Muscle and nerve stimulating currents. | 2004.0 | 260 | 12.000 | 1.0 | R | 64.00 | |
| 107 | Interferential Therapy. | 2004.0 0 | 260 | 10.000 | 1.0 | R | 53.30 | |
| 3 | HIGH FREQUENCY CURRENTS | | | | | | | |
| 201 | Shortwave diathermy. | 2004.0 | 260 | 5.000 | 1.0 | R | 26,70 | |
| 203 | Ultrasound. | 2004.0 | 260 | 10.000 | 1.0 | R | 53.30 | |
| 205 | Microwave. | 2004.0 | 260 | 5.000 | 1.0 | R | 26.70 | |
| 4 | PHYSICAL MODALITIES | | | | | | | |
| 300 | Vibration | 2004.0 | 260 | 10.000 | 1.0 | R | 53.30 | |
| 301 | Percussion | 2004.0 | 260 | 16.100 | 1.0 | R | 85.80 | |
| 302 | Massage | 2004.0 | 260 | 10.000 | 1.0 | R | 53.30 | |
| 303 | Myofacial release/soft tissue mobilisation, one or more body parts | 2004.0 | 260 | 20.090 | 1.0 | R | 107.10 | |
| 304 | Acupuncture | 2004.0 | 260 | 15.000 | 1.0 | R | 80.00 | _ |
| 305 | Re-education of movement/Exercises (excluding ante- and post-natal exercises) | 2004.0 | 260 | 10.000 | 1.0 | R | 53.30 | |
| 307 | Pre- and post-operative exercises and/or breathing exercises | 2004.0 | 260 | 10.000 | 1.0 | R | 53.30 | |
| 308 | Group exercises (excluding ante- and post-natal exercises - maximum of 10 in a group) | 2004.0 | 260 | 10.000 | 1.0 | R | 53.30 | |
| 309 | Isokinetic treatment. | 2004.0 | 260 | 10.000 | 1.0 | R | 53.30 | |

30410-4

| 245 | Neural tissue mobilisation | 00045 | | 000 | 00.000 | 4.0 | _ | 400.00 | |
|-----|---|-------------|--------|--------|--------|-----|---|--------|--|
| 310 | Neural lissue mobilisation | 2004.0 | 1 1 | 260 | 20.000 | 1.0 | ĸ | 106.60 | |
| 313 | Ante and post natal exercises/counselling | 2004.0 | | 260 | 10.000 | 1.0 | R | 53.30 | |
| 314 | Lymph drainage | 2004.0 | \Box | 260 | 5.000 | 1.0 | R | 26.70 | |
| 315 | Postural drainage. | 2004.0 | | 260 | 10.000 | 1.0 | R | 53.30 | |
| 317 | Traction. | 2004.0 | Н | 260 | 10.000 | 1.0 | R | 53.30 | |
| 318 | Upper respiratory nebulisation and/or lavage | 2004.0 | Н | 260 | 10.000 | 1.0 | R | 53.30 | |
| 319 | Nebulisation | 2004.0 | | 260 | 10.000 | 1.0 | R | 53.30 | |
| 321 | Intermittent positive pressure ventilation. | 2004.0 | П | 260 | 10.000 | 1.0 | R | 53.30 | |
| 323 | Suction: Level 1 (including sputum specimen taken by suction) | 2004.0 | П | 260 | 5.000 | 1.0 | R | 26.70 | |
| 325 | Suction: Level 2 (Suction with involvement of lavage as a treatment in a special unit situation or in the respiratory compromised patient) | 2004.0 | | 260 | 20.090 | 1.0 | R | 107.10 | |
| 327 | Bagging (used on the intubated unconscious patient or in the severely respiratory distressed patient). | 2004.0 | | 260 | 5.000 | 1.0 | R | 26.70 | |
| 328 | Dry needling | 2004.0 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 5 | MANIPULATION/MOBILISATION OF JOINTS OR IMMOBILISATION | | | 一 | | | | | |
| 401 | Spinal. | 2004.0 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 402 | Pre meditated manipulation | 2004.0 | | 260 | 10.000 | 1.0 | R | 53.30 | |
| 405 | All other joints. | 2004.0 0 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 407 | Immobilisation (excluding materials). Rule 008 does not apply. | 2004.0 0 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 6 | REHABILITATION | | П | \neg | | | | | |
| 501 | Rehabilitation where the pathology requires the undivided attention of the physiotherapist. Rule 008 does not apply. Duration: 30min. | 2004.0 | | 260 | 25.000 | 1.0 | R | 133.30 | |
| 502 | Hydrotherapy where the pathology requires the undivided attention of the physiotherapist, Rule 008 does not apply. Duration: 30min. | 2004.0 | | 260 | 25.000 | 1.0 | R | 133.30 | |
| 503 | Rehabilitation for Central Nervous System disorders - condition to be clearly stated and fully documented (No other treatment modality may be charged in conjunction with this). Duration: 60min. | 2004.0 0 | \Box | 260 | 55.000 | 1.0 | R | 293.20 | |
| 504 | EMG Biofeedback treatment | 2004.0 0 | | 260 | 15.000 | 1.0 | R | 80.00 | |

| 505 | Group rehabilitation. Treatment of a patient with disabling pathology in an appropriate facility requiring specific equipment and supervision, without individual attention for the whole treatment | 2005.0 5 | | 260 | 12.000 | 1.0 | R | 64.00 | |
|-----|---|-------------|----|----------|--------|-----|---|--------|---|
| | session, no charge may be levied by facility | | ll | - 1 | | | | | 1 |
| 506 | Stress management | 2004.0 0 | | 260 | 20.000 | 1.0 | R | 106.60 | |
| 507 | Respiratory Re-education and Training. Duration: 30min. | 2004.0 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 509 | Rehabilitation. Each additional full 15 mins. Where the pathology requires the undivided attention of the physiotherapist. (Rule 0008 does not apply.) Can only be used with codes 501, 502, 507 or 503 to indicate the completion of an additional 15 minutes. A maximum of two instances of this code may be charged per session. | 2006.0 2 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 7 | EVALUATION | | | \dashv | | | | | ┢ |
| 701 | Evaluation/counselling at the first visit only (to be fully documented) | 2004.0 0 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 702 | Complex evaluation/counselling at the first visit only (to be fully documented). | 2004.0 0 | | 260 | 30.000 | 1.0 | R | 159.90 | |
| 703 | One complete re-assessment of a patient's condition during the course of treatment. To be used only once per episode of care. | 2004.0 0 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 704 | Lung function: Peak flow (once per treatment). | 2004.0 0 | П | 260 | 5.000 | 1.0 | R | 26.70 | |
| 705 | Computerised/Electronic test for lung pathology | 2004.0 0 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 706 | Reports. To be used to motivate for therapy and/or give a progress report and/or a pre-authorisation report, where such a report is specifically required by the medical scheme. | 2005.0 3 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 707 | Physical Performance test, Must be fully documented. | 2004.0 0 | | 260 | 20.000 | 1.0 | R | 106.60 | |
| 708 | Interview, guidance or consultation with the patient or his family. To be used only once per episode of care. | 2005.0 2 | | 260 | 15.000 | 1.0 | R | 80.00 | |
| 801 | Electrical test for diagnostic purposes (including IT curve and isoldnetic tests) for a specific medical condition | 2004.0 0 | | 260 | 35.000 | 1.0 | R | 186.60 | |
| 803 | Effort test - multistage treadmill. | 2004.0 | | 260 | 35.000 | 1.0 | R | 186.60 | |
| 8 | VISITING CODES | | | | | | | | |
| 901 | Treatment at a nursing home: Relevant fee plus (to be charged only once per day and not with every hospital visit | 2004.0 0 | | 260 | 10.000 | 1.0 | R | 53.30 | |
| 903 | Domiciliary treatments : Relevant fee plus, | 2004.0 0 | | 260 | 20.000 | 1.0 | R | 106.60 | |
| 10 | OTHER | | | | | | | | |
| 117 | Appointment not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 2004.0 | | 260 | - | 1.0 | R | • | |
| 937 | Bird or equivalent freestanding nebuliser excluding oxygen at hospital per day. | 2004.0 | | 260 | 10.000 | 1.0 | R | 53.30 | |
| 938 | Bird or equivalent freestanding nebuliser excluding oxygen domicilliary per day. | 2004.0 | | 260 | 10.000 | 1.0 | R | 53.30 | |

| 939 | Cost of material: Items to be charged (exclusive of VAT) at net acquisition price plus - | 2004.0 | | 260 | _ | 1.0 | R | - 7 | |
|-----|---|--------|---------------|-----|---|-----|---|-----|--------------|
| | 26% of the net acquisition price where the net acquisition price of that material is less than one | 0 | | - 1 | | | | | |
| | hundred rands; | l | | - 1 | | | | | |
| | a maximum of twenty six rands where the net acquisition price of that material is greater than or | ı | 1 1 | - 1 | | | | | ĺ |
| | equal to one hundred rands. | | $\sqcup \bot$ | | | | | | |
| 940 | Cost of appliances: items to be charged (exclusive of VAT) at net acquisition price plus- | 2004.0 | | 260 | - | 0.0 | R | - | |
| | 26% of the net acquisition price where the net acquisition price of that appliance is less than one | 0 | 1 1 | - 1 | | | | | |
| | hundred rands; | [| | - 1 | | | | | |
| | a maximum of twenty six rands where the net acquisition price of that appliance is greater than or | l | 1 I | ı | | | İ | | |
| | equal to one hundred rands. | | | | | | | | |
| 941 | Hiring equipment: 1% of the current replacement value of the equipment per day. Total charge not to | 2004.0 | | - 1 | | | | | ĺ |
| | exceed 50% of replacement value. Description of equipment to be supplied. | 0 | Ш | | | | | | |
| | Payment of this item is at the discretion of medical scheme concerned, and should be considered in | 2005.0 | | | | | | | |
| | instances where cost savings can be achieved. By prior arrangement with the medical scheme. | 3 | ΙI | | | | | | ĺ |
| | | L | | | | | | | $oxed{oxed}$ |

| | | = |
|-------|---------------|---|
| Code | Description | |
| 37200 | Physiotherapy | |

| | | i nyotouton |
|-------|---------------|-------------|
| Code | Description | |
| 37200 | Physiotherapy | |

| Code | Description | RCF |
|------|------------------|-------|
| 260 | Physiotherapists | 5.331 |
| | - | |

NATIONAL REFERENCE PRICE LIST FOR SERVICES BY PHYTOTHERAPISTS EFFECTIVE FROM 1 JANUARY 2008

The following reference price list is not a set of tanffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures, on some other basis without reference to this list, they may do so as well.

In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded to the nearest cent. When new item prices are calculated, e.g. when applying a modifier, the same rounding scheme should be followed.
VAT EXCLUSIVE PRICES APPEAR IN BRACKETS.

RULES ITEMS Consultations

Consultation encompasses consultation, history taking, patient examination and assessment, side room diagnostic tests, counseling and/or preparation of medicines.

| Code | Description | Ver | Add | Phyt | otherapy |
|-------|---|-------|---------------------------------------|--------|--------------------|
| VIII. | | | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | RVU | Fee |
| 130 | Consultation (initial or follow up). Duration 1 - 15 mins | 06.04 | | 7.500 | 35.90 (31.50) |
| 131 | Consultation (initial or follow up). Duration 16 - 30 mins | 06.04 | | 22.500 | 107.60 (94.40) |
| 132 | Consultation (initial or follow up), Duration 31 - 45 mins | 06.04 | | 37.500 | 179.30 (157.30) |
| 133 | Consultation (initial or follow up). Duration 48 - 60 mins | 06.04 | | 52.500 | 251.00 (220.20) |
| 134 | Consultation, each additional full 15 mins, to a maximum of 60 mins | 06.04 | | 15.000 | 71.70 (62.90) |

Preparation and Dispensing of Medicaments

| Med | caments | ذء |
|---------------|---------|--------|
| $\overline{}$ | | |

| | The amount charged in respect of proprietary medicines shall be at net acquisition price. | | | | | 06.04 |
|----|--|-----------|--------|-----------|------|-------|
| | In relation to all other materials, items are to be charged (exclusive of VAT) at net acquisition price pl | us - | | | | |
| | * 26% of the net acquisition price where the net acquisition price of that material is less than one hun | dred rar | nds; a | nd | | |
| | * a maximum of twenty six rands where the net acquisition price of that material is greater than or equ | ial to or | e hur | dred rand | ds. | |
| 10 | Tinctures, per 10 ml | 06.02 | | 2.700 | 2.99 | (2.62 |

| | 2.700 | 2.99 (2.62) |
|------|----------------------------------|------------------------|
| 6.02 | 1.000 | 1.11 (0.97) |
| 3.02 | 3.400 | 3.76 (3.30) |
| 5.02 | 20.100 | 22.20 |
| | | (19.50) |
| 3.02 | 2.800 | 3.10 (2.72) |
| 5.02 | 1.300 | 1.44 (1.26) |
| 3.02 | | - |
| 5.02 | | |
| 16 | 06.02 06.02 06.02 06.02 | 06.02 1.300 06.02 - |

| | | | | 4130 | 00 | | | |
|----|--|-------------|----------|--------------|----------|----------|-------------------|-------------|
| | NATIONAL REFERENCE PRICE LIST FOR SERVICES BY PHYTOTHERAPISTS EFFECTIVE FROM 1 JANUARY 2008 | Versio n | Ađ d | CF | Units | BF | Value | Fla |
| | The following reference price list is not a set of tariffs that must be applied by medical schemes | 2006.0 | | | | | | 1 |
| | and/or providers. It is rather intended to serve as a baseline against which medical schemes can | 2 | l | | | | | - |
| | lindividually determine benefit levels and health service providers can individually determine fees | l | l | | | ' | | |
| | charged to patients. Medical schemes may, for example, determine in their rules that their benefit in | l | l | | | | | 1 |
| | respect of a particular health service is equivalent to a specified percentage of the national health | l | l | | | | | |
| | reference price list. It is especially intended to serve as a basis for negotiation between individual | l | l | | | | | |
| | funders and individual health care providers with a view to facilitating agreements which will minimise | l | l | | | | | |
| | balance billing against members of medical schemes. Should individual medical schemes wish to | l | l | | | | | |
| | determine benefit structures, and individual providers determine fee structures, on some other basis | l | l | l | | | | |
| | without reference to this list, they may do so as well. | l | l | | | į į | | |
| | In calculating the prices in this schedule, the following rounding method is used: Values R10 and | l | l | | | | | |
| | below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded | l | l | 1 | | | | |
| | RULES | | \vdash | | | \vdash | | + |
| _ | ITEMS | - | ┰ | | - | | | + |
| _ | Consultations | \vdash | ┢ | | \vdash | | | ╌ |
| | Consultation encompasses consultation, history taking, patient examination and assessment, side | 2006.0 | - | ┢ | - | | | ┿ |
| | froom diagnostic tests, counseling and/or preparation of medicines. | 4 | 1 | 1 | | | | |
| 30 | Consultation (initial or follow up). Duration 1 - 15 mins | 2006.0 | ⊢ | 510 | 7.500 | 1.0 | R 35.9 | |
| 30 | Consultation (must or follow up). Duration 1 - 15 mins | 4 | | الا | 7.500 | 1.0 | K 35.8 | ~ |
| 31 | Consultation (initial or follow up). Duration 16 - 30 mins | 2006.0 4 | | 510 | 22.500 | 1.0 | R 107.6 | ю |
| 32 | Consultation (initial or follow up). Duration 31 - 45 mins | 2006.0 | | 510 | 37.500 | 1.0 | R 179.3 | ,o |
| 33 | Consultation (initial or follow up). Duration 46 - 60 mins | 2006.0 | | 510 | 52.500 | 1.0 | R 251.0 | χ |
| 34 | Consultation, each additional full 15 mins, to a maximum of 60 mins | 2006.0 | | 510 | 15.000 | 1.0 | R 71.7 | 'n |
| | Preparation and Dispensing of Medicaments | | | | | | | 士 |
| | Medicaments | | | | | | | |
| | The amount charged in respect of proprietary medicines shall be at net acquisition price. | 2006.0 4 | | | | | | |
| | in relation to all other materials, items are to be charged (exclusive of VAT) at net acquisition price | | | | | | | |
| | In | | | | | | | |
| | * 26% of the net acquisition price where the net acquisition price of that material is less than one hundred rands; and | | | | | | | |
| | Thuring to rous, and the second secon | | 1 | | | | | |
| | * a maximum of twenty six rands where the net acquisition price of that material is greater than or | | | | | | | |
| 10 | equal to one hundred rands. | 2006.0 | 1 | 520 | 2,700 | 10 | R 2.9 | <u></u> |
| U | Tinctures, per 10 ml | 2000.0 | 1 | 1 320 |] 2.700 | ۱.۵ | '` ^{2.3} | ,3 |
| | | <u> </u> | _ | Ь. | <u> </u> | | | _ |

| Code | | Description | |
|-------|--------------|-------------|--|
| 41300 | Phytotherapy | | |

| Code | Description | RCF |
|------|---|-------|
| 510 | Phytotherapy | 4.781 |
| 520 | Phytotherapy materials | 1.106 |
| | - · · · · · · · · · · · · · · · · · · · | |

Version 2008.01

| 320 | Tea mixes, per 10g | 2006.0 2 | 520 | 1.000 | 1.0 | R | 1.11 | |
|-----|-------------------------------|-------------|-----|--------|-----|---|-------|--|
| 330 | Capsules/tablets, per capsule | 2006.0 2 | 520 | 3.400 | 1.0 | R | 3.76 | |
| 340 | Creams/Ointments, per 10ml | 2006.0 2 | 520 | 20.100 | 1.0 | R | 22.20 | |
| 350 | Syrups, per 10ml | 2006.0 2 | 520 | 2.800 | 1.0 | R | 3.10 | |
| 360 | Medicinal oils, per 10ml | 2006.0 2 | 520 | 1.300 | 1.0 | æ | 1.44 | |
| 390 | Proprietary materials | 2006.0 2 | 520 | | 1.0 | R | - | |
| 395 | Proprietary medicines | 2006.0 | 520 | | 1.0 | R | - | |

PODIATRY

Podiatry 2008

NATIONAL REFERENCE PRICE LIST FOR SERVICES BY PODIATRISTS, EFFECTIVE FROM 1 JANUARY 2008

The following reference price list is not a set of tariffs that must be applied by medical schemes and/or providers. It is rather intended to serve as a baseline against which medical schemes can individually determine benefit levels and health service providers can individually determine fees charged to patients. Medical schemes may, for example, determine in their rules that their benefit in respect of a particular health service is equivalent to a specified percentage of the national health reference price list. It is especially intended to serve as a basis for negotiation between individual funders and individual health care providers with a view to facilitating agreements which will minimise balance billing against members of medical schemes. Should individual medical schemes wish to determine benefit structures, and individual providers determine fee structures. on some other basis without reference to this list, they may do so as well.

In calculating the prices in this schedule, the following rounding method is used: Values R10 and below rounded to the nearest cent, R10+ rounded to the nearest 10cent. Modifier values are rounded to the nearest cent. When new item prices are calculated, e.g. when applying a modifier, the same rounding scheme should be followed.

| Α | al Rules (2004) Commission from the commission of the commission o | | 1 4 7 1 1 1 1 1 1 1 1 | A 60000 A 7 |
|---|--|---|-------------------------------------|---|
| | All accounts must be presented with the following information clearly stated: | | | 05.03 |
| | name of practitioner | | | |
| | · qualifications of the practitioner; · BHF practice number; | | | |
| | · postal address and telephone number; | | | |
| | · date on which service(s) were provided; | | | |
| | The relevant diagnostic codes and NHRPL item code numbers relating to the health service render | ered; | | |
| | the surname and initials of the member; | | | i |
| | the first name of the patient; the name of the scheme; | | | |
| | the membership number of the member; and | | | |
| | . the name and practice number of the referring practitioner, if applicable. | | | |
| В | The rate in respect of more than one procedure performed at the same consultation or visit, shall be procedure plus half the rate in respect of each additional procedure carried out in the treatment of an | | | or 04.00 |
| С | It is recommended that, when such benefits are granted, drugs, consumables and disposable items issued to a patient on discharge will only be reimbursed by a medical scheme if the appropriate code | used during | a procedu | |
| D | The amount charged in respect of medicines and scheduled substances shall not exceed the limits probability and scheduled Substances, dated 30 April 2 Medicines and Related Substances Act, 1965 (Act No 101 of 1965). In relation to all other materials, items are to be charged (exclusive of VAT) at net acquisition price probability. | 2004, made | | |
| | | | and | |
| | * 26% of the net acquisition price where the net acquisition price of that material is less than one hur * a maximum of twenty six rands where the net acquisition price of that material is greater than or eq | | | de |
| Modif | | | | war Der Green |
| 0002 | For procedures 021 to 031 carried out in a day clinic or unattached operating theatre unit, the rate si | | 5,000,00 | 30 50 5 |
| 0004 | Consultation or treatment in a nursing facility/hospital | ian be reduc | ZEG TO TMO-T | 04.00 |
| 0006 | Consultation or treatment at the patient's recidence | | | |
| | | | | 113411101 |
| | 나는 아이들 사람들이 되었다. 그는 사람들은 사람들이 가장 그렇게 되었다. 그 그 그 그 그 그 그 그 그 그를 가장 하는 것이 없었다. | | | 04.00 |
| ITEMS | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. | 2420 | | 04.00 |
| ITEMS | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. | | | 04.00 04.00 |
| ITEMS CONS | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS: | | | 04.00 04.00 |
| ITEMS | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS: | Ver Ad | d Po | 04.00 04.00 odlatry |
| ITEMS CONS | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS: Description | | | 04.00 04.00 |
| CONS | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS: Description | | d Po | 04.00 04.00 odlatry |
| CONS | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS: Description | Ver Aid | d Po RVU | 04.00 04.00 odiatry Fee |
| CONS Code 301 | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS. Description Consultation (initial or follow up) 5-10 minutes | Ver Ad | 7.500 | 04.00 04.00 odlatry Fee 60.70 (53.20) 121.50 |
| CONS Code 301 302 303 304 | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS: Description Consultation (initial or follow up) 5-10 minutes Consultation (initial or follow up) 11-20 minutes | Ver Ad 06.04 06.03 | 7.500 15.000 | 04.00 04.00 04.00 Fee 60.70 (53.20) 121.50 (106.60) 202.50 (177.60) |
| CONS Code 301 302 303 | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS: Description: Consultation (initial or follow up) 5-10 minutes Consultation (initial or follow up) 11-20 minutes Consultation (initial or follow up) 21-30 minutes Consultation (initial or follow up) 31-45 minutes More than one patient seen at a residence (See note below). | 06.04 06.03 06.03 | 7.500 15.000 25.000 | 04.00 04.00 04.00 Fee 60.70 (53.20) 121.50 (106.60) 202.50 (177.60) 303.70 |
| CONS Code 301 302 303 304 | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS: Description: Consultation (initial or follow up) 5-10 minutes Consultation (initial or follow up) 11-20 minutes Consultation (initial or follow up) 21-30 minutes Consultation (initial or follow up) 31-45 minutes | 06.04 06.03 06.03 | 7.500 15.000 25.000 37.500 | 04.00 04.00 04.00 Fee: 60.70 (53.20) 121.50 (106.60) 202.50 (177.60) 303.70 (266.40) 62.20 |
| CONS Code 301 302 303 304 006 | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS. Description: Consultation (initial or follow up) 5-10 minutes Consultation (initial or follow up) 11-20 minutes Consultation (initial or follow up) 21-30 minutes Consultation (initial or follow up) 31-45 minutes More than one patient seen at a residence (See note below). NOTE: This code is a blanket code for home visits away from the practitioners rooms where more than one but up to and including six patients are treated. The code may be used again if seven to twelve patients are seen. Appointments not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 06.04 06.03 06.03 06.03 06.03 06.02 06.02 | 7.500 15.000 25.000 37.500 | 60.70 (53.20) 121.50 (106.60) 202.50 (177.60) 303.70 (266.40) 62.20 (54.60) |
| CONS Code 301 302 303 304 006 | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS. Description Consultation (initial or follow up) 5-10 minutes Consultation (initial or follow up) 11-20 minutes Consultation (initial or follow up) 21-30 minutes Consultation (initial or follow up) 31-45 minutes More than one patient seen at a residence (See note below). NOTE: This code is a blanket code for home visits away from the practitioners rooms where more than one but up to and including six patients are treated. The code may be used again if seven to twelve patients are seen. Appointments not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 06.04 06.03 06.03 06.03 06.02 06.02 | 7.500 15.000 25.000 37.500 | 04.00 04.00 04.00 60.70 (53.20) 121.50 (106.60) 202.50 (177.60) 303.70 (266.40) 62.20 (54.60) |
| CONS Code 301 302 303 304 006 | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS: Description Consultation (initial or follow up) 5-10 minutes Consultation (initial or follow up) 11-20 minutes Consultation (initial or follow up) 21-30 minutes Consultation (initial or follow up) 31-45 minutes More than one patient seen at a residence (See note below). NOTE: This code is a blanket code for home visits away from the practitioners rooms where more than one but up to and including six patients are treated. The code may be used again if seven to twelve patients are seen. Appointments not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 06.04 06.03 06.03 06.03 06.03 06.02 06.02 | 7.500 15.000 25.000 37.500 | 04.00 04.00 04.00 50.70 (53.20) 121.50 (106.60) 202.50 (177.60) 303.70 (266.40) 62.20 (54.60) |
| CONS Code 301 302 303 304 006 | Modifier 0004 must be quoted for consultation or treatment rendered in a nursing home or hospital. Modifier 0006 must be quoted for consultations or treatment rendered at the patient's residence. ULTATIONS. Description Consultation (initial or follow up) 5-10 minutes Consultation (initial or follow up) 11-20 minutes Consultation (initial or follow up) 21-30 minutes Consultation (initial or follow up) 31-45 minutes More than one patient seen at a residence (See note below). NOTE: This code is a blanket code for home visits away from the practitioners rooms where more than one but up to and including six patients are treated. The code may be used again if seven to twelve patients are seen. Appointments not kept (schemes will not necessarily grant benefits in respect of this item, it will fall into the "By arrangement with the scheme" or "Patient own account" category). | 06.04 06.03 06.03 06.03 06.02 06.02 | 7.500 15.000 25.000 37.500 | 04.00 04.00 04.00 60.70 (53.20) 121.50 (106.60) 202.50 (177.60) 303.70 (266.40) 62.20 (54.60) |